

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
17 June 2004 (17.06.2004)

PCT

(10) International Publication Number
WO 2004/050068 A1

(51) International Patent Classification⁷: **A61K 9/48**,
47/12, 47/38, 47/44

(21) International Application Number:
PCT/EP2002/013558

(22) International Filing Date:
29 November 2002 (29.11.2002)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (for all designated States except US):
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turn-
houtseweg 30, B-2340 Beerse (BE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **VANDECRUYS,**
Roger, Petrus, Gerebern [BE/BE]; Janssen Pharmaceu-
tica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Common Representative: **JANSSEN PHARMACEU-**
TICA N.V.; Turnhoutseweg 30, B-2340 Beerse (BE).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 2004/050068 A1

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING A BASIC RESPECTIVELY ACIDIC DRUG COMPOUND,
A SURFACTANT AND A PHYSIOLOGICALLY TOLERABLE WATER-SOLUBLE ACID RESPECTIVELY BASE

(57) Abstract: The invention provides a novel pharmaceutical composition comprising a basic respectively acidic drug compound,
a surfactant and a physiologically tolerable water-soluble acid respectively base characterized in that the acid respectively base:drug
compound ratio is at least 1:1 by weight.

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

REC'D 16 JUN 2003

WIPO PCT

Applicant's or agent's file reference PRD2017p-PCT	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/EP 02/ 13558	International filing date (day/month/year) 29/11/2002	(Earliest) Priority Date (day/month/year)
Applicant JANSSEN PHARMACEUTICA N.V.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 8 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ Certain claims were found unsearchable (See Box I).

3. ☐ Unity of invention is lacking (see Box II).

4. With regard to the title,

☐ the text is approved as submitted by the applicant.

☒ the text has been established by this Authority to read as follows:

PHARMACEUTICAL COMPOSITIONS COMPRISING A BASIC RESPECTIVELY ACIDIC DRUG COMPOUND, A SURFACTANT AND A PHYSIOLOGICALLY TOLERABLE WATER-SOLUBLE ACID RESPECTIVELY BASE

5. With regard to the abstract,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

PHARMACEUTICAL COMPOSITIONS COMPRISING A BASIC RESPECTIVELY ACIDIC DRUG
COMPOUND, A SURFACTANT AND A PHYSIOLOGICALLY TOLERABLE WATER-SOLUBLE ACID
RESPECTIVELY BASE

5 This invention relates to novel pharmaceutical compositions, in particular compositions
and dosage forms providing improved drug release and uptake on administration into
externally voiding body cavities (e.g. the gastro-intestinal tract) or on topical
administration, especially for acid solubilized drug compounds.

10 Many drug compounds, while possessing desired therapeutic properties, are used
inefficiently due to their poor water solubilities. Thus for example where such
compounds are administered orally, only a small fraction of the drug is taken up into
the blood during transit of the gastro-intestinal tract. As a result, to achieve adequate
drug uptake it may be necessary to administer high doses of the drug compound, to
15 prolong the period of drug administration or to make frequent administrations of the
drug compound. Indeed, the poor solubility and hence poor bioavailability of a drug
may cause an alternative drug, perhaps one with undesired side effects or one which
requires invasive administration (e.g. by injection or infusion), to be used in place of
the poorly soluble drug.

20 One approach to poor solubility is to derivatise the drug molecule to introduce water
solubilizing groups, e.g. ionic groups such as carboxyl groups or non-ionic groups such
as polyhydroxyalkyl groups, so as to produce a more soluble derivative. This approach
however is not always successful as it may not be possible to maintain adequately high
therapeutic efficacy and adequately low toxicity or other side effects. Thus one
25 example of a poorly water soluble drug which has not been superseded by a solubilized
derivative is the antifungal agent itraconazole.

Attempts have therefore been made to enhance the uptake of drugs such as itraconazole
by increasing the surface area of the drug compound exposed to saliva or gastric fluid,
and hence promote dissolution of the drug compound, by thinly coating the drug
30 compound onto essentially inert carrier particles, e.g. sugar beads. This however has
the drawback that the volume of solid composition required to administer a given
quantity of the drug compound is quite high since the carrier contributes significantly to
the overall administration volume. Since administration of large volume capsules or
tablets, or of large quantities of smaller volume capsules or tablets, provides difficulties
35 for the patient, the drawbacks of this approach are obvious.

Yet another approach has been to administer the drug compound in the form of a

-2-

solution of the drug compound and a drug complexing agent such as a cyclodextrin. This approach has limitations also in that the formulation is constrained to those drugs which are able to form complexes with cyclodextrins, in that the dosage volume is constrained by the solubilizing power of the complexing agent, in that readily unitized
5 solid dosage forms can not be used, and in that there is no gradual release of the drug compound for biological uptake.

The drug compound can also be formulated as a solid dispersion in cyclodextrins together with a physiologically tolerable water soluble acid and a physiologically
10 tolerable water soluble organic polymer. Reference therefore is made to WO 98/55148. This approach has limitations in that the formulation is constrained to those drugs which are able to form complexes with cyclodextrins and in that the dosage volume is constrained by the solubilizing power of the complexing agent.

15 Another approach to increase drug release from the dosage form and hence to enhance the oral bioavailability of the drug is to administer the drug together with a suitable surfactant.

WO 97/35587 describes a liquid formulation comprising an HIV protease inhibitor and
20 a water soluble tocopherol derivative, in particular Vitamin E-TPGS.

WO 98/08490 describes a solid dry coprecipitate composition comprising tocopherol polyethyleneglycol succinate, a lipophilic active ingredient and a dispersion adjuvant.

25 WO 99/26607 describes solid dispersions of a drug and Vitamin E TPGS.

WO 99/45918 describes compositions comprising a taxane, one or more surfactants and an acid. The acid is included in the formulation to improve the stability of the taxane.

30 WO 97/02017 describes solid dispersions comprising a poorly soluble active ingredient in a hydrophilic poloxamer polymer. The dispersion may further contain an acid. The acid is included in the solid dispersion in order to provide for a gradual availability of the acid to promote the solubilization of the active ingredient over the bulk of the release rate curve.

35

The compositions of the present invention are distinguishable from the prior art compositions in that they provide for a faster dissolution profile of the drug compound

and/or in that they are able to provide for a higher solubility for the drug compound (creating a supersaturated condition). This results in an enhanced bioavailability for the drug compound; an improved biological uptake of the drug compound (an improved time profile for the drug content of the plasma of the patient, *i.e.* the pharmacokinetic profile defined by such parameters as AUC, t_{\max} , C_{\max} , etc. is improved). The incorporation of the drug compound in the compositions of the present invention is also independent on complex formation, which makes the present compositions suitable for the formulation of a broad range of drug compounds.

- 10 We have now found that the above described characteristics of the present compositions could be achieved by combining a basic respectively acidic drug compound with a surfactant and a significant amount of a water-soluble acid respectively base.
- 15 Thus viewed from one aspect the invention provides a pharmaceutical composition comprising a basic drug compound, a surfactant and a physiologically tolerable water-soluble acid characterized in that the acid:drug compound ratio is at least 1:1 by weight or
- 20 comprising an acidic drug compound, a surfactant and a physiologically tolerable water-soluble base characterized in that the base:drug compound ratio is at least 1:1 by weight.

In other words, the present invention provides a pharmaceutical composition comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base characterized in that the acid respectively base:drug compound ratio is at least 1:1 by weight.

Viewed from a further aspect the invention provides the use of a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base in an acid respectively base:drug ratio of at least 1:1 by weight for the manufacture of a pharmaceutical composition according to the invention for use in a method of prophylaxis, therapy or diagnosis of the human or non-human animal (e.g. mammalian, reptilian or avian) body.

35 Viewed from a still further aspect the invention provides a method of prophylaxis, therapy or diagnosis of the human or non-human animal (e.g. mammalian, reptilian or avian) body which comprises administering to said body a prophylactically,

-4-

therapeutically or diagnostically effective dose of a pharmaceutical composition, the improvement comprising using as said composition a composition according to the present invention.

- 5 While not wishing to be bound by theory it is thought that the advantageous drug compound dissolution profile for the compositions of the invention is achieved as a result of a combination of the effects of the components of the composition on exposure to water or aqueous body fluids.

In the case the composition comprises a basic drug compound and a physiologically
10 tolerable water-soluble acid, the water and the acid provide upon exposure to water or aqueous body fluids for an acidic microenvironment in which the solubility of the basic drug compound is increased. The presence of the surfactant causes a further increase in the solubility of the drug compound thereby producing a supersaturated solution of the drug compound.

15

In case the composition comprises an acidic drug compound and a physiologically tolerable water-soluble base, the water and the base provide upon administration for an alkaline microenvironment in which the solubility of the acidic drug compound is increased. The surfactant, as described above, causes the production of a supersaturated
20 solution of the drug compound.

The supersaturated solution which is created upon administration of the present compositions provides for an increased bioavailability of the drug compound.

Since the present compositions provide themselves for a microenvironment in which
25 the solubility of the drug compound is increased, they can be orally administered at any time of the day independently of the food taken in by the individual to whom they are administered.

Preferred compositions are those compositions comprising a basic drug compound, a
30 surfactant and a physiologically tolerable water-soluble acid characterized in that the acid:drug compound ratio is at least 1:1 by weight.

As for the surfactant in the compositions of the invention, there may be used any of the physiologically tolerable surfactants suitable for use in a pharmaceutical composition.

35

It is well-known in the art that a surfactant is an amphiphilic compound; it contains polar, hydrophilic moieties as well as non-polar, hydrophobic moieties.

The terms "hydrophilic" or "hydrophobic" are relative terms.

5 The relative hydrophilicity or hydrophobicity of a surfactant may be expressed by its hydrophilic-lipophilic balance value ("HLB value). Surfactants with a lower HLB value are catagorized as being "hydrophobic" surfactants whereas surfactants with a higher HLB value are catagorized as being "hydrophilic" surfactants. As a rule of thumb, surfactants having a HLB value greater than about 10 are generally considered as being hydrophilic surfactants; surfactants having a HLB value lower than about 10
10 are generally considered as being hydrophobic surfactants.

The present compositions preferably comprise a hydrophilic surfactant. It should be appreciated that the HLB value of a surfactant is only a rough guide to indicate the hydrophilicity/hydrophobicity of a surfactant. The HLB value of a
15 particular surfactant may vary depending upon the method used to determine the HLB value; may vary depending on its commercial source; is subject to batch to batch variability. A person skilled in the art can readily identify hydrophilic surfactants suitable for use in the pharmaceutical compositions of the present invention.

20 The surfactant of the present invention can be an anionic, a cationic, a zwitterionic or a non-ionic surfactant, the latter being preferred. The surfactant of the present invention can also be a mixture of two or more surfactants.

The choice of surfactant may be directed by the particular drug compound to be used in
25 the composition of the invention. Thus the surfactant with greater solubilizing capacity for the particular drug compound, with an enhanced capacity to provide for a supersaturated condition, may be preferred.

Suitable surfactants for use in the compositions of the present invention are listed
30 below. It should be emphasized that said list of surfactants is only illustrative, representative and not exclusive. Thus the invention is not limited to the surfactants listed below. In the present compositions, also mixtures of surfactants may be used.

Suitable surfactants which may be used in the present invention comprise :
35 a) Polyethylene glycol fatty acid monoesters comprising esters of lauric acid, oleic acid, stearic acid, ricinoic acid and the like with PEG 6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 32, 40, 45, 50, 55, 100, 200, 300, 400, 600 and the like, for instance PEG-6 laurate or stearate,

- PEG-7 oleate or laurate, PEG-8 laurate or oleate or stearate, PEG-9 oleate or stearate, PEG-10 laurate or oleate or stearate, PEG-12 laurate or oleate or stearate or ricinoleate, PEG-15 stearate or oleate, PEG-20 laurate or oleate or stearate, PEG-25 stearate, PEG-32 laurate or oleate or stearate, PEG-30 stearate, PEG-40 laurate or oleate or stearate, PEG-45 stearate, PEG-50 stearate, PEG-55 stearate, PEG-100 oleate or stearate, PEG-200 oleate, PEG-400 oleate, PEG-600 oleate; (the surfactants belonging to this group are for instance known as Cithrol, Algon, Kessco, Lauridac, Mapeg, Cremophor, Emulgante, Nikkol, Myrj, Crodet, Albunol, Lactomul)
- b) Polyethylene glycol fatty acid diesters comprising diesters of lauric acid, stearic acid, palmitic acid, oleic acid and the like with PEG-8, 10, 12, 20, 32, 400 and the like, for instance PEG-8 dilaurate or distearate, PEG-10 dipalmitate, PEG-12 dilaurate or distearate or dioleate, PEG-20 dilaurate or distearate or dioleate, PEG-32 dilaurate or distearate or dioleate, PEG-400 dioleate or distearate; (the surfactants belonging to this group are for instance known as Mapeg, Polyalso, Kessco, Cithrol)
- c) Polyethylene glycol fatty acid mono- and diester mixtures such as for example PEG 4-150 mono and dilaurate, PEG 4-150 mono and dioleate, PEG 4-150 mono and distearate and the like; (the surfactants belonging to this group are for instance known as Kessco)
- d) Polyethylene glycol glycerol fatty acid esters such as for instance PEG-20 glyceryl laurate or glyceryl stearate or glyceryl oleate, PEG-30 glyceryl laurate or glyceryl oleate, PEG-15 glyceryl laurate, PEG-40 glyceryl laurate and the like; (the surfactants belonging to this group are for instance known as Tagat, Glycerox L, Capmul)
- e) Alcohol-oil transesterification products comprising esters of alcohols or polyalcohols such as glycerol, propylene glycol, ethylene glycol, polyethylene glycol, sorbitol, pentaerythritol and the like with natural and/or hydrogenated oils or oil-soluble vitamins such as castor oil, hydrogenated castor oil, vitamin A, vitamin D, vitamin E, vitamin K, an edible vegetable oil e.g. corn oil, olive oil, peanut oil, palm kernel oil, apricot kernel oil, almond oil and the like, such as PEG-20 castor oil or hydrogenated castor oil or corn glycerides or almond glycerides, PEG-23 castor oil, PEG-25 hydrogenated castor oil or trioleate, PEG-35 castor oil, PEG-30 castor oil or hydrogenated castor oil, PEG-38 castor oil, PEG-40 castor oil or hydrogenated castor oil or palm kernel oil, PEG-45 hydrogenated castor oil, PEG-50 castor oil or hydrogenated castor oil, PEG-56 castor oil, PEG-60 castor oil or hydrogenated castor oil or corn glycerides or almond glycerides, PEG-80 hydrogenated castor oil, PEG-100 castor oil or hydrogenated castor oil, PEG-200 castor oil, PEG-8 caprylic/capric glycerides, PEG-6 caprylic/capric glycerides, lauroyl macrogol-32 glyceride, stearyl macrogol glyceride, tocopheryl PEG-1000 succinate (TPGS); (the surfactants belonging

-7-

to this group are for instance known as Emalex, Cremophor, Emulgante, Eumulgin, Nikkol, Thornley, Simulsol, Cerex, Crovol, Labrasol, Softigen, Gelucire, Vitamin E TPGS)

5 f) polyglycerized fatty acids comprising polyglycerol esters of fatty acids such as for instance polyglyceryl-10 laurate or oleate or stearate, polyglyceryl-10 mono and dioleate, polyglyceryl polyricinoleate and the like; (the surfactants belonging to this group are for instance known as Nikkol Decaglyn, Caprol or Polymuls)

g) Sterol derivatives comprising polyethylene glycol derivatives of sterol such as PEG-24 cholesterol ether, PEG-30 cholestanol, PEG-25 phyto sterol, PEG-30 soya sterol and
10 the like; (the surfactants belonging to this group are for instance known as Solulan or Nikkol BPSH)

h) Polyethylene glycol sorbitan fatty acid esters such as for example PEG-10 sorbitan laurate, PEG-20 sorbitan monolaurate or sorbitan tristearate or sorbitan monooleate or sorbitan trioleate or sorbitan monoisostearate or sorbitan monopalmitate or sorbitan
15 monostearate, PEG-4 sorbitan monolaurate, PEG-5 sorbitan monooleate, PEG-6 sorbitan monooleate or sorbitan monolaurate or sorbitan monostearate, PEG-8 sorbitan monostearate, PEG-30 sorbitan tetraoleate, PEG-40 sorbitan oleate or sorbitan tetraoleate, PEG-60 sorbitan tetrastearate, PEG-80 sorbitan monolaurate, PEG sorbitol hexaoleate (Atlas G-1086) and the like; (the surfactants belonging to this group are for
20 instance known as Liposorb, Tween, Dacol MSS, Nikkol, Emalex, Atlas)

i) Polyethylene glycol alkyl ethers such as for instance PEG-10 oleyl ether or cetyl ether or stearyl ether, PEG-20 oleyl ether or cetyl ether or stearyl ether, PEG-9 lauryl ether, PEG-23 lauryl ether (laureth-23), PEG-100 stearyl ether and the like; (the surfactants belonging to this group are for instance known as Volpo, Brij)

25 j) Sugar esters such as for instance sucrose distearate/monostearate, sucrose monostearate or monopalmitate or monolaurate and the like; (the surfactants belonging to this group are for instance known as Sucro ester, Crodesta, Saccharose monolaurate)

k) Polyethylene glycol alkyl phenols such as for instance PEG-10-100 nonyl phenol (Triton X series), PEG-15-100 oyl phenol ether (Triton N series) and the like;

30 l) Polyoxyethylene-polyoxypropylene block copolymers (poloxamers) such as for instance poloxamer 108, poloxamer 188, poloxamer 237, poloxamer 288 and the like; (the surfactants belonging to this group are for instance known as Synperonic PE, Pluronic, Emkalyx, Lutrol, Supronic, Monolan, Pluracare, Pluradac)

m) ionic surfactants including cationic, anionic and zwitterionic surfactants such as the
35 fatty acid salts e.g. sodium oleate, sodium lauryl sulfate, sodium lauryl sarcosinate, sodium dioctyl sulfosuccinate, sodium myristate, sodium palmitate, sodium stearate, sodium ricinoleate and the like; such as bile salts e.g. sodium cholate, sodium

taurocholate, sodium glycocholate and the like; such as phospholipids e.g. egg/soy lecithin, hydroxylated lecithin, lysophosphatidylcholine, phosphatidylcholine, phosphatidyl ethanolamine, phosphatidyl glycerol, phosphatidyl serine and the like; such as phosphoric acid esters e.g. diethanolammonium polyoxyethylene-10 oleyl ether phosphate, esterification products of fatty alcohols or fatty alcohol ethoxylates with phosphoric acid or anhydride; such as carboxylates e.g. succinylated monoglycerides, sodium stearyl fumarate, stearyl propylene glycol hydrogen succinate, mono/diacetylated tartaric acid esters of mono-and diglycerides, citric acid esters of mono-and diglycerides, glyceryl-lacto esters of fatty acids, lactic esters of fatty acids, calcium/sodium stearyl-2-lactylate, calcium/sodium stearyl lactylate, alginate salts, propylene glycol alginate, ether carboxylates and the like; such as sulfates and sulfonates e.g. ethoxylated alkyl sulfates, alkyl benzene sulfates, alpha-olefin sulfonates, acyl isethionates, acyl taurates, alkyl glyceryl ether sulfonates, octyl sulfosuccinate disodium, disodium undecyleneamido-MEA-sulfosuccinate and the like; such as cationic surfactants e.g. hexadecyl triammonium bromide, decyl trimethyl ammonium bromide, cetyl trimethyl ammonium bromide, dodecyl ammonium chloride, alkyl benzyldimethylammonium salts, diisobutyl phenoxyethoxydimethyl benzylammonium salts, alkylpyridinium salts, betaines (lauryl betaine), ethoxylated amines (polyoxyethylene-15 coconut amine) and the like.

When in the above list of suitable surfactants, different possibilities are listed such as for example PEG-20 oleyl ether or cetyl ether or stearyl ether, this means that PEG-20 oleyl ether and PEG-20 cetyl ether and PEG-20 stearyl ether are intended. Thus for instance PEG-20 castor oil or hydrogenated castor oil or corn glycerides or almond glycerides has to be read as PEG-20 castor oil and PEG-20 hydrogenated castor oil and PEG-20 corn glycerides and PEG-20 almond glycerides.

In the compositions of the invention, the surfactant is preferably present at 1 to 70% by weight, more preferably 5 to 55%, most preferably 10 to 50% by weight (relative to the total weight of surfactant, acid and drug). The quantity of surfactant used however will generally be dependent on the quantity of drug and on the drug compound itself. The weight by weight ratio of surfactant to drug will preferably lie in the range 100:1 to 1:5, especially 50:1 to 1:2, more especially 10:1 to 1:1.

Preferred surfactants in the present compositions belong to the group of the polyethylene glycol sorbitan fatty acid esters, the group of the alcohol-oil transesterification products or the group of the polyoxyethylene-polyoxypropylene

block copolymers. More preferably, the surfactants in the present compositions belong to the group of the polyethylene glycol sorbitan fatty acid esters or the group of the alcohol-oil transesterification products. Most preferred surfactants are the surfactants known as Tween, the surfactants known as Cremophor, and Vitamin E TPGS (α -
5 tocopheryl polyethylene glycol succinate, also abbreviated as TPGS), especially Cremophor RH 40 and Vitamin E TPGS.

As an alternative embodiment of the compositions of the present invention, the surfactant may be replaced by a suitable wax, such as for example polyethylene glycol
10 and the like.

The acid used in the compositions of the invention may be any of the water-soluble physiologically tolerable acids, in particular any of the inorganic or, more preferably, organic acids conventionally used in the preparation of acid salts of drug compounds,
15 e.g. citric, fumaric, tartaric, maleic, malic, succinic, oxalic, malonic, benzoic, mandelic and ascorbic acids.

Tartaric acid and more especially citric acid are preferred since the salts they form with drug compounds usually have a reduced tendency to precipitate from aqueous solutions.
20 In general however, any acid which is not so strong as to cause degradation of the surfactant and yet which is capable, on the addition of water, of generating a low pH environment, preferably lower than pH 4 and ideally about pH 2, may be used. The acid may be in liquid (e.g. solution) or solid form; however acids which are solid at ambient conditions in their anhydrous or hydrate forms will generally be preferred.

25 The base used in the compositions of the invention may be any of the water-soluble physiologically tolerable bases, in particular any of the inorganic or, organic bases conventionally used in the preparation of alkaline salts of drug compounds, e.g. the alkali and earth alkaline metal bases, e.g. lithium-, sodium-, potassium-, magnesium- or
30 calcium hydroxide, hydrocarbonate or carbonate and the like, NH_3 , benzathine, *N*-methyl-D-glucamine, hydrabamine, ethanolamine, diethanolamine, triethanolamine and the like, amino acids such as, for example, arginine, lysine and the like.

In the compositions of the invention, the acid is present at a acid:drug ratio of at least
35 1:1 by weight, preferably the weight by weight ratio of acid:drug lies in the range of from 1:1 to 100:1, more preferably from 1:1 to 50:1, even more preferably from 1:1 to 10:1 and most preferred from 3:1 to 10:1. The amount of acid used will be dependent upon the selected acid and drug compound, but in general an increase in the relative

-10-

proportion of acid will result in an acceleration of drug dissolution on contact with water. The amount of acid used will normally be at least the amount necessary to form an acidic microenvironment upon contact with water, in particular an aqueous body fluid, in which the solubility of the drug compound is increased.

5

The acid forms a significant proportion of the present compositions that dissolve rapidly in body fluids.

Therefore the present invention also relates to a pharmaceutical composition comprising a basic drug compound, a surfactant and a physiologically tolerable water-soluble acid characterized in that the weight by weight percentage of acid lies in the range from 30 to 95%, preferably from 45 to 95%, more preferably from 50 to 90%, most preferred from 50 to 65%. Preferably the weight by weight percentage is relative to the weight of the basic drug compound, the surfactant and the physiologically tolerable water-soluble acid and optionally the polymer.

Alternatively, the present invention also relates to a pharmaceutical composition comprising a basic drug compound, a surfactant and a physiologically tolerable water-soluble acid characterized in that the acid:drug compound molar ratio is at least 3:1, preferably at least 5:1, more preferably at least 10:1.

The present invention also relates to a pharmaceutical composition comprising a basic drug compound, a surfactant and a physiologically tolerable water-soluble acid characterized in that the weight by weight percentage of acid lies in the range from 30 to 95% and characterized in that the acid:drug compound ratio is at least 1:1 by weight. Alternatively, the present invention also relates to a pharmaceutical composition comprising a basic drug compound, a surfactant and a physiologically tolerable water-soluble acid characterized in that the weight by weight percentage of acid lies in the range from 30 to 95% and characterized in that the acid:drug compound molar ratio is at least 3:1.

The quantities specified above for the acid also account for the base in those compositions of the present invention which comprise an acidic drug compound, a surfactant and a base.

While the benefits of the compositions of the invention are most pronounced where the drug compound is no more than sparingly soluble, the drug dissolution profiles achievable using the combination of drug, surfactant and acid (or base) are such that particularly improved drug uptake profiles may be achieved even where the drug

-11-

compound is more soluble.

Hence, the drug compound used in the compositions of the invention may be any organic or inorganic material. The drug compound may exert a local physiological effect, as well as a systemic effect, either after penetrating the mucosa or - in the case of oral administration - after transport to the gastro-intestinal tract with saliva.

Preferably, the drug compound is no more than sparingly soluble, *i.e.* which is sparingly soluble, slightly soluble, very slightly soluble, or practically insoluble in pure water at 21°C (ie. requiring from 30, from 100, from 1000 or from 10000 parts water to put 1 part by weight drug compound into solution). In particular, the drug is a basic drug compound. The term basic drug compound defines a drug compound with a pKa value above 7 or a drug compound which may be solubilized in acid/acidic medium. The term acidic drug compound defines a drug compound with a pKa under 7 or a drug compound which may be solubilized in base/basic (alkaline) medium.


Examples of poorly water-soluble compounds that may be used in the compositions of the invention include

nifedipine,

- itraconazole (described in EP-A-6711),
saperconazole (see US-A-4916134),
(-)-[2S-[2 α ,4 α (S*)]]-4-[4-[4-[2-(4-chlorophenyl)-2-[(4-methyl-4H-1,2,4-triazol-3-yl)thio]methyl]-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one (Compound 40 in WO96/13499),
cisapride (described in EP-A-76530),
(B)-N-[4-[2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl]phenyl]-2-benzothiazolamine (described in WO-97/49704); methyl 6,11-dihydro-11-[1-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]-4-piperidinyldene]-5H-imidazo[2,1-b][3]benzazepine-3-carboxylate (described in WO-97/34897);
4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-1,3,5-triazin-2-yl]amino]benzonitrile (described in EP-0,834,507);
(B-cis)-1-[4-[4-[4-[4-(2,4-difluorophenyl)-4-(1H-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-2-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-3-(1-methylethyl)-2-imidazolidinone;
(2S-cis)-1-[4-[4-[4-[4-(2,4-difluorophenyl)-4-(1H-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-2-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-3-(1-methylethyl)-2-imidazolidinone;

-12-

- 3-[2-[3,4-dihydrobenzofuro[3,2-c]pyridin-2(1*H*)-yl]ethyl]-2-methyl-4*H*-pyrido-
[1,2-a]pyrimidin-4-one;
N-[2-[4-(4-chlorophenyl)-1-piperazinyl]ethyl]-2-benzothiazolamine;
(B1)-*N*-[4-[2-(dimethylamino)-1-(1*H*-imidazol-1-yl)propyl]phenyl]-2-benzo-
thiazolamine (described in WO-97/49704)
5 (B)-6-[amino(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-
1-methyl-2(1*H*)-quinolinone;
(B)-*N*-[4-[2-ethyl-1-(1*H*-1,2,4-triazol-1-yl)butyl]phenyl]-2-benzothiazolamine;
3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-*N,N*-dipropylpyrazolo-
10 [2,3-a]pyrimidin-7-amine monohydrochloride;
(S)-[1-[2-[3-[(2,3-dihydro-1*H*-inden-2-yl)oxy]-4-methoxyphenyl]propyl]-1*H*-imidazol-
2-yl]cyanamide;
(+)-(B-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-
N-(2,6-dimethylphenyl)-1-piperazineacetamide (S)-hydroxybutanedioate (1:1);
15 (-)-[2*S*-[2 α ,4 α (S*)]]-4-[4-[4-[4-[[2-(4-chlorophenyl)-2-[[[(4-methyl-4*H*-1,2,4-triazol-3-
yl)thio]methyl]-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-
2-(1-methylpropyl)-3*H*-1,2,4-triazol-3-one;
(+)-(trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-*N*-
(2,6-dimethylphenyl)-1-piperazine acetamide;
20 the compounds described in WO 99/50256, WO 00/27828, WO 01/85699, WO
01/85700, WO 01/64674 and EP 0,834,507; said documents incorporated herein as
reference;
compounds of formula (I) (reference therefore is made to PCT/EP02/08953)



- 25 a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a
stereochemically isomeric form thereof, wherein

-a¹=a²-a³=a⁴- represents a bivalent radical of formula

-CH=CH-CH=CH- (a-1);

-N=CH-CH=CH- (a-2);

30 -N=CH-N=CH- (a-3);

-N=CH-CH=N- (a-4);

-N=N-CH=CH- (a-5);

-b¹=b²-b³=b⁴- represents a bivalent radical of formula

-CH=CH-CH=CH- (b-1);

-13-

-N=CH-CH=CH- (b-2);

-N=CH-N=CH- (b-3);

-N=CH-CH=N- (b-4);

-N=N-CH=CH- (b-5);

5 n is 0, 1, 2, 3 or 4; and in case $-a^1=a^2-a^3=a^4-$ is (a-1), then n may also be 5;

m is 1, 2, 3 and in case $-b^1=b^2-b^3=b^4-$ is (b-1), then m may also be 4;

R¹ is hydrogen; aryl; formyl; C₁₋₆alkylcarbonyl; C₁₋₆alkyl; C₁₋₆alkyloxycarbonyl;

C₁₋₆alkyl substituted with formyl, C₁₋₆alkylcarbonyl, C₁₋₆alkyloxycarbonyl,

C₁₋₆alkylcarbonyloxy; C₁₋₆alkyloxyC₁₋₆alkylcarbonyl substituted with

10 C₁₋₆alkyloxycarbonyl;

each R² independently is hydroxy, halo, C₁₋₆alkyl optionally substituted with cyano or

-C(=O)R⁶, C₃₋₇cycloalkyl, C₂₋₆alkenyl optionally substituted with one or more


halogen atoms or cyano, C₂₋₆alkynyl optionally substituted with one or more halogen

atoms or cyano, C₁₋₆alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or

15 di(C₁₋₆alkyl)amino, polyhalomethyl, polyhalomethylthio, -S(=O)_pR⁶, -NH-S(=O)_pR⁶,

-C(=O)R⁶, -NHC(=O)H, -C(=O)NHNH₂, -NHC(=O)R⁶, -C(=NH)R⁶ or a radical of

formula



wherein each A₁ independently is N, CH or CR⁶; and

20 A₂ is NH, O, S or NR⁶;

X₁ is -NR⁵-, -NH-NH-, -N=N-, -O-, -C(=O)-, C₁₋₄alkanediyl, -CHOH-, -S-, -S(=O)_p-,
-X₂-C₁₋₄alkanediyl- or -C₁₋₄alkanediyl-X₂-;

X₂ is -NR⁵-, -NH-NH-, -N=N-, -O-, -C(=O)-, -CHOH-, -S-, -S(=O)_p-;

R³ is NHR¹³; NR¹³R¹⁴; -C(=O)-NHR¹³; -C(=O)-NR¹³R¹⁴; -C(=O)-R¹⁵; -CH=N-NH-

25 C(=O)-R¹⁶; C₁₋₆alkyl substituted with one or more substituents each

independently selected from cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷;

C₁₋₆alkyl substituted with one or more substituents each independently

selected from cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷ and

wherein 2 hydrogen atoms bound at the same carbon atom are replaced by

30 C₁₋₄alkanediyl; C₁₋₆alkyl substituted with hydroxy and a second substituent

selected from cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷;

C₁₋₆alkyloxyC₁₋₆alkyl optionally substituted with one or more substituents each

independently selected from cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷;

35 C₂₋₆alkenyl substituted with one or more substituents each independently


selected from halo, cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷;

- C2-6alkynyl substituted with one or more substituents each independently selected from halo, cyano, NR^9R^{10} , $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 ; $-\text{C}(=\text{N}-\text{O}-\text{R}^8)-\text{C}_{1-4}\text{alkyl}$; R^7 or $-\text{X}_3-\text{R}^7$;
- X_3 is $-\text{NR}^5-$, $-\text{NH}-\text{NH}-$, $-\text{N}=\text{N}-$, $-\text{O}-$, $-\text{C}(=\text{O})-$, $-\text{S}-$, $-\text{S}(=\text{O})_p-$, $-\text{X}_2-\text{C}_{1-4}\text{alkanediyl}-$,
 5 $-\text{C}_{1-4}\text{alkanediyl}-\text{X}_{2a}-$, $-\text{C}_{1-4}\text{alkanediyl}-\text{X}_{2b}-\text{C}_{1-4}\text{alkanediyl}$,
 $-\text{C}(=\text{N}-\text{OR}^8)-\text{C}_{1-4}\text{alkanediyl}-$;
 with X_{2a} being $-\text{NH}-\text{NH}-$, $-\text{N}=\text{N}-$, $-\text{O}-$, $-\text{C}(=\text{O})-$, $-\text{S}-$, $-\text{S}(=\text{O})_p-$; and
 with X_{2b} being $-\text{NH}-\text{NH}-$, $-\text{N}=\text{N}-$, $-\text{C}(=\text{O})-$, $-\text{S}-$, $-\text{S}(=\text{O})_p-$;
- R^4 is halo, hydroxy, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{3-7}\text{cycloalkyl}$, $\text{C}_{1-6}\text{alkyloxy}$, cyano, nitro,
 10 $\text{polyhaloC}_{1-6}\text{alkyl}$, $\text{polyhaloC}_{1-6}\text{alkyloxy}$, aminocarbonyl, $\text{C}_{1-6}\text{alkyloxycarbonyl}$,
 $\text{C}_{1-6}\text{alkylcarbonyl}$, formyl, amino, mono- or di($\text{C}_{1-4}\text{alkyl}$)amino or R^7 ;
- R^5 is hydrogen; aryl; formyl; $\text{C}_{1-6}\text{alkylcarbonyl}$; $\text{C}_{1-6}\text{alkyl}$; $\text{C}_{1-6}\text{alkyloxycarbonyl}$;
 $\text{C}_{1-6}\text{alkyl}$ substituted with formyl, $\text{C}_{1-6}\text{alkylcarbonyl}$, $\text{C}_{1-6}\text{alkyloxycarbonyl}$ or
 $\text{C}_{1-6}\text{alkylcarbonyloxy}$; $\text{C}_{1-6}\text{alkyloxyC}_{1-6}\text{alkylcarbonyl}$ substituted with
 15 $\text{C}_{1-6}\text{alkyloxycarbonyl}$;
- R^6 is $\text{C}_{1-4}\text{alkyl}$, amino, mono- or di($\text{C}_{1-4}\text{alkyl}$)amino or $\text{polyhaloC}_{1-4}\text{alkyl}$;
- R^7 is a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic
 carbocycle or a monocyclic, bicyclic or tricyclic saturated, partially saturated or
 aromatic heterocycle, wherein each of said carbocyclic or heterocyclic ring systems
 20 may optionally be substituted with one, two, three, four or five substituents each
 independently selected from halo, hydroxy, mercapto, $\text{C}_{1-6}\text{alkyl}$, hydroxy $\text{C}_{1-6}\text{alkyl}$,
 amino $\text{C}_{1-6}\text{alkyl}$, mono or di($\text{C}_{1-6}\text{alkyl}$)amino $\text{C}_{1-6}\text{alkyl}$, formyl, $\text{C}_{1-6}\text{alkylcarbonyl}$,
 $\text{C}_{3-7}\text{cycloalkyl}$, $\text{C}_{1-6}\text{alkyloxy}$, $\text{C}_{1-6}\text{alkyloxycarbonyl}$, $\text{C}_{1-6}\text{alkylthio}$, cyano, nitro,
 $\text{polyhaloC}_{1-6}\text{alkyl}$, $\text{polyhaloC}_{1-6}\text{alkyloxy}$, aminocarbonyl, $-\text{CH}(=\text{N}-\text{O}-\text{R}^8)$, R^{7a} ,
 25 $-\text{X}_3-\text{R}^{7a}$ or $\text{R}^{7a}-\text{C}_{1-4}\text{alkyl}$;
- R^{7a} is a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic
 carbocycle or a monocyclic, bicyclic or tricyclic saturated, partially saturated or
 aromatic heterocycle, wherein each of said carbocyclic or heterocyclic ring systems
 may optionally be substituted with one, two, three, four or five substituents each
 30 independently selected from halo, hydroxy, mercapto, $\text{C}_{1-6}\text{alkyl}$, hydroxy $\text{C}_{1-6}\text{alkyl}$,
 amino $\text{C}_{1-6}\text{alkyl}$, mono or di($\text{C}_{1-6}\text{alkyl}$)amino $\text{C}_{1-6}\text{alkyl}$, formyl, $\text{C}_{1-6}\text{alkylcarbonyl}$,
 $\text{C}_{3-7}\text{cycloalkyl}$, $\text{C}_{1-6}\text{alkyloxy}$, $\text{C}_{1-6}\text{alkyloxycarbonyl}$, $\text{C}_{1-6}\text{alkylthio}$, cyano, nitro,
 $\text{polyhaloC}_{1-6}\text{alkyl}$, $\text{polyhaloC}_{1-6}\text{alkyloxy}$, aminocarbonyl, $-\text{CH}(=\text{N}-\text{O}-\text{R}^8)$;
- R^8 is hydrogen, $\text{C}_{1-4}\text{alkyl}$, aryl or aryl $\text{C}_{1-4}\text{alkyl}$;
- 35 R^9 and R^{10} each independently are hydrogen; hydroxy; $\text{C}_{1-6}\text{alkyl}$; $\text{C}_{1-6}\text{alkyloxy}$;
 $\text{C}_{1-6}\text{alkylcarbonyl}$; $\text{C}_{1-6}\text{alkyloxycarbonyl}$; amino; mono- or di($\text{C}_{1-6}\text{alkyl}$)amino;
 mono- or di($\text{C}_{1-6}\text{alkyl}$)aminocarbonyl; $-\text{CH}(=\text{NR}^{11})$ or R^7 , wherein each of the

-15-

- aforementioned C₁₋₆alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C₁₋₆alkyloxy, hydroxyC₁₋₆alkyloxy, carboxyl, C₁₋₆alkyloxycarbonyl, cyano, amino, imino, mono- or di(C₁₋₄alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O)_pR⁶, -NH-S(=O)_pR⁶, -C(=O)R⁶, -NHC(=O)H, -C(=O)NHNH₂, -NHC(=O)R⁶, -C(=NH)R⁶, R⁷; or

R⁹ and R¹⁰ may be taken together to form a bivalent or trivalent radical of formula



- R¹¹ is cyano; C₁₋₄alkyl optionally substituted with C₁₋₄alkyloxy, cyano, amino, mono- or di(C₁₋₄alkyl)amino or aminocarbonyl; C₁₋₄alkylcarbonyl; C₁₋₄alkyloxycarbonyl; aminocarbonyl; mono- or di(C₁₋₄alkyl)aminocarbonyl;

R¹² is hydrogen or C₁₋₄alkyl;


- R¹³ and R¹⁴ each independently are C₁₋₆alkyl optionally substituted with cyano or aminocarbonyl, C₂₋₆alkenyl optionally substituted with cyano or aminocarbonyl, C₂₋₆alkynyl optionally substituted with cyano or aminocarbonyl;

R¹⁵ is C₁₋₆alkyl substituted with cyano or aminocarbonyl;

R¹⁶ is C₁₋₆alkyl optionally substituted with cyano or aminocarbonyl, or R⁷;

p is 1 or 2;

- aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl, mono or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, C₁₋₆alkylcarbonyl, C₃₋₇cycloalkyl, C₁₋₆alkyloxy, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylthio, cyano, nitro, polyhaloC₁₋₆alkyl, polyhaloC₁₋₆alkyloxy, aminocarbonyl, R⁷ or -X₃-R⁷;
- compounds as described in WO99/50250 incorporated herein as reference, namely compounds of formula (I-A)



-16-

a *N*-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein

A is CH, CR⁴ or N;

n is 0, 1, 2, 3 or 4;

5 Q is hydrogen or -NR¹R²;

R¹ and R² are each independently selected from hydrogen, hydroxy, C₁-12alkyl, C₁-12alkyloxy, C₁-12alkylcarbonyl, C₁-12alkyloxycarbonyl, aryl, amino, mono- or di(C₁-12alkyl)amino, mono- or di(C₁-12alkyl)aminocarbonyl wherein each of the
10 aforementioned C₁-12alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C₁-6alkyloxy, hydroxyC₁-6alkyloxy, carboxyl, C₁-6alkyloxycarbonyl, cyano, amino, imino, aminocarbonyl, aminocarbonylamino, mono- or di(C₁-6alkyl)amino, aryl and Het; or

15 R¹ and R² taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C₁-12alkyl)aminoC₁-4alkylidene;

R³ is hydrogen, aryl, C₁-6alkylcarbonyl, C₁-6alkyl, C₁-6alkyloxycarbonyl, C₁-6alkyl substituted with C₁-6alkyloxycarbonyl; and

each R⁴ independently is hydroxy, halo, C₁-6alkyl, C₁-6alkyloxy, cyano, amino-carbonyl, nitro, amino, trihalomethyl, trihalomethyloxy or C₁-6alkyl substituted with
20 cyano or aminocarbonyl;

R⁵ is hydrogen or C₁-4alkyl;

L is C₁-10alkyl, C₃-10alkenyl, C₃-10alkynyl, C₃-7cycloalkyl, or C₁-10alkyl substituted with one or two substituents independently selected from C₃-7cycloalkyl, indanyl, indolyl and phenyl, wherein said phenyl, indanyl and indolyl may be substituted with one, two,
25 three, four or where possible five substituents each independently selected from halo, hydroxy, C₁-6alkyl, C₁-6alkyloxy, cyano, aminocarbonyl, C₁-6alkyloxycarbonyl, formyl, nitro, amino, trihalomethyl, trihalomethyloxy and C₁-6alkylcarbonyl; or

L is -X¹-R⁶ or -X²-Alk-R⁷ wherein

30 R⁶ and R⁷ each independently are phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, C₁-6alkyl, C₁-6alkyloxy, C₁-6alkylcarbonyl, C₁-6alkyloxycarbonyl, formyl, cyano, aminocarbonyl, nitro, amino, trihalomethyloxy and trihalomethyl; and X¹ and X² are each independently -NR³-, -NH-NH-, -N=N-, -O-, -S-, -S(=O)- or -S(=O)₂-;


35 Alk is C₁-4alkanediyl;

-17-

aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, nitro and trifluoromethyl;

Het is an aliphatic or aromatic heterocyclic radical; said aliphatic heterocyclic radical is selected from pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl and tetrahydrothienyl wherein each of said aliphatic heterocyclic radical may optionally be substituted with an oxo group; and said aromatic heterocyclic radical is selected from pyrrolyl, furanyl, thienyl, pyridyl, pyrimidinyl, pyrazinyl and pyridazinyl wherein each of said aromatic heterocyclic radical may optionally be substituted with hydroxy;

compounds described in WO 00/27825 incorporated herein as reference, namely compounds of formula (I-B)



the *N*-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, wherein

-a¹=a²-a³=a⁴- represents a bivalent radical of formula

-CH=CH-CH=CH- (a-1);

-N=CH-CH=CH- (a-2);

-N=CH-N=CH- (a-3);

-N=CH-CH=N- (a-4);

-N=N-CH=CH- (a-5);

n is 0, 1, 2, 3 or 4; and in case -a¹=a²-a³=a⁴- is (a-1), then n may also be 5;

R¹ is hydrogen; aryl; formyl; C₁₋₆alkylcarbonyl; C₁₋₆alkyl; C₁₋₆alkyloxycarbonyl;

C₁₋₆alkyl substituted with formyl, C₁₋₆alkylcarbonyl, C₁₋₆alkyloxycarbonyl,

C₁₋₆alkylcarbonyloxy; C₁₋₆alkyloxyC₁₋₆alkylcarbonyl substituted with C₁₋₆alkyloxycarbonyl;

each R² independently is hydroxy, halo, C₁₋₆alkyl optionally substituted with cyano or

-C(=O)R⁶, C₃₋₇cycloalkyl, C₂₋₆alkenyl optionally substituted with one or more

halogen atoms or cyano, C₂₋₆alkynyl optionally substituted with one or more halogen


atoms or cyano, C₁₋₆alkyloxy, C₁₋₆alkyloxycarbonyl, carboxyl, cyano, nitro, amino,

mono- or di(C₁₋₆alkyl)amino, polyhalomethyl, polyhalomethyloxy,

polyhalomethylthio, -S(=O)_pR⁶, -NH-S(=O)_pR⁶, -C(=O)R⁶, -NHC(=O)H,

-C(=O)NHNH₂, -NHC(=O)R⁶, -C(=NH)R⁶ or a radical of formula

-18-



wherein each A independently is N, CH or CR⁶;

B is NH, O, S or NR⁶;

p is 1 or 2; and

R⁶ is methyl, amino, mono- or

dimethylamino or polyhalomethyl;

L is C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₇cycloalkyl, whereby each of said aliphatic group may be substituted with one or two substituents independently selected from

* C₃₋₇cycloalkyl,

* indolyl or isoindolyl, each optionally substituted with one, two, three or four substituents each independently selected from halo, C₁₋₆alkyl, hydroxy, C₁₋₆alkyloxy, cyano, aminocarbonyl, nitro, amino, polyhalomethyl, polyhalomethyloxy and C₁₋₆alkylcarbonyl,

* phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in R²; or

L is -X-R³ wherein

R³ is phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five

substituents each independently selected from the substituents defined in R²; and

X is -NR¹-, -NH-NH-, -N=N-, -O-, -C(=O)-, -CHOH-, -S-, -S(=O)- or -S(=O)₂-;

Q represents hydrogen, C₁₋₆alkyl, halo, polyhaloC₁₋₆alkyl or -NR⁴R⁵; and

R⁴ and R⁵ are each independently selected from hydrogen, hydroxy, C₁₋₁₂alkyl,

C₁₋₁₂alkyloxy, C₁₋₁₂alkylcarbonyl, C₁₋₁₂alkyloxycarbonyl, aryl, amino, mono- or di(C₁₋₁₂alkyl)amino, mono- or di(C₁₋₁₂alkyl)aminocarbonyl wherein each of the aforementioned C₁₋₁₂alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C₁₋₆alkyloxy, hydroxyC₁₋₆alkyloxy, carboxyl, C₁₋₆alkyloxycarbonyl, cyano, amino, imino, mono- or di(C₁₋₆alkyl)amino, polyhalomethyl, polyhalomethyloxy,

polyhalomethylthio, -S(=O)_pR⁶, -NH-S(=O)_pR⁶, -C(=O)R⁶, -NHC(=O)H, -C(=O)NHNH₂, -NHC(=O)R⁶, -C(=NH)R⁶, aryl and Het; or

R⁴ and R⁵ taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C₁₋₁₂alkyl)aminoC₁₋₄alkylidene;

Y represents hydroxy, halo, C₃₋₇cycloalkyl, C₂₋₆alkenyl optionally substituted with one

-19-

- or more halogen atoms, C₂₋₆alkynyl optionally substituted with one or more halogen atoms, C₁₋₆alkyl substituted with cyano or -C(=O)R⁶, C₁₋₆alkyloxy, C₁₋₆alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C₁₋₆alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O)_pR⁶, -NH-S(=O)_pR⁶, -C(=O)R⁶, -NHC(=O)H, -C(=O)NHNH₂, -NHC(=O)R⁶, -C(=NH)R⁶ or aryl;
- aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₁₋₆alkyloxy, cyano, nitro, polyhaloC₁₋₆alkyl and polyhaloC₁₋₆alkyloxy;
- Het is an aliphatic or aromatic heterocyclic radical; said aliphatic heterocyclic radical is selected from pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl and tetrahydrothienyl wherein each of said aliphatic heterocyclic radical may optionally be substituted with an oxo group; and said aromatic heterocyclic radical is selected from pyrrolyl, furanyl, thienyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl wherein each of said aromatic heterocyclic radical may optionally be substituted with hydroxy;

Particular compounds of formula (I) are compounds 1, 25, 84, 133, 152, 179, 233, 239, 247, 248 (see Tables 3, 4 and 5), their *N*-oxides, pharmaceutically acceptable addition salts, quaternary amines and stereochemically isomeric forms thereof.

Most preferred compound of formula (I) is :
 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile;
 a *N*-oxide, an addition salt, a quaternary amine and a stereochemically isomeric form thereof.

Particular compounds of formula (I-A) are :
 4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-2-pyrimidinyl]amino]benzonitrile;
 6-[(2,6-dichlorophenyl)methyl]-*N*2-(4-fluorophenyl)-2,4-pyrimidinediamine;
 4-[[4-[(2,4-dichlorophenyl)methyl]-6-[(4-hydroxybutyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[(3-hydroxypropyl)amino]-2-pyrimidinyl]amino]benzonitrile;
N-[2-[(4-cyanophenyl)amino]-6-[(2,6-dichlorophenyl)methyl]-4-pyrimidinyl]-acetamide;

- N*-[2-[(4-cyanophenyl)amino]-6-[(2,6-dichlorophenyl)methyl]-4-pyrimidinyl]-butanamide;
- 4-[[2-amino-6-(2,6-dichlorophenoxy)-4-pyrimidinyl]amino]benzonitrile;
- 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[(2-hydroxy-2-phenylethyl)amino]-2-pyrimidinyl]amino]benzonitrile;
- 5 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]-2-pyrimidinyl]amino]benzonitrile;
- 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[[2-(2-hydroxyethoxy)ethyl]amino]-2-pyrimidinyl]amino]benzonitrile;
- 10 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[(2,3-dihydroxypropyl)amino]-2-pyrimidinyl]amino]benzonitrile;
- 4-[[4-[(2,6-dichlorophenyl)methyl]-6-(hydroxyamino)-2-pyrimidinyl]amino]benzonitrile;
- 4-[[4-[(2-cyanoethyl)amino]-6-[(2,6-dichlorophenyl)methyl]-2-pyrimidinyl]amino]benzonitrile;
- 15 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-pyrimidinyl]amino]benzonitrile;
- 4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-5-methyl-2-pyrimidinyl]amino]benzonitrile;
- 20 *N*2-(4-bromophenyl)-6-[(2,6-dichlorophenyl)methyl]-5-methyl-2,4-pyrimidinediamine;
- 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
- 4-[[2-[(2,4,6-trimethylphenyl)amino]-4-pyrimidinyl]amino]benzonitrile;
- 4-[[4-[(2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
- 4-[[4-(2,4,6-trimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile;
- 25 4-[[4-[(2,6-dichlorophenyl)thio]-2-pyrimidinyl]amino]benzonitrile;
- 4-[[4-[[2,6-dibromo-4-(1-methylethyl)phenyl]amino]-2-pyrimidinyl]amino]benzonitrile;
- 4-[[4-[[2,6-dichloro-4-(trifluoromethyl)phenyl]amino]-2-pyrimidinyl]amino]benzonitrile;
- 30 4-[[4-[(2,4-dichloro-6-methylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
- 4-[[2-[(cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylbenzonitrile;
- 4-[[4-[(2,4-dibromo-6-fluorophenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
- 4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-5-methyl-2-pyrimidinyl]amino]benzeneacetonitrile;
- 35 4-[[4-[methyl(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
- 4-[[4-[(2,4,6-trichlorophenyl)amino]-2-pyrimidinyl]amino]benzonitrile ;
- 4-[[4-[(2,4,6-trimethylphenyl)thio]-2-pyrimidinyl]amino]benzonitrile;

- 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 4-[[4-amino-6-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 4-[[2-amino-6-[(2,4,6-trimethylphenyl)amino]-4-pyrimidinyl]amino]benzonitrile;
 4-[[4-(2-bromo-4-chloro-6-methylphenoxy)-2-pyrimidinyl]amino]benzonitrile;
 5 4-[[4-[(4-chloro-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 3,5-dichloro-4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]benzonitrile;
 4-[[4-[[2,6-dichloro-4-(trifluoromethoxy)phenyl]amino]-2-pyrimidinyl]amino]-
 benzonitrile;
 4-[[4-[(2,4-dibromo-3,6-dichlorophenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 10 4-[[4-[(2,6-dibromo-4-propylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzamide;
 4-[[4-[(4-(1,1-dimethylethyl)-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]-
 benzonitrile;
 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethylbenzonitrile;
 15 4-[[4-[(4-chloro-2,6-dimethylphenyl)amino]-5-methyl-2-pyrimidinyl]amino]-
 benzonitrile;
 4-[[2-[(4-cyanophenyl)amino]-5-methyl-4-pyrimidinyl]amino]-3,5-dimethylbenzonitrile;
 4-[[4-[[4-(1,1-dimethylethyl)-2,6-dimethylphenyl]amino]-5-methyl-2-pyrimidinyl]-
 amino]benzonitrile;
 20 4-[[4-[(4-bromo-2,6-dimethylphenyl)amino]-5-methyl-2-pyrimidinyl]amino]-
 benzonitrile;
 4-[[5-methyl-4-[(2,4,6-trimethylphenyl)thio]-2-pyrimidinyl]amino]benzonitrile;
 4-[[4-[(2,6-dibromo-4-propylphenyl)amino]-5-methyl-2-pyrimidinyl]amino]-
 benzonitrile;
 25 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzamide, *N*3-oxide;
*N*2-(4-chlorophenyl)-*N*4-(2,4,6-trimethylphenyl)-2,4-pyrimidinediamine;
 4-[[4-[[2,6-dibromo-4-(1-methylethyl)phenyl]amino]-5-methyl-2-pyrimidinyl]amino]-
 benzonitrile;
 4-[[2-[(4-cyanophenyl)amino]-5-methyl-4-pyrimidinyl]amino]-3,5-dimethyl-
 30 benzonitrile;
 4-[[4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 a *N*-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric
 form thereof.

- 35 Most preferred compounds of formula (I-A) are :

4-[[2-[(cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylbenzonitrile; or
 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;

-22-

a *N*-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof.

Particular compounds of formula (I-B) are :

- 5 4-[[4-amino-5-chloro-6-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]-benzonitrile;
- 4-[[5-chloro-4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
- 4-[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile;
- 4-[[4-amino-5-chloro-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]-
- 10 benzonitrile;
- 4-[[5-bromo-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]-benzonitrile;
- 4-[[4-amino-5-chloro-6-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]-benzonitrile; or
- 15 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]-benzonitrile;
- a *N*-oxide, an addition salt, a quaternary amine and a stereochemically isomeric form thereof.

- 20 Most preferred compound of formula (I-B) is ;
- 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]-benzonitrile;
- a *N*-oxide, an addition salt, a quaternary amine and a stereochemically isomeric form thereof.

25

Other suitable drug compounds in the compositions of the present invention are

- analgesic and anti-inflammatory drugs (NSAIDs, fentanyl, indomethacin, ibuprofen, ketoprofen, nabumetone, paracetamol, piroxicam, tramadol, COX-2 inhibitors such as celecoxib and rofecoxib) ;
- 30 - anti-arrhythmic drugs (procainamide, quinidine, verapamil) ;
- antibacterial and antiprotozoal agents (amoxicillin, ampicillin, benzathine penicillin, benzylpenicillin, cefaclor, cefadroxil, cefprozil, cefuroxime axetil, cephalixin, chloramphenicol, chloroquine, ciprofloxacin, clarithromycin, clavulanic acid, clindamycin, doxyxycline, erythromycin, flucloxacillin sodium, halofantrine,
- 35 isoniazid, kanamycin sulphate, lincomycin, mefloquine, minocycline, nafcillin sodium, nalidixic acid, neomycin, norfloxacin, ofloxacin, oxacillin, phenoxymethyl-penicillin potassium, pyrimethamine-sulfadoxime, streptomycin);

-23-

- anti-coagulants (warfarin) ;
- antidepressants (amitriptyline, amoxapine, butriptyline, clomipramine, desipramine, dothiepin, doxepin, fluoxetine, reboxetine, amineptine, selegiline, gepirone, imipramine, lithium carbonate, mianserin, milnacipran, nortriptyline, paroxetine, sertraline ; 3-[2-[3,4-dihydrobenzofuro[3,2-c]pyridin-2(1*H*)-yl]ethyl]-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one) ;
- 5 - anti-diabetic drugs (glibenclamide, metformin, RWJ-394718, RWJ-394720, RWJ-666589, RWJ-37082) ;
- anti-epileptic drugs (carbamazepine, clonazepam, ethosuximide, gabapentin, lamotrigine, levetiracetam, phenobarbitone, phenytoin, primidone, tiagabine, topiramate, valpromide, vigabatrin) ;
- 10 - antifungal agents (amphotericin, clotrimazole, econazole, fluconazole, flucytosine, griseofulvin, itraconazole, ketoconazole, miconazole nitrate, nystatin, terbinafine, voriconazole, echinocandins) ;
- 15 - antihistamines (astemizole, cinnarizine, cyproheptadine, decarboethoxyloratadine, fexofenadine, flunarizine, levocabastine, loratadine, norastemizole, oxatomide, promethazine, terfenadine, cetirizine) ;
- anti-hypertensive drugs (captopril, enalapril, ketanserin, lisinopril, minoxidil, prazosin, ramipril, reserpine, terazosin) ;
- 20 - anti-muscarinic agents (atropine sulphate, hyoscine) ;
- antineoplastic agents and antimetabolites (platinum compounds, such as cisplatin, carboplatin; taxanes, such as paclitaxel, docetaxel; tecans, such as camptothecin, irinotecan, topotecan; vinca alkaloids, such as vinblastine, vindesine, vincristine, vinorelbine; nucleoside derivatives and folic acid antagonists such as 5-fluorouracil, capecitabine, gemcitabine, mercaptopurine, thioguanine, cladribine, methotrexate; 25 alkylating agents, such as the nitrogen mustards, e.g. cyclophosphamide, chlorambucil, chlormethine, iphosphamide, melphalan, or the nitrosoureas, e.g. carmustine, lomustine, or other alkylating agents, e.g. busulphan, dacarbazine, procarbazine, thiotepa; antibiotics, such as daunorubicin, doxorubicin, idarubicin, epirubicin, bleomycin, dactinomycin, mitomycin; HER 2 antibody, such as trastuzumab; podophyllotoxin derivatives, such as etoposide, teniposide; farnesyl transferase inhibitors, e.g. zarrestin; anthracycline derivatives, such as mitoxantrone); imatinib ;
- 30 - anti-migraine drugs (alniditan, naratriptan, sumatriptan, almotriptan) ;
- 35 - anti-Parkinsonian drugs (bromocriptine mesylate, levodopa, selegiline, rasagiline) ;
- antipsychotic, hypnotic and sedating agents (alprazolam, buspirone, chlordiazepoxide, chlorpromazine, clozapine, diazepam, flupenthixol, fluphenazine, flurazepam,

-24-

- 9-hydroxyrisperidone, lorazepam, mazapertine, olanzapine, oxazepam, pimozone, pipamperone, piracetam, promazine, risperidone, selfotel, seroquel, sertindole, sulpiride, temazepam, thiothixene, triazolam, trifluoperidol, ziprasidone, zolpidem, bromperidol, fluperidol, haloperidol, quetiapine, aripiprazole) ;
- 5 - anti-stroke agents (lubeluzole, lubeluzole oxide, riluzole, aptiganel, eliprodil, remacemide) ;
- antitussive (dextromethorphan, laevodropropizine) ;
- antivirals (acyclovir, ganciclovir, loviride, zidovudine, lamivudine, zidovudine + lamivudine, didanosine, zalcitabine, stavudine, abacavir, lopinavir, amprenavir, nevirapine, efavirenz, delavirdine, indinavir, nelfinavir, ritonavir, saquinavir, adefovir, hydroxyurea, TMC-114) ;
- 10 - beta-adrenoceptor blocking agents (atenolol, carvedilol, metoprolol, nebivolol, propanolol) ;
- cardiac inotropic agents (amrinone, digitoxin, digoxin, milrinone) ;
- 15 - corticosteroids (beclomethasone dipropionate, betamethasone, budesonide, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone) ;
- disinfectants (chlorhexidine) ;
- diuretics (acetazolamide, frusemide, hydrochlorothiazide, isosorbide) ;
- 20 - enzymes ;
- essential oils (anethole, anise oil, caraway, cardamom, cassia oil, cineole, cinnamon oil, clove oil, coriander oil, dementholised mint oil, dill oil, eucalyptus oil, eugenol, ginger, lemon oil, mustard oil, neroli oil, nutmeg oil, orange oil, peppermint, sage, spearmint, terpineol, thyme) ;
- 25 - gastro-intestinal agents (cimetidine, cisapride, clebopride, diphenoxylate, domperidone, famotidine, lansoprazole, loperamide, loperamide oxide, mesalazine, metoclopramide, mosapride, nizatidine, norcisapride, olsalazine, omeprazole, pantoprazole, perprazole, prucalopride, rabeprazole, ranitidine, ridogrel, sulphasalazine, esomeprazole) ;
- 30 - haemostatics (aminocaproic acid) ;
- lipid regulating agents (atorvastatin, lovastatin, pravastatin, probucol, simvastatin, rosuvastatin) ;
- local anaesthetics (benzocaine, lignocaine) ;
- opioid analgesics (buprenorphine, codeine, dextromoramide, dihydrocodeine, hydrocodone, oxycodone, morphine) ;
- 35

-25-

- parasympathomimetics and anti-dementia drugs (AIT-082, eptastigmine, galantamine, metrifonate, milameline, neostigmine, physostigmine, tacrine, donepezil, rivastigmine, sabcomeline, talsaclidine, xanomeline, memantine, lazabemide) ;
- peptides and proteins (antibodies, becaplermin, cyclosporine, erythropoietin, immunoglobulins, insuline, growth factors, botulinum toxin, infliximab);
- sex hormones (oestrogens : conjugated oestrogens, ethinyloestradiol, mestranol, oestradiol, oestriol, oestrone ; progestogens ; chlormadinone acetate, cyproterone acetate, 17-deacetyl norgestimate, desogestrel, dienogest, dydrogesterone, ethynodiol diacetate, gestodene, 3-keto desogestrel, levonorgestrel, lynestrenol, medroxy-progesterone acetate, megestrol, norethindrone, norethindrone acetate, norethisterone, norethisterone acetate, norethynodrel, norgestimate, norgestrel, norgestrienone, progesterone, quingestanol acetate) ;
- stimulating agents (sildenafil, tadalafil, apomorphine, vardenafil) ;
- vasodilators (amlodipine, buflomedil, amyl nitrite, diltiazem, dipyridamole, glyceryl trinitrate, isosorbide dinitrate, lidoflazine, molsidomine, nicardipine, nifedipine, oxypentifylline, pentaerythritol tetranitrate);
- their *N*-oxides, their pharmaceutically acceptable acid or base addition salts and their stereochemically isomeric forms.

Other examples include the following:

8-Methoxypsoralen	lithium salts	phytomenadione
Allopurinol	magnesium salts	propylthiouracil
alpha.-Tocopherol	menadione	
iron salts	methylthiouracil	

- Drug compounds suitable for use in the compositions of the invention include drugs of all types conventionally administered topically (e.g. in a gel patch) or into an externally voiding body duct, e.g. orally, nasally, aurally, rectally or vaginally. Such drugs include in particular antifungals, calcium channel blockers, antibacterials, antihypertensives, antivirals, analgesics, apolipoprotein B synthesis inhibitors, and drugs which modify transit of gastro-intestinal tract contents (e.g. antidiarrhoea agents or motility promoters).
- The invention is particularly applicable to anti-HIV agents, in particular non-nucleoside reverse transcriptase inhibitors, more in particular non-nucleoside reverse transcriptase inhibiting pyrimidine derivatives.

The compositions of the invention may conveniently contain the drug compound at 0.001 to 50% by weight, preferably 0.1 to 35%, more preferably 0.5 to 30%, especially 8 to 25% and most especially 10 to 15% by weight (relative to the total weight of acid (base), surfactant and drug compound). The quantity of drug will of course depend upon the desired dissolution profile, the intrinsic solubility of the drug compound and the drug dosage required where the drug is to be delivered in dosage units (e.g. capsules, coated tablets, etc).

In the compounds of formula (I), (I-A) or (I-B), C₁₋₄alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as methyl, ethyl, propyl, 1-methylethyl, butyl; C₁₋₆alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as the group defined for C₁₋₄alkyl and pentyl, hexyl, 2-methylbutyl and the like; C₂₋₆alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 2 to 6 carbon atoms such as ethyl, propyl, 1-methylethyl, butyl, pentyl, hexyl, 2-methylbutyl and the like; C₁₋₄alkanediyl defines straight or branched chain saturated bivalent hydrocarbon radicals having from 1 to 4 carbon atoms such as methylene, 1,2-ethanediyl or 1,2-ethylidene, 1,3-propanediyl or 1,3-propylidene, 1,4-butanediyl or 1,4-butyliidene and the like; C₃₋₇cycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl; C₂₋₆alkenyl defines straight and branched chain hydrocarbon radicals having from 2 to 6 carbon atoms containing a double bond such as ethenyl, propenyl, butenyl, pentenyl, hexenyl and the like; C₂₋₆alkynyl defines straight and branched chain hydrocarbon radicals having from 2 to 6 carbon atoms containing a triple bond such as ethynyl, propynyl, butynyl, pentynyl, hexynyl and the like; a monocyclic, bicyclic or tricyclic saturated carbocycle represents a ring system consisting of 1, 2 or 3 rings, said ring system being composed of only carbon atoms and said ring system containing only single bonds; a monocyclic, bicyclic or tricyclic partially saturated carbocycle represents a ring system consisting of 1, 2 or 3 rings, said ring system being composed of only carbon atoms and comprising at least one double bond provided that the ring system is not an aromatic ring system; a monocyclic, bicyclic or tricyclic aromatic carbocycle represents an aromatic ring system consisting of 1, 2 or 3 rings, said ring system being composed of only carbon atoms; the term aromatic is well known to a person skilled in the art and designates cyclically conjugated systems of 4n + 2 electrons, that is with 6, 10, 14 etc. π -electrons (rule of Hückel) ; a monocyclic, bicyclic or tricyclic saturated heterocycle represents a ring system consisting of 1, 2 or 3 rings and comprising at least one heteroatom selected

-27-

from O, N or S, said ring system containing only single bonds; a monocyclic, bicyclic or tricyclic partially saturated heterocycle represents a ring system consisting of 1, 2 or 3 rings and comprising at least one heteroatom selected from O, N or S, and at least one double bond provided that the ring system is not an aromatic ring system; a monocyclic, bicyclic or tricyclic aromatic heterocycle represents an aromatic ring system consisting of 1, 2 or 3 rings and comprising at least one heteroatom selected from O, N or S.

For therapeutic use, salts of the drug compounds are those wherein the counterion is pharmaceutically acceptable. However, salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.

The pharmaceutically acceptable addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms which the drug compounds are able to form. The latter can conveniently be obtained by treating the base form with such appropriate acids as inorganic acids, for example, hydrohalic acids, e.g. hydrochloric, hydrobromic and the like; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids, for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids. Conversely the salt form can be converted by treatment with alkali into the free base form.

The drug compounds containing acidic protons may be converted into their therapeutically active non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. primary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquinoline, the benzathine, *N*-methyl-D-glucamine, 2-amino-2-(hydroxymethyl)-1,3-propanediol, hydrabamine salts, and salts

with amino acids such as, for example, arginine, lysine and the like. Conversely the salt form can be converted by treatment with acid into the free acid form.

The term addition salt also comprises the hydrates and solvent addition forms which the drug compounds are able to form. Examples of such forms are e.g. hydrates,
5 alcohols and the like.

The term "quaternary amine" as used hereinbefore defines the quaternary ammonium salts which the drug compounds are able to form by reaction between a basic nitrogen of a drug compound and an appropriate quaternizing agent, such as, for example, an
10 optionally substituted alkylhalide, arylhalide or arylalkylhalide, e.g. methyl iodide or benzyl iodide. Other reactants with good leaving groups may also be used, such as alkyl trifluoromethanesulfonates, alkyl methanesulfonates, and alkyl p-toluenesulfonates. A quaternary amine has a positively charged nitrogen. Pharmaceutically acceptable counterions include chloro, bromo, iodo, trifluoroacetate and acetate. The counterion
15 of choice can be introduced using ion exchange resins.

The *N*-oxide forms are meant to comprise the drug compounds wherein one or several tertiary nitrogen atoms are oxidized to the so-called *N*-oxide.

20 It will be appreciated that some of the drug compounds and their *N*-oxides; addition salts, quaternary amines and stereochemically isomeric forms may contain one or more centers of chirality and exist as stereochemically isomeric forms.

The term "stereochemically isomeric forms" as used hereinbefore defines all the
25 possible stereoisomeric forms which the drug compounds, and their *N*-oxides, addition salts, quaternary amines or physiologically functional derivatives may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure as well as each of the
30 individual isomeric forms and their *N*-oxides, salts, solvates or quaternary amines substantially free, *i.e.* associated with less than 10%, preferably less than 5%, in particular less than 2% and most preferably less than 1% of the other isomers. Thus, when a compound of formula (I) is for instance specified as (E), this means that the compound is substantially free of the (Z) isomer.

35 In particular, stereogenic centers may have the R- or S-configuration; substituents on bivalent cyclic (partially) saturated radicals may have either the *cis*- or *trans*-configuration. Compounds encompassing double bonds can have an E (entgegen) or Z

-29-


(zusammen) -stereochemistry at said double bond. The terms cis, trans, R, S, E and Z are well known to a person skilled in the art.

Stereochemically isomeric forms of the drug compounds are obviously intended to be embraced within the scope of this invention.

5

Some of the drug compounds may also exist in their tautomeric form. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.

- 10 The compounds of formula (I) can be prepared by reacting an intermediate of formula (II) wherein W_1 is a suitable leaving group such as, for example, halo, triflate, tosylate, methylsulfonyl and the like, with an intermediate of formula (III). This reaction can be performed at elevated temperature.




- 15 Alternatively, the above reaction can be performed in the presence of a suitable solvent. Suitable solvents are for example acetonitrile, an alcohol, such as for example ethanol, 2-propanol, 2-propanol-HCl; *N,N*-dimethylformamide; *N,N*-dimethylacetamide, 1-methyl-2-pyrrolidinone; 1,4-dioxane, propyleneglycol monomethylether. Preferably the solvent is 2-propanol, 6 N HCl in 2-propanol or acetonitrile, especially acetonitrile.
- 20 Optionally, sodium hydride may be present.

In this and the following preparations, the reaction products may be isolated from the reaction medium and, if necessary, further purified according to methodologies generally known in the art such as, for example, extraction, crystallization, distillation, trituration and chromatography.


- Compounds of formula (I) wherein R^3 is R^7 representing a monocyclic, bicyclic or tricyclic aromatic ring system, said R^3 being represented by R^7 and said compounds being represented by formula (I-a), can be prepared by reacting an intermediate of
- 30 formula (IV) wherein W_2 represents a suitable leaving group such as, for example, halo, hydroxy, triflate, tosylate, thiomethyl, methylsulfonyl, trifluoromethylsulfonyl and the like, with an intermediate of formula (V) wherein R^a represents a boronate or a

-30-

- tri(C₁₋₄alkyl)stannane, such as tributylstannane, in the presence of a suitable catalyst, such as for example palladium tetrakis(triphenylphosphine), a suitable salt, such as for example disodium carbonate, dipotassium carbonate, and Cs₂CO₃, and a suitable solvent, such as for example dioxane, dimethyl ether, toluene or an alcohol/water mixture, e.g. MeOH/H₂O. R^a may also represent halo, such as for example bromo, in which case the reaction is performed in the presence of 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane.




- Compounds of formula (I) wherein R³ is R⁷ representing a monocyclic, bicyclic or tricyclic saturated ring system, said R³ being represented by R^{7'} and said compounds being represented by formula (I-b), can be prepared by reacting an intermediate of formula (IV) with an intermediate of formula (VI).




- Compounds of formula (I) wherein R³ represents C₁₋₆alkyl substituted with cyano, said R³ being represented by C₁₋₆alkyl-CN and said compounds being represented by formula (I-c), can be prepared by reacting an intermediate of formula (VII) wherein W₃ represents a suitable leaving group, such as for example, halo, e.g. chloro, with a suitable cyanide salt, such as for example sodium cyanide or potassium cyanide, in the presence of a suitable solvent, such as for example *N,N*-dimethylformamide or dimethylsulfoxide.


-31-



Compounds of formula (I) wherein R^3 represents C_{1-6} alkyl substituted with R^7 ; NR^9R^{10} or C_{1-6} alkyloxy optionally substituted with CN, R^7 or NR^9R^{10} , said R^3 being represented by C_{1-6} alkyl-Q wherein Q represents R^7 ; NR^9R^{10} or C_{1-6} alkyloxy optionally substituted with CN, R^7 or NR^9R^{10} , and said compounds being represented by formula (I-d), can be prepared by reacting an intermediate of formula (VII) with an intermediate of formula (VIII), optionally in the presence of a suitable salt, such as for example dipotassium carbonate, potassium cyanide, potassium iodide, and a suitable solvent, such as for example acetonitrile.




Compounds of formula (I) wherein R^3 represents $-C(=N-O-R^8)-C_{1-4}$ alkyl, said compounds being represented by formula (I-e), can be prepared by reacting an intermediate of formula (IX) with an intermediate of formula (X) in the presence of a suitable solvent, such as an alcohol, e.g. ethanol.




Compounds of formula (I) wherein R^3 represents $CR^c=CR^c-CN$ wherein R^c represents hydrogen or C_{1-4} alkyl and R^c represents hydrogen, C_{1-4} alkyl or R^7 , provided that $CR^c=CR^c$ is limited to C_{2-6} alkenyl, said compounds being represented by formula (I-f), can be prepared by reacting an intermediate of formula (XI) with a Wittig or Horner-Emmons reagent of formula (XII), wherein R^b represents for example $(Phenyl)_3P^+-Cl^-$ or $(CH_3CH_2-O)_2P(=O)^-$, which can be considered as a suitable

-32-

precursor of a phosphorus ylide, in the presence of a suitable salt, such as for example potassium tert.-butoxide, and a suitable solvent, such as for example tetrahydrofuran.



Compounds of formula (I-f-1) and (I-f-2) as depicted below can be prepared by reacting an intermediate of formula (XXXIX) or an appropriate addition salt thereof, wherein W_5 represents a suitable leaving group, with acrylonitrile or acrylamide in the presence of a suitable palladium catalyst, a suitable base and a suitable solvent.



10

Suitable leaving groups in the above reaction are for example halo, triflate, tosylate, mesylate and the like. Preferably, W_5 is halo, more particularly iodo or bromo.

The palladium (Pd) catalyst may be a homogeneous Pd catalyst, such as for example $Pd(OAc)_2$, $PdCl_2$, $Pd(PPh_3)_4$, $Pd(PPh_3)_2Cl_2$, bis(dibenzylidene acetone) palladium, palladium thiomethylphenylglutaramide metallacycle and the like, or a heterogeneous Pd catalyst, such as for example palladium on charcoal, palladium on metal oxides, palladium on zeolites.

Preferably, the palladium catalyst is a heterogeneous Pd catalyst, more preferably palladium on charcoal (Pd/C). Pd/C is a recoverable catalyst, is stable and relatively inexpensive. It can be easily separated (filtration) from the reaction mixture thereby

20


-33-

reducing the risk of Pd traces in the final product. The use of Pd/C also avoids the need for ligands, such as for example phosphine ligands, which are expensive, toxic and contaminants of the synthesized products.

- 5 Suitable bases in the above reaction are for example sodium acetate, potassium acetate, *N,N*-diethylethanamine, sodium hydrogencarbonate, sodium hydroxide and the like.


- Suitable solvents in the above reaction are for example acetonitrile, *N,N*-dimethylacetamide, an ionic liquid e.g. [bmim]PF₆, *N,N*-dimethylformamide, water,
10 tetrahydrofuran, dimethylsulphoxide, 1-methyl-2-pyrrolidinone and the like.

- Compounds of formula (I) wherein R³ represents CR^c=CR^{c'}-CN with R^c being as defined hereinabove and R^{c'} representing NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷, said compounds being represented by formula (I-g), can be prepared by reacting an
15 intermediate of formula (XI-a) with an intermediate of formula (XIII) in the presence of a suitable solvent, such as for example an alcohol and an alcoholate, e.g. methanol and sodium ethanolate.




- Compounds of formula (I) wherein R³ represents CH=C(CN)-CH₂-CN, said
20 compounds being represented by formula (I-h), can be prepared by reacting an intermediate of formula (XI-b) with 2-butenedinitrile in the presence of tributylphosphine and a suitable solvent, such as for example tetrahydrofuran.


-34-



- Compounds of formula (I) wherein R^3 represents $\text{CH}=\text{C}(\text{CN})_2$, said compounds being represented by formula (I-h'), can be prepared by reacting an intermediate of formula (XI-b) with propanedinitrile in the presence of a suitable base, such as for example piperidine, and a suitable solvent, such as for example an alcohol, e.g. ethanol and the like.




- Compounds of formula (I) wherein R^3 represents $-\text{CHOH}-\text{CH}_2-\text{CN}$, said compounds being represented by formula (I-i), can be prepared by reacting an intermediate of formula (XI-b) with CH_3-CN in the presence of a suitable proton-abstrating agent, such as for example butyl lithium, in the presence of a suitable substrate for the proton-abstrating agent, for example *N*-(1-methylethyl)-2-propanamine, and in the presence of a suitable solvent, such as for example tetrahydrofuran.




- Compounds of formula (I) wherein R^3 represents $\text{CR}^c=\text{CR}^c\text{-halo}$ wherein R^c represents hydrogen or C_{1-4} alkyl and R^c represents hydrogen, C_{1-4} alkyl or R^7 , provided that $\text{CR}^c=\text{CR}^c$ is limited to C_{2-6} alkenyl, said compounds being represented by formula (I-j),

-35-

- can be prepared by reacting an intermediate of formula (XI) with a Wittig or Horner-Emmons reagent of formula (XII'), wherein R^b represents for example $(\text{Phenyl})_3\text{P}^+-\text{Cl}^-$ or $(\text{CH}_3\text{CH}_2-\text{O})_2\text{P}(=\text{O})^-$, which can be considered as a suitable precursor of a phosphorus ylide, in the presence of $n\text{BuLi}$, and a suitable solvent, such as for example tetrahydrofuran.




- Compounds of formula (I) wherein R^3 represents $\text{CR}^c=\text{CR}^{c''}$ -halo with R^c being as defined hereinabove and $R^{c''}$ representing CN , NR^9R^{10} , $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 , said compounds being represented by formula (I-k), can be prepared by reacting an intermediate of formula (XI-a) with an intermediate of formula (XIII-a) in the presence of a Horner-Emmons reagent such as for example $(\text{CH}_3\text{CH}_2-\text{O})_2\text{P}(=\text{O})-\text{Cl}$, $n\text{BuLi}$, 1,1,1-trimethyl-*N*-(trimethylsilyl)-silanamine, and a suitable solvent, such as for example tetrahydrofuran.




- Compounds of formula (I) wherein R^3 represents $\text{CH}=\text{C}(\text{Br})_2$, said compounds being represented by formula (I-l), can be prepared by reacting an intermediate of formula (XVIII) with CBr_4 , in the presence of a suitable catalyst salt, such as for example $(\text{CuCl})_2$, and in the presence of a suitable base, such as for example NH_3 , and a suitable solvent, such as for example dimethylsulfoxide.


-36-



Compounds of formula (I-m) can be prepared by reacting an intermediate of formula (XIV) with $\text{Cl}_2\text{C}=\text{S}$ in the presence of a suitable solvent, such as for example dioxane.




- 5 Compounds of formula (I-n) can be prepared by reacting an intermediate of formula (XV) with an intermediate of formula (XVI) in the presence of a suitable solvent, such as for example an alcohol or an alcoholate, e.g. ethanol or sodium methanolate.





- Compounds of formula (I) wherein R^3 represents C_{2-6} alkenyl substituted with $\text{C}(=\text{O})\text{NR}^9\text{R}^{10}$ and optionally further substituted with cyano, said compounds being represented by formula (I-o) wherein C_{2-6} alkenyl' represents C_{2-6} alkenyl optionally substituted with cyano, can be prepared by reacting an intermediate of formula (XXIX) with an intermediate of formula (XXX) in the presence of hydroxybenzotriazole and ethyldimethylaminopropyl carbodiimide and a suitable solvent, such as for example methylene chloride or tetrahydrofuran, and optionally in the presence of a suitable base, such as for example *N,N*-diethylethanamine, NH_4OH and the like.


-37-




- Compounds of formula (I) wherein R^3 represents $-C(=O)NR^{13}R^{14}$ or $-C(=O)NHR^{13}$, said compounds being represented by formula (I-p-1) and (I-p-2) can be prepared by reacting an intermediate of formula (XXXI) with an intermediate of formula (XXXII-1) or (XXXII-2) in the presence of hydroxybenzotriazole and ethyldimethylaminopropyl carbodiimide and a suitable solvent, such as for example methylene chloride or tetrahydrofuran, and optionally in the presence of a suitable base, such as for example *N,N*-diethylethanamine.




- Compounds of formula (I) wherein R^3 represents $CH=N-NH-C(=O)-R^{16}$, said compounds being represented by formula (I-q), can be prepared by reacting an intermediate of formula (XI-b) with an intermediate of formula (XXXIII) in the presence of a suitable solvent, such as for example methylene chloride and an alcohol, e.g. methanol, ethanol and the like.



- Compounds of formula (I) wherein R^3 represents $N(CH_3)_2$, said compounds being represented by formula (I-r), can be prepared by reductive methylation of an intermediate of formula (XXXIV) with formaldehyde in the presence of a suitable catalyst, such as for example a suitable acid, i.e. acetic acid and the like, palladium on charcoal, Raney Nickel, and in the presence of a suitable reductive agent, such as for example sodium cyanoborohydride or H_2 , and a suitable solvent, such as for example acetonitrile.




- Compounds of formula (I) wherein R^3 represents pyrrolyl, said compounds being represented by formula (I-s), can be prepared by reacting an intermediate of formula (XXXIV) with 2,5-dimethoxytetrahydrofuran in the presence of a suitable acid, such as for example acetic acid.



- Compounds of formula (I) wherein R^3 represents $CH=CH-R^7$, said compounds being represented by formula (I-t), can be prepared by reacting an intermediate of formula (XXXV) (Ph indicates phenyl) with an intermediate of formula (XXXVI) in the presence of $nBuLi$ and a suitable solvent, such as for example tetrahydrofuran.

-39-



The compounds of formula (I) may further be prepared by converting compounds of formula (I) into each other according to art-known group transformation reactions.

- 5 The compounds of formula (I) may be converted to the corresponding *N*-oxide forms following art-known procedures for converting a trivalent nitrogen into its *N*-oxide form. Said *N*-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth
- 10 alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboxy-peroxy acid or halo substituted benzenecarboxy-peroxy acid, e.g. 3-chlorobenzenecarboxy-peroxy acid, peroxyalkanoic acids, e.g. peroxyacetic acid, alkylhydroperoxides, e.g. tert.butyl hydro-peroxide. Suitable solvents are, for example, water, lower alcohols,
- 15 e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.

- For instance, a compound of formula (I) wherein R^3 comprises cyano, can be converted into a compound of formula (I) wherein R^3 comprises aminocarbonyl, by reaction with
- 20 HCOOH, in the presence of a suitable acid, such as hydrochloric acid. A compound of formula (I) wherein R^3 comprises cyano, can also further be converted into a compound of formula (I) wherein R^3 comprises tetrazolyl, by reaction with sodium azide in the presence of ammonium chloride and *N,N*-dimethylacetamide.

- 25 Compounds of formula (I) wherein R^3 comprises aminocarbonyl, can be converted into a compound of formula (I) wherein R^3 comprises cyano, in the presence of a suitable dehydrating agent. The dehydration can be performed according to methodologies well-known to the person skilled in the art, such as the ones disclosed in "Comprehensive Organic Transformations. A guide to functional group preparations"
- 30 by Richard C. Larock, John Wiley & Sons, Inc, 1999, p 1983-1985, which is


- incorporated herein as reference. Different suitable reagents are enumerated in said reference, such as for example SOCl_2 , HOSO_2NH_2 , ClSO_2NCO , $\text{MeO}_2\text{CNSO}_2\text{NEt}_3$, PhSO_2Cl , TsCl , P_2O_5 , $(\text{Ph}_3\text{PO}_3\text{SCF}_3)_3\text{O}_3\text{SCF}_3$, polyphosphate ester, $(\text{EtO})_2\text{POP}(\text{OEt})_2$, $(\text{EtO})_3\text{PI}_2$, 2-chloro-1,3,2-dioxaphospholane, 2,2,2-trichloro-2,2-dihydro-1,3,2-dioxaphospholane, POCl_3 , PPh_3 , $\text{P}(\text{NCl}_2)_3$, $\text{P}(\text{NEt}_2)_3$, COCl_2 , $\text{NaCl} \cdot \text{AlCl}_3$, $\text{ClCOCOC}_2\text{H}_5$, $\text{ClCOCOC}_2\text{H}_5$, Cl_3CCOCl , $(\text{CF}_3\text{CO})_2\text{O}$, $\text{Cl}_3\text{CN}=\text{CCl}_2$, 2,4,6-trichloro-1,3,5-triazine, $\text{NaCl} \cdot \text{AlCl}_3$, $\text{HN}(\text{SiMe}_2)_3$, $\text{N}(\text{SiMe}_2)_4$, LiAlH_4 and the like. All the reagents listed in said publication are incorporated herein as reference.
- 10 Compounds of formula (I) wherein R^3 comprises C_{2-6} alkenyl can be converted into a compound of formula (I) wherein R^3 comprises C_{1-6} alkyl by reduction in the presence of a suitable reducing agent, such as for example H_2 , in the presence of a suitable catalyst, such as for example palladium on charcoal, and in the presence of a suitable solvent, such as for example an alcohol, e.g. methanol.
- 15 Compounds of formula (I) wherein R^3 represents $\text{CH}(\text{OH})-\text{R}^{16}$, can be converted into a compound of formula (I) wherein R^3 represents $\text{C}(=\text{O})-\text{R}^{16}$ by reaction with Jones's reagent in the presence of a suitable solvent, such as for example 2-propanone.
- 20 Compound of formula (I) wherein R^3 represents $\text{C}(=\text{O})-\text{CH}_2-\text{R}^{16a}$, wherein R^{16a} represents cyano or aminocarbonyl, can be converted into a compound of formula (I) wherein R^3 represents $\text{C}(\text{Cl})=\text{CH}-\text{R}^{16a}$ by reaction with POCl_3 .
- 25 Compounds of formula (I) wherein R^3 represents a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic carbocycle or a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic heterocycle substituted with formyl can be converted into compounds of formula (I) wherein R^3 represents a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic carbocycle or a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic heterocycle substituted with $\text{CH}(=\text{N}-\text{O}-\text{R}^8)$ by reaction with NH_2OR^8 in the presence of a suitable base, such as for example sodium hydroxide and a suitable solvent, such as for example an alcohol, e.g. ethanol and the like. Compounds of formula (I) wherein R^3 represents a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic carbocycle or a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic heterocycle substituted with $\text{CH}(=\text{N}-\text{O}-\text{R}^8)$ can be converted into a compound of formula (I) wherein R^3 represents a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic carbocycle or a monocyclic, bicyclic or tricyclic saturated, partially saturated
- 30
- 35

or aromatic heterocycle substituted with CN by reaction with a carbodiimide in the presence of a suitable solvent, such as for example tetrahydrofuran.


- Compounds of formula (I) wherein R^4 represents nitro, can be converted into a compound of formula (I) wherein R^4 is amino, in the presence of a suitable reducing agent, such as for example H_2 , in the presence of a suitable catalyst, such as for example Raney Nickel, and in the presence of a suitable solvent, such as for example an alcohol, e.g. methanol.
- 10 Compounds of formula (I) wherein R^1 is hydrogen, can be converted into a compound of formula (I) wherein R^1 is C_{1-6} alkyl, by reaction with a suitable alkylating agent, such as for example iodo- C_{1-6} alkyl, in the presence of a suitable base, such as for example sodium hydride, and a suitable solvent, such as for example tetrahydrofuran.
- 15 Some of the compounds of formula (I) and some of the intermediates in the present invention may contain an asymmetric carbon atom. Pure stereochemically isomeric forms of said compounds and said intermediates can be obtained by the application of art-known procedures. For example, diastereoisomers can be separated by physical methods such as selective crystallization or chromatographic techniques, e.g. counter
- 20 current distribution, liquid chromatography and the like methods. Enantiomers can be obtained from racemic mixtures by first converting said racemic mixtures with suitable resolving agents such as, for example, chiral acids, to mixtures of diastereomeric salts or compounds; then physically separating said mixtures of diastereomeric salts or compounds by, for example, selective crystallization or chromatographic techniques,
- 25 e.g. liquid chromatography and the like methods; and finally converting said separated diastereomeric salts or compounds into the corresponding enantiomers. Pure stereochemically isomeric forms may also be obtained from the pure stereochemically isomeric forms of the appropriate intermediates and starting materials, provided that the intervening reactions occur stereospecifically.
- 30 An alternative manner of separating the enantiomeric forms of the compounds of formula (I) and intermediates involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase.
- 35 Some of the intermediates and starting materials are known compounds and may be

commercially available or may be prepared according to art-known procedures or some of the compounds of formula (I) or the described intermediates may be prepared according to the procedures described in WO 99/50250 and WO 00/27825.


- 5 Intermediates of formula (II) can be prepared by reacting an intermediate of formula (XVII) with a leaving group introducing agent of formula (XIX) wherein W_1 represents the leaving group and R represents the remaining of the leaving group introducing agent, such as for example $POCl_3$.



- 10 Intermediates of formula (III) wherein X_1 represents NH , said intermediates being represented by formula (III-a), can be prepared from an intermediate of formula (XX) in the presence of $ZnCl_2$ and in the presence of a suitable solvent, such as for example an alcohol, for example ethanol.




- 15 Intermediates of formula (III'-a) as depicted below can be prepared from an intermediate of formula (XX) wherein R^3 represents C_{2-6} alkenyl substituted with CN, said intermediate being represented by formula (XX-a), in the presence of $ZnCl_2$ and in the presence of a suitable C_{1-4} alkyl-OH, such as for example ethanol.



- 20 Intermediates of formula (III-b-1) and (III-b-2) as depicted below can be prepared by reacting an intermediate of formula (XLI) or an appropriate acid addition salt thereof,

wherein W_6 represents a suitable leaving group, with acrylonitrile or acrylamide in the presence of a suitable palladium catalyst, a suitable base and a suitable solvent.



- 5 Suitable leaving groups in the above reaction are for example halo, triflate, tosylate, mesylate and the like. Preferably, W_6 is halo, more preferably iodo or bromo.


- The palladium (Pd) catalyst may be a homogeneous Pd catalyst, such as for example $Pd(OAc)_2$, $PdCl_2$, $Pd(PPh_3)_4$, $Pd(PPh_3)_2Cl_2$, bis(dibenzylidene acetone) palladium, palladium thiomethylphenylglutaramide metallacycle and the like, or a heterogeneous Pd catalyst, such as for example palladium on charcoal, palladium on metal oxides, palladium on zeolites.

- 15 Preferably, the palladium catalyst is a heterogeneous Pd catalyst, more preferably palladium on charcoal (Pd/C). Pd/C is a recoverable catalyst, is stable and relatively inexpensive. It can be easily separated (filtration) from the reaction mixture thereby reducing the risk of Pd traces in the final product. The use of Pd/C also avoids the need for ligands, such as for example phosphine ligands, which are expensive, toxic and contaminants of the synthesized products.


- 20 Suitable bases in the above reaction are for example sodium acetate, potassium acetate, *N,N*-diethylethanamine, sodium hydrogencarbonate, sodium hydroxide and the like.

- Suitable solvents in the above reaction are for example acetonitrile, *N,N*-dimethylacetamide, an ionic liquid e.g. [bmim]PF₆, *N,N*-dimethylformamide, water, 25 tetrahydrofuran, dimethylsulphoxide, 1-methyl-2-pyrrolidinone and the like.

- Intermediates of formula (III-b-2) can be converted into an intermediate of formula (III-b-1) in the presence of a suitable dehydrating agent. The dehydration can be performed according to methodologies well-known to the person skilled in the art, such as the ones disclosed in "Comprehensive Organic Transformations. A guide to functional group preparations" by Richard C. Larock, John Wiley & Sons, Inc, 1999, p. 1983-1985, which is incorporated herein as reference. Different suitable reagents are enumerated in said reference, such as for example SOCl_2 , HOSO_2NH_2 , ClSO_2NCO , $\text{MeO}_2\text{CNSO}_2\text{NEt}_3$, PhSO_2Cl , TsCl , P_2O_5 , $(\text{Ph}_3\text{PO}_3\text{SCF}_3)_3\text{O}_3\text{SCF}_3$, polyphosphate ester, $(\text{EtO})_2\text{POP}(\text{OEt})_2$, $(\text{EtO})_3\text{PI}_2$, 2-chloro-1,3,2-dioxaphospholane, 2,2,2-trichloro-2,2-dihydro-1,3,2-dioxaphospholane, POCl_3 , PPh_3 , $\text{P}(\text{NCl}_2)_3$, $\text{P}(\text{NEt}_2)_3$, COCl_2 , $\text{NaCl} \cdot \text{AlCl}_3$, $\text{ClCOCOC}_2\text{Me}$, Cl_3CCOCl , $(\text{CF}_3\text{CO})_2\text{O}$, $\text{Cl}_3\text{CN}=\text{CCl}_2$, 2,4,6-trichloro-1,3,5-triazine, $\text{NaCl} \cdot \text{AlCl}_3$, $\text{HN}(\text{SiMe}_2)_3$, $\text{N}(\text{SiMe}_2)_4$, LiAlH_4 and the like. All the reagents listed in said publication are incorporated herein as reference.
- 15 Intermediates of formula (XX) wherein R^3 represents $\text{CR}^c=\text{CR}^{c'}-\text{CN}$ with R^c and $\text{R}^{c'}$ as described hereinabove, said intermediates being represented by formula (XX-b), can be prepared from an intermediate of formula (XXI) by the reaction described above for the preparation of a compound of formula (I-f).




- 20 Intermediates of formula (XXI) can be prepared by oxidation of an intermediate of formula (XXII) in the presence of a suitable oxidizing agent, such as for example KMnO_4 , in the presence of a suitable solvent, such as for example methylene chloride and tris[2-(2-methoxyethoxy)ethyl]amine.




- 25 Intermediates of formula (XXI) wherein $\text{R}^{c'}$ is H, said intermediates being represented by formula (XXI-a), can also be prepared by reacting an intermediate of formula


(XXIII) wherein W_4 represents a suitable leaving group, such as halo, e.g. bromo, with *N,N*-dimethylformamide in the presence of *n*BuLi and in the presence of a suitable solvent, such as for example tetrahydrofuran.



- 5 Intermediates of formula (XXII) wherein R^c represents C_{1-4} alkyl, said intermediates being represented by formula (XXII-a), can be prepared by reacting an intermediate of formula (XXIII) with an intermediate of formula (XXIV) in the presence of *n*BuLi and in the presence of a suitable solvent, such as for example tetrahydrofuran.




- 10 Intermediates of formula (XI) can be prepared by reacting an intermediate of formula (XXV) with an intermediate of formula (II), optionally in the presence of a suitable base, such as for example 1-methyl-pyrrolidin-2-one, or a suitable acid, such as for example hydrochloric acid.




- 15 Intermediates of formula (XV) can be prepared by reacting an intermediate of formula (XXVI) with an intermediate of formula (II) in the presence of a suitable base, such as for example 1-methyl-pyrrolidin-2-one and sodium hydride and a suitable solvent, such as for example dioxane.


-46-



Intermediates of formula (VII) can be prepared by reacting an intermediate of formula (XXVII) with a leaving group introducing agent of formula (XIX'), such as for example $SOCl_2$, in the presence of a suitable solvent, such as for example methylene chloride.




Intermediates of formula (XXVII) wherein $C_{1-6}alkyl$ represents CH_2 , said intermediates being represented by formula (XXVII-a), can be prepared by reducing an intermediate of formula (XV) or formula (XXXI) with a suitable reducing agent, such as for example $LiAlH_4$, in the presence of a suitable solvent, such as for example tetrahydrofuran.




Intermediates of formula (XXVII-a) can be converted to an intermediate of formula (XXXI) by reaction with Jones reagent in the presence of a suitable solvent, such as for example acetone.


-47-





Intermediates of formula (XI-b) can be prepared by oxidizing an intermediate of formula (XXVII-a) in the presence of a suitable oxidizing agent, such as for example MnO_2 , and a suitable solvent, such as for example methylene chloride, *N,N*-dimethylformamide.




Intermediates of formula (XIV) can be prepared by reacting an intermediate of formula (XV) with H_2N-NH_2 in the presence of a suitable solvent, such as for example an alcohol, e.g. ethanol and the like.




Intermediates of formula (IX) and (XI-a) can be reduced to an intermediate of formula (XXVII'-a) and (XXVII'-b) in the presence of a suitable reducing agent, such as for example $NaBH_4$, $LiAlH_4$ or $BuLi$ and a suitable solvent, such as for example tetrahydrofuran or an alcohol, e.g. methanol, ethanol and the like.



An intermediate of formula (XI-b) can be converted into an intermediate of formula (XXVII'-a) by reaction with C₁₋₄alkyl-Iodide in the presence of Mg and a suitable solvent, such as for example diethylether and tetrahydrofuran.




Intermediates of formula (XVIII) can be prepared by reacting an intermediate of formula (XI-b) with $\text{H}_2\text{N-NH}_2$ in the presence of a suitable solvent, such as for example an alcohol, e.g. ethanol and the like.




10 Intermediates of formula (XXIX) or (XXXI) can be prepared by hydrolizing an
intermediate of formula (XXXVII) wherein C₂₋₆alkenyl' represents C₂₋₆alkenyl
optionally substituted cyano, or an intermediate of formula (XV) in the presence of a
suitable aqueous acid solution, such as for example hydrochloric acid 2N and the like,
and in the presence of a suitable solvent, such as for example an alcohol, e.g.
15 isopropanol and the like.


-49-




- Intermediates of formula (XXXVII) wherein C_{2-6} alkenyl' is $CH=CH$, said intermediates being represented by formula (XXXVII-a), can be prepared by reacting an intermediate of formula (XI-b) with a Wittig or Horner-Emmons reagent of formula (XII'), wherein
- 5 R^b represents for example $(Phenyl)_3P^+ Cl^-$ or $(CH_3CH_2O)_2P(=O)^-$, which can be considered as a suitable precursor of a phosphorus ylide, in the presence of a suitable solvent, such as for example tetrahydrofuran.




- 10 Intermediates of formula (XXXVII) wherein C_{2-6} alkenyl' is $-CH=C(CN)-$, said intermediates being represented by formula (XXXVII-b), can be prepared by reacting an intermediate of formula (XI-b) with $NC-CH_2-C(=O)O-C_{1-6}alkyl$, in the presence of a suitable base, such as for example piperidine, and a suitable solvent, such as for example an alcohol, e.g. ethanol.



Intermediates of formula (XXXIV) can be prepared by reducing an intermediate of formula (XXXVIII) in the presence H₂ and a suitable catalyst, such as for example palladium on charcoal or Raney Nickel, and in the presence of a suitable solvent, such as for example an alcohol, e.g. methanol and the like.




Intermediates of formula (XXXV) can be prepared by reacting an intermediate of formula (VII-a) in the presence of triphenylphosphine and a suitable solvent, such as for example acetonitrile.



Intermediates of formula (XXXIX) can be prepared by reacting an intermediate of formula (XL) with an intermediate of formula (II-a) wherein W₅ and W₁ are as defined hereinbefore.

-51-



The compounds of formula (I) as prepared in the hereinabove described processes may be synthesized as a mixture of stereoisomeric forms, in particular in the form of racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures. The racemic compounds of formula (I) may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali. An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.

It will be appreciated by those skilled in the art that in the processes described above the functional groups of intermediate compounds may need to be blocked by protecting groups.

Functional groups which it is desirable to protect include hydroxy, amino and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl groups (e.g. *tert*-butyldimethylsilyl, *tert*-butyldiphenylsilyl or trimethylsilyl), benzyl and tetrahydropyranyl. Suitable protecting groups for amino include *tert*-butoxycarbonyl or benzyloxycarbonyl. Suitable protecting groups for carboxylic acid include C₁₋₆alkyl or benzyl esters.

The protection and deprotection of functional groups may take place before or after a reaction step.

The use of protecting groups is fully described in 'Protective Groups in Organic Chemistry', edited by J W F McOmie, Plenum Press (1973), and 'Protective Groups in Organic Synthesis' 2nd edition, T W Greene & P G M Wutz, Wiley Interscience (1991).

- 5 The compounds of formula (I) or any subgroup thereof show antiretroviral properties (reverse transcriptase inhibiting properties), in particular against Human Immunodeficiency Virus (HIV), which is the aetiological agent of Acquired Immune Deficiency Syndrome (AIDS) in humans.
- 10 The compounds of formula (I) or any subgroup thereof also show activity against (multi) drug resistant HIV strains, in particular (multi) drug resistant HIV-1 strains, more in particular the present compounds show activity against HIV strains, especially HIV-1 strains, that have acquired resistance to one or more art-known non-nucleoside reverse transcriptase inhibitors. Art-known non-nucleoside reverse transcriptase
- 15 inhibitors are those non-nucleoside reverse transcriptase inhibitors other than the present compounds and in particular commercial non-nucleoside reverse transcriptase inhibitors. The present compounds also have little or no binding affinity to human α -1 acid glycoprotein; human α -1 acid glycoprotein does not or only weakly affect the anti-HIV activity of the present compounds.
- 20 Those of skill in the treatment of HIV-infection could determine the effective daily amount from the test results presented here. In general it is contemplated that an effective daily amount would be from 0.01 mg/kg to 50 mg/kg body weight, more preferably from 0.1 mg/kg to 10 mg/kg body weight. It may be appropriate to
- 25 administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 1 to 1000 mg, and in particular 5 to 200 mg of active ingredient per unit dosage form.
- 30 The exact dosage and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or
- 35 increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. The

effective daily amount ranges mentioned hereinabove are therefore only guidelines and are not intended to limit the scope or use of the invention to any extent.

The following examples are intended to illustrate the compounds of formula (I).

5


Hereinafter, "DMF" is defined as *N,N*-dimethylformamide, "DIPE" is defined as diisopropyl ether, "THF" is defined as tetrahydrofuran, "DMA" is defined as *N,N*-dimethylacetamide, "DMSO" is defined as dimethylsulfoxide, "DME" is defined as dimethyl ether, "EtOAc" is defined as ethylacetate, "EDCI" is defined as

10 *N'*-(ethylcarbonimidoyl)-*N,N*-dimethyl-1,3-propanediamine.

A. Preparation of the intermediate compounds

Example A1

a) The preparation of intermediate 1




nBuLi (0.012 mol) was added dropwise at -70°C to a mixture of *N'*-(4-bromo-2,6-dimethylphenyl)-*N,N*-dimethylmethanimidamide (0.0078 mol) in THF (20 ml) under N₂ flow. The mixture was stirred at -30°C for 30 minutes, then cooled to -70°C. A mixture of DMF (0.078 mol) in THF (30 ml) was added dropwise. The mixture was stirred at

-70°C for 2 hours, then brought to 0°C, poured out into H₂O and extracted with ethyl acetate. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. Yield: 1.8 g of intermediate 1.

20

b) The preparation of intermediate 2




A mixture of diethyl (cyanomethyl)phosphonate (0.0037 mol) in THF (10 ml) was cooled to 5°C under N₂ flow. Potassium tert.-butoxide (0.0037 mol) was added portionwise. The mixture was stirred at 5°C for 30 minutes, then stirred at room temperature for 30 minutes. A mixture of intermediate 1 (0.0024 mol) in THF (10 ml) was added. The mixture was stirred at room temperature for 1 hour, then poured out into H₂O and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. Yield : 0.82 g (100%) of intermediate 2.


25

-54-

- c) The preparation of intermediate 3 and intermediate 22



Intermediate 3



Intermediate 22

- A mixture of intermediate 2 (0.059 mol) and ZnCl_2 (0.299 mol) in ethanol (150 ml) was stirred and refluxed for 24 hours, then poured out into K_2CO_3 solution (10 % in water) and extracted with CH_2Cl_2 . The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The residue (9 g) was crystallized from DIPE.
- 5 The precipitate was filtered off and dried. Yield: 0.8 g (6%) of intermediate 22. The filtrate was concentrated and recrystallized from DIPE to obtain 6 g of intermediate 3.

Alternatively, intermediate 3 was also prepared as follows:


- To a solution of 159 g of 4-iodo-2,6-dimethyl-benzenamine was added 63.8 g of sodium acetate. The reaction mixture was kept under nitrogen atmosphere. 7 g of
- 10 moistened palladium on charcoal (Pd/C 10 %) and 64.4 ml of acrylonitrile was added. The reaction mixture was heated to 130°C and stirred overnight. After cooling to room temperature, 0.5 l of toluene and 0.5 l of *N,N*-dimethylacetamide was added. The reaction mixture was filtered over Dicalite and the filter was washed with 0.5 l of
- 15 toluene. Water (6 l) was added to the mixture which was stirred for 30 minutes. The layers were separated. To the aqueous layer, 1 l of toluene was added and the mixture was stirred for 30 minutes. The layers were separated again. The separated organic layers were collected and the solvent was evaporated, yielding 123 g of intermediate 3.

- 20 Intermediate 3 was converted into its hydrochloric acid salt as follows :

- To a mixture of 123 g of intermediate 3 in 630 ml of ethanol was added 1,25 l of diisopropyl ether. The reaction mixture was kept under nitrogen atmosphere. The mixture was heated to 60°C and stirred for 30 minutes. 120 ml of a 6 N solution of hydrochloric acid in 2-propanol was added and the mixture was stirred for 30 minutes.
- 25 After cooling to room temperature, the reaction mixture was filtered and the residue was washed with 100 ml of 2-propanol. The resulting residue was dried under reduced pressure at 50°C . Yield : 103 g (77 %) of the hydrochloric acid salt (1:1) of intermediate 3.

- 30 Intermediate 3 (E) was prepared as follows :


x) Preparation of intermediate 3a (E)



Intermediate 3a (E)

In 10 ml acetonitrile, dry, was dissolved 2.00 g (10.0 mol) of 4-bromo-2,6-
 5 dimethylaniline, 1.07 g (1.5 eq) of acrylamide, 224 mg (0.1 eq) of Pd(OAc)₂, 609 mg
 (0.2 eq) of tris(2-methylphenyl)phosphine and 1.52 g of *N,N*-diethylethanamine. The
 mixture was purged with N₂ for 20 minutes and stirred overnight at 70 °C. The mixture
 was diluted with 150 ml of methylene chloride, washed with saturated aqueous
 NaHCO₃ solution, dried (sat. NaCl, Na₂SO₄) and filtered. The solvent was evaporated
 10 and the residue was stirred in diisopropyl ether followed by filtration. Yield : 1.51 g
 (79.5 %) of intermediate 3a (E).


y) Preparation of intermediate 3 (E)



Intermediate 3 (E)

15 POCl₃ (3 ml) was cooled to 0°C and 500 mg (2.63 mmol) of intermediate 3a (E) was
 added. After 30 minutes, the cooling bath was removed and the mixture was stirred
 overnight at 20 °C. The mixture was added dropwise to 150 ml of diisopropyl ether
 while stirring vigorously. The precipitate was filtered and washed with diisopropyl
 ether. The residue was added to 100 ml ethyl acetate/100 ml of saturated aqueous
 20 NaHCO₃ solution and stirred. The ethyl acetate layer was separated, dried (sat. NaCl,
 Na₂SO₄) and filtered. The solvent was evaporated. Yield : 380 mg (84 %) of
 intermediate 3 (E).

d) The preparation of intermediate 4




A mixture of 4-bromo-2,6-dimethylbenzenamine (0.024 mol) in H₂SO₄ (30 ml) was

stirred at -5°C . KNO_3 (0.024 mol) was added slowly. The mixture was stirred at -5°C for 30 minutes, poured out into H_2O and extracted with ethyl acetate. The organic layer was washed with H_2O , separated, dried (MgSO_4), filtered and the solvent was evaporated. The residue (0.058 g, 95%) was purified by column chromatography over silica gel (eluent: cyclohexane/ethyl acetate; 70/30; 15-40 μm). The pure fractions were collected and the solvent was evaporated. Yield: 4.1 g of intermediate 4.

Example A1A

The preparation of intermediate 28




1-chloro-pyrrolidine-2,5-dione (0.032 mol) was added at 60°C to a mixture of 4-amino-3-methyl-benzoic acid ethyl ester [CAS 40800-65-5] (0.029 mol) in CH_3CN (50 ml). The mixture was stirred and refluxed slowly. K_2CO_3 10% was added. The mixture was extracted with CH_2Cl_2 . The organic layer was evaporated. The residue (6.6 g) was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 85/15; 15-40 μm). The pure fractions were collected and the solvent was evaporated. Yield: 5.2 g of intermediate 28 (84%).

Example A2

A mixture of 4-[(1,4-dihydro-4-oxo-2-pyrimidinyl)amino]benzonitrile (0.12 mol) in POCl_3 (90 ml) was stirred and refluxed under Argon for 20 minutes. The reaction mixture was slowly poured onto 750 ml ice/water, and the solid was separated by filtration. The solid was suspended in 500 ml water, and the pH of the suspension was adjusted to neutral by adding a 20% NaOH solution. The solid was again separated by filtration, suspended in 200 ml 2-propanone, and 1000 ml CH_2Cl_2 was added. The mixture was heated until all solid had dissolved. After cooling to room temperature, the aqueous layer was separated, and the organic layer was dried. During removal of the drying agent by filtration, a white solid formed in the filtrate. Further cooling of the filtrate in the freezer, followed by filtration, yielded 21.38 g (77.2%) of 4-[(4-chloro-2-pyrimidinyl)amino]benzonitrile (interm. 5).

Example A3

a) The preparation of intermediate 6




$n\text{BuLi}$ (0.024 mol) was added dropwise at -70°C to a mixture of N' -(4-bromo-2,6-dimethylphenyl)- N,N -dimethylmethanimidamide (0.0157 mol) in THF (50 ml) under

-57-

N₂ flow. The mixture was stirred at -30°C for 30 minutes, then cooled to -70°C. A solution of 2-methylpropanal (0.055 mol) in THF (50 ml) was added. The mixture was stirred at


- 70°C for 2 hours, then brought to 0°C, poured out into H₂O and extracted with
 5 CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue (6.7 g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 95/5/0.5; 15-40μm). Two fractions were collected and the solvent was evaporated. Fraction 1 : yield : 1.5 g of intermediate 6 (38%).

b) The preparation of intermediate 7




- Tris[2-(2-methoxyethoxy)ethyl]amine (0.0193 mol) was added at room temperature to a
 10 solution of intermediate 6 (0.0048 mol) in CH₂Cl₂ (20 ml). KMnO₄ (0.0193 mol) was added portionwise. The mixture was stirred at room temperature overnight, then filtered over celite and washed with CH₂Cl₂. The organic layer was washed with K₂CO₃ 10%, separated, dried (MgSO₄), filtered and the solvent was evaporated. Yield: 1.2 g (100%) of intermediate 7.

c) The preparation of intermediate 8



- 15 A mixture of intermediate 7 (0.0043 mol) and ZnCl₂ (0.017 mol) in ethanol (20 ml) was stirred and refluxed overnight, poured out into H₂O and extracted with CH₂Cl₂/CH₃OH. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. Yield: 0.94 g (82%) of intermediate 8.


d-1) The preparation of intermediate 9



- A mixture of intermediate 8 (0.0049 mol) and intermediate 5 (0.0025 mol) was stirred
 20 at 150°C for 2 hours and taken up in K₂CO₃ 10%/CH₂Cl₂/CH₃OH. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue (1.3 g) was crystallized from DIPE. The precipitate was filtered off and dried. The mother layer was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 98.5/1.5; 15-40μm). The pure fractions were collected and the solvent
 25 was evaporated. Yield: 0.21 g of intermediate 9.


-58-

d-2) The preparation of intermediate 29




A mixture of intermediate 28 (0.023 mol) and intermediate 5 (prepared according to A2) (0.025 mol) in HCl 3N (10 ml) was stirred at 105°C then brought to room temperature and filtered. The precipitate was washed with DIPE and dried. Yield: 8.4 g of intermediate 29 (96%)

d-3) The preparation of intermediate 30




- 5 A mixture of 4-amino-3-chloro benzoic acid ethyl ester [CAS 82765-44-4] (0.02 mol) and intermediate 5 (prepared according to A2) (0.0243 mol) in 1-methyl-pyrrolidin-2-one (40 ml) was stirred at 180°C for 2 hours, then poured out into H₂O and extracted three times with EtOAc (80 ml). The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue (10 g)
- 10 was purified by column chromatography over silica gel (eluent: CH₂Cl₂ 100; 15-30μm). Two fractions were collected and the solvent was evaporated. Yield: 1.7 g F1 and 1 g F2. F2 was taken up in diethyl ether. The precipitate was filtered off and dried. Yield: 0.95 g of intermediate 30 (12%).

e-1) The preparation of intermediate 17




- NaBH₄ (0.0001 mol) was added portionwise at 5°C to a mixture of intermediate 9 (0.0001 mol) in ethanol (7 ml) under N₂ flow. The mixture was stirred at 5°C for 1
- 15 hour, poured out on ice and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue (0.1 g) was crystallized from DIPE. The precipitate was filtered off and dried. Yield: 0.044 g of intermediate 17.

e-2) The preparation of intermediate 32



- 20 BuLi 1.6 M (0.009 mol) was added at -78°C to a mixture of




(intermediate 31) (prepared according to A4a) (0.0029 mol) in


-59-

THF (25 ml) under N₂ flow. The mixture was stirred at -78°C for 10 minutes, then brought to room temperature and stirred for 3 hours. H₂O was added. The mixture was extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue (1.28 g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 98/2/0.1; 15-40μm). Three fractions were collected and the solvent was evaporated. Yield: 0.189 g of fraction 1, 0.14 g of fraction 2 and 0.5 g of fraction 3 (48%). Fraction 3 was purified by column chromatography over kromasil (eluent: CH₂Cl₂/EtOAc 80/20; 10μm). Two fractions (F1, F2) were collected and the solvent was evaporated. Yield: 0.25 g F1 (24%) and 0.1 g of F2. F1 was crystallized from diethyl ether. The precipitate was filtered off and dried. Yield: 0.21 g of intermediate 32 (20%).

e-3) The preparation of intermediate 34




A solution of methylmagnesium iodide (1.0M solution in diethylether) (0.6ml)

was added to a solution of  intermediate 33 (prepared according to A5.a) (0.0006 mol) in THF (3 ml). The mixture was stirred for 2 hours. H₂O was added. The mixture was filtered over celite. H₂O was added. The mixture was extracted with EtOAc. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue (0.05 g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 96/4; 15-40μm). The pure fractions were collected and the solvent was evaporated. Yield: 0.015 g of intermediate 34 (7.2%).

Example A4

a) The preparation of intermediate 10




A mixture of ethyl 3,5-dimethyl-4-hydroxy benzoate (0.0025 mol) in 1,4-dioxane (2.5 ml) was stirred at room temperature under N₂ flow. Sodium hydride (0.0033 mol) was added. The mixture was stirred for 2 minutes. Intermediate 5 (0.0028 mol) was added. The mixture was stirred for 10 minutes. 1-methyl-2-pyrrolidinone (2.5 ml) was added. The mixture was stirred at 150°C for 12 hours, poured out into H₂O and extracted with

-60-


$\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$. The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The residue (1.7 g) was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 92/8; 15-40 μm). The pure fractions were collected and the solvent was evaporated. Yield: 0.7 g of intermediate 10 (70%).

b-1) The preparation of intermediate 11




- 5 A solution of intermediate 10 (0.0005 mol) in THF (5 ml) was added dropwise at 0°C to a suspension of LiAlH_4 (0.001 mol) in THF (5 ml) under N_2 flow. The mixture was stirred at 0°C for 1 hour and poured out into H_2O (0.5 ml). CH_2Cl_2 was added. The organic layer was separated, dried (MgSO_4), filtered, and the solvent was evaporated. The residue was purified by column chromatography over kromasil (eluent: CH_2Cl_2 100 to $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 99/1; 5 μm). The pure fractions were collected and the solvent was
- 10 evaporated. The residue (0.1 g) was crystallized from diethyl ether. The precipitate was filtered off and dried. Yield: 0.043 g of intermediate 11 (24%).

b-2) The preparation of intermediate 37



- LiAlH_4 (0.0196 mol, 0.75 g) was added portionwise at 5°C to a mixture of intermediate 29 (prepared according to A3d-2) (0.0098 mol) in THF (100 ml) under N_2 flow. The
- 15 mixture was stirred at room temperature overnight, poured out into EtOAc, then into H_2O and filtered over celite. The organic layer was separated, dried (MgSO_4), filtered, and the solvent was evaporated. Yield : 3.4 g. This fraction was purified by column chromatography over kromasil (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 97/3/0.1; 15-40 μm). The pure fractions were collected and the solvent was evaporated. Yield 1 g (27%).
- 20 This fraction was crystallized from DIPE/ CH_3CN . The precipitate was filtered off and dried. Yield: 0.03 g of intermediate 37.


c) The preparation of intermediate 12



-61-

A mixture of intermediate 11 (0.0043 mol) in CH_2Cl_2 (50 ml) was stirred at 0°C . SOCl_2 (0.0206 mol) was added dropwise. The mixture was poured out into ice water/ K_2CO_3 . The mixture was stirred at room temperature for 5 minutes. The organic layer was separated, dried (MgSO_4), filtered, and the solvent was evaporated. Yield: 1.5 g of intermediate 12 (98%).


d) The preparation of intermediate 55



Jones's reagent (0.0084 mol) was added to a mixture of intermediate 19 (see Table 1) (prepared according to A4b-1) (0.0028 mol) in acetone (50 ml). The mixture was stirred at room temperature for 2 hours then poured out into H_2O and basified with NaHCO_3 . The precipitate was filtered off and dried. Yield : 1.39 g. The residue (0.1 g) was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 85/15/1 then CH_3OH 100). The pure fraction was crystallized from isopropanol/DIPE. Yield : 0.071 g of intermediate 55.


Example A5

a) The preparation of intermediate 13



A mixture of intermediate 19 (see Table 1) (prepared according to A4.b-1) (0.0037 mol) and MnO_2 (0.0185 mol) in CH_2Cl_2 (100 ml) was stirred at room temperature overnight, then filtered over celite. The filtrate was evaporated. Yield: 1.3 g of intermediate 13.

b) The preparation of intermediate 21




A mixture of intermediate 13 (prepared according to A5.a) (0.0029 mol) and $\text{H}_2\text{N}-\text{NH}_2$, H_2O (0.0058 mol) in EtOH (10 ml) was stirred at room temperature overnight. The solvent was evaporated till dryness. Yield: 0.53 g of intermediate 21.

Example A6

-62-


The preparation of intermediate 14



Hydrazine (0.0077 mol) was added to a mixture of according to A3.d-1) (0.0005 mol) in EtOH (10 ml). The mixture was stirred and refluxed overnight. Hydrazine (0.028 mol) was added. The mixture was stirred and refluxed overnight. Yield: 0.28 g of intermediate 14.


5 Example A7

a) The preparation of intermediate 23



A mixture of intermediate 35 (0.0056 mol) in HCl 3N (60 ml) and *i*PrOH (15 ml) was stirred and refluxed overnight. The precipitate was filtered, washed with H₂O, taken up in DIPE and dried. Yield: 2.3 g of intermediate 23 (100%).

b) The preparation of intermediate 56




- 10 A mixture of intermediate 10 (prepared according to A4.a) (0.0012 mol) in HCl 3N (26 ml) and *i*PrOH (4 ml) was stirred and refluxed for 12 hours. The solvent was evaporated till dryness. The residue was taken up in (CH₃)₂CO. The solvent was evaporated. The residue was taken up in diethyl ether. The precipitate was filtered off and dried. Yield: 0.4 g (78.5%). This fraction was stirred at 60°C for 20 minutes.

-63-

Yield: 0.19 g. This fraction was crystallized from H₂O/2-propanone. The precipitate was filtered off and dried. Yield: 0.12 g of intermediate 56 (26%).


Example A8

a) The preparation of intermediate 24



- A mixture of intermediate 31 (prepared according to A4.a) (0.0005 mol) and (triphenylphosphoranylidene)acetic acid ethyl ester [CAS 1099-45-2] (0.0006 mol) in THF (5 ml) was stirred at 80°C for 48 hours, poured out into H₂O and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue (0.4 g) was crystallized from DIPE. The precipitate was filtered off and dried. Yield: 0.08 g (33%). This fraction was crystallized from DIPE/CH₃CN.
- The precipitate was filtered off and dried. Yield: intermediate 24 (33%).


b) The preparation of intermediate 25




- Piperidine (0.0011 mol) was added at room temperature for 30 minutes. Intermediate 31 (prepared according to A4.a) (0.0005 mol) was added. The mixture was stirred at room temperature for 1 hour, poured out into H₂O and extracted with CH₂Cl₂. The precipitate was filtered off and dried. The residue (0.2 g) was crystallized from CH₃CN/DIPE. The precipitate was filtered off and dried. Yield: 0.048 g of intermediate 25 (19%) (mp. 222°C).

Example A9

The preparation of intermediate 26





-64-



- A mixture of (prepared according to A3.d-1) (0.0011 mol) and Pd/C (0.2 g) in methanol (30 ml) was hydrogenated at room temperature for 2 hours under one bar pressure, then filtered over celite. Celite was washed with CH₃OH. The filtrate was evaporated till dryness. The residue (0.3 g) was crystallized from 2-propanone/CH₃OH/diethyl ether. The precipitate was filtered off and dried. Yield: 0.07 g of fraction 1. Fraction 1 was purified by column chromatography over kromasyl (eluent: CH₂Cl₂/CH₃OH 99.5/0.5; 5 μ m). Three fractions (F1, F2, F3) were collected and the solvent was evaporated. Yield: 0.0516 g F1, 0.1g F2 and 0.15 g F3. F1 was taken up in diethyl ether. The precipitate was filtered off and dried. Yield: 0.028 g of intermediate 26 (8%) (mp. 272°C).

Example A10


The preparation of intermediate 27



- A mixture of (prepared according to A4.c) (0.0005 mol) and triphenylphosphine (0.0005 mol) in CH₃CN (10 ml) was stirred and refluxed for a week end. The solvent was evaporated till dryness. The residue was taken up in diethyl ether. The precipitate was filtered off and dried. Yield: 0.34 g of intermediate 27 (94%).

Example A11

The preparation of intermediate 58




- A mixture of 4-bromo-2,6-dimethylbenzenamine (0.013 mol) and intermediate 5 (0.013 mol) was stirred at 150°C for 1 hour. The mixture was poured into K₂CO₃ 10% aqueous solution and extracted with CH₂Cl₂/ MeOH (95/5). The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue was crystallized from diisopropyl ether. The precipitate was filtered off and dried. Yield : 2.3g (45%). The mother layer was purified by column chromatography over silica gel (eluent:

-65-

$\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}-\text{NH}_4\text{OH}$ 98.5/1.5; 15-40 μm). The pure fractions were collected and the solvent was evaporated. Yield: 0.90 g (17%). The global yield of intermediate 5 was: 3.2 g (62%).

- 5 Intermediate 59 was prepared analogously.





Intermediate 59

Table 1 and 2 list intermediates which intervene in the preparation of compounds of formula (I).

10


Table 1



Interm. No.	Ex. No.	X ₁	R ³	R ^{4a}	R ^{4b}	Physical data
11	A4b-1	O	-CH ₂ -OH	CH ₃	CH ₃	
12	A4c	O	-CH ₂ -Cl	CH ₃	CH ₃	
16	A3e	NH	-CH(OH)-CH ₃	CH ₃	CH ₃	
17	A3e	NH	-CH(OH)-CH(CH ₃) ₂	CH ₃	CH ₃	
18	A3e	NH	-CH(OH)-CH ₂ -CH ₃	CH ₃	CH ₃	
19	A4b-1	NH	-CH ₂ -OH	CH ₃	CH ₃	
15	A4c	NH	-CH ₂ -Cl	CH ₃	CH ₃	
24	A8a	O	-CH=CH-C(=O)-O-C ₂ H ₅	CH ₃	CH ₃	mp. 180°C; (E)
25	A8b	O		CH ₃	CH ₃	mp. 222°C; (A)
35	A3d-1	NH	-CH=CH-C(=O)-O-C ₂ H ₅	CH ₃	CH ₃	mp. 200°C; (E)
23	A7a	NH	-CH=CH-COOH	CH ₃	CH ₃	
34	A3e-3	NH	-CH(OH)-CH ₃	CH ₃	H	mp. 182°C
36	A4b-1	NH	-CH ₂ -OH	CH ₃	H	mp. 210°C

Interm. No.	Ex. No.	X ₁	R ³	R ^{4a}	R ^{4b}	Physical data
37	A4b-2	NH	-CH ₂ -OH	Cl	CH ₃	
38	A4b-1	NH	-CH ₂ -OH	Cl	H	mp. 226°C
39	A3e-1	O	-CH(OH)-CH ₃	CH ₃	H	mp. 160°C
40	A4b-1	S	-CH ₂ -OH	CH ₃	CH ₃	mp. 173°C
41	A4b-1	NH	-CH ₂ -OH	Br	H	mp. 234°C
32	A3e-2	O	-CH(OH)-CH ₃	CH ₃	CH ₃	mp. 193°C
42	A4b-1	NH	-CH ₂ -OH	Br	CH ₃	mp. 250°C
43	A4b-1	NH	-CH ₂ -OH	OH	H	mp. 124°C
44	A4b-1	NH	-CH ₂ -OH	H	H	mp. 215°C
45	A4b-1	NH	-CH ₂ -OH	O-CH ₃	H	
46	A4b-1	NH	-CH ₂ -OH	CF ₃	H	mp. 194°C
47	A4c	NH	-CH ₂ -Cl	Cl	CH ₃	
48	A4c	NH	-CH ₂ -Cl	Cl	H	
49	A3e-1	O	-CH ₂ -OH	CH ₃	H	
50	A4c	O	-CH ₂ -Cl	CH ₃	H	
51	A4b-1	NH	-CH ₂ -OH	C(CH ₃) ₃	H	
52	A4c	NH	-CH ₂ -Cl	CH ₃	H	
53	A4b-1	NH	-CH ₂ -OH	2-furanyl	CH ₃	
54	A4c	NH	-CH ₂ -Cl	Br	CH ₃	
57	A7b	O	-CH=CH-COOH	CH ₃	CH ₃	

Table 2




Interm. No.	Ex. No.	X ₁	R ³	Physical data
20	A3e	NH	-CHOH-CH ₃	

B. Preparation of the final compoundsExample B1

-67-

The preparation of compound 1



A mixture of intermediate 3 (0.034 mol) and intermediate 5 (0.0174 mol) was stirred at 150°C for 1 hour and taken up in K_2CO_3 10%/CH₂Cl₂/CH₃OH. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue (10 g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/ethyl acetate 80/20; 15-40 μm). Fraction 1 was crystallized from iPrOH. The precipitate was filtered off and dried. Yield: 1.3 g of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (E) (compound 1) (20%).

Example B1A

Compound 1 was also prepared as follows :

A mixture of 93.9 g (0.45 mol) of the hydrochloric acid salt of intermediate 3, prepared according to Example A1c), and 109 g (0.4725 mol) of intermediate 5 in 1.8 l of acetonitrile was prepared under nitrogen atmosphere. The mixture was stirred and refluxed for 69 hours, then allowed to cool to 55 °C. The mixture was filtered and the residue was washed with 200 ml of acetonitrile, followed by drying under reduced pressure at 50°C overnight. 144,6 g (0.3666 mol) of the obtained solid was brought in 1 l of K_2CO_3 10% aqueous solution. The mixture was stirred at room temperature followed by filtration. The obtained residue was washed twice with water followed by drying at 50°C under reduced pressure. The residue was brought in 6.55 l isopropanol and the mixture was refluxed, then stirred overnight and filtered at room temperature. The residue was dried at 50°C under reduced pressure. Yield : 113.2 g (68.6 %) of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (E) (compound 1).

Example B1B

Alternatively, compound 1 was also prepared as follows :


a) A mixture of intermediate 58 (0.00021 mol), prepared according to Example A11, acrylonitrile (CH₂=CH-CN) (0.00213 mol), Pd(OAc)₂ (0.000043 mol), *N,N*-diethylethanamine (0.000043 mol) and tris(2-methylphenyl)phosphine (0.00021 mol) in CH₃CN (7 ml) was stirred in a sealed vessel at 150°C overnight. H₂O was added. The mixture was extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue (0.15 g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/ethyl acetate 80/20; 15-40 μm).

Fraction 1 was collected and the solvent was evaporated, yielding 0.045g of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (E/Z=80/20). The solid was crystallized from diethylether. Yield: 0.035g of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (E) (compound 1) (55%).

b) 4,41g (10 mmol) of intermediate 59 and 15 ml of *N,N*-dimethylacetamide were brought in a 100 ml flask under nitrogen. To this mixture were added 0,98g of sodium acetate (12 mmol), 107 mg (0,1 mmol Pd) of Pd/C 10% (wet) and 1 ml (15 mmol) of acrylonitrile. The mixture was heated at 140°C and the evolution of the reaction was followed by liquid chromatography. The reaction yielded 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (E/Z=80/20) which can be converted to 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (E) as described above in Example B1Ba).


Example B2

a) The preparation of compound 2



A mixture of 4-bromo-2,6-dimethylphenylboronic acid (prepared according to A3.d-1) (0.0002 mol), 2-benzofuranylboronic acid (0.0005 mol), Pd(PPh₃)₄ (0.00002 mol) and Na₂CO₃ (0.0007 mol) in DME (3 ml) was stirred and refluxed in a sealed tube for 3 hours. H₂O was added. The mixture was extracted with ethyl acetate. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue (0.126 g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 98/2; 15-40μm). The pure fractions were collected and the solvent was evaporated. Yield: 0.011 g of compound 2 (10%).

b) The preparation of compound 3




A mixture of 4-bromo-2,6-dimethylphenylboronic acid (prepared according to A3.d-1) (0.0002 mol), tributyl-2-furanylstannane (0.0005 mol) and Pd(PPh₃)₄ (0.00001 mol) in dioxane


-69-

- (5 ml) was stirred at 80°C. The solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 98/2; 15-40 μm). The pure fractions were collected and the solvent was evaporated. The residue (0.025 g) was crystallized from DIPE. The precipitate was filtered off and dried. Yield: 0.021 g of compound 3 (22%).

c) The preparation of compound 104




A mixture of 5-bromo-2-(2-cyano-4-methylphenyl)-5-furancarboxaldehyde (prepared according to A3.d) (0.005 mol),



- [CAS 73183-34-3] (0.0055 mol), Pd(PPh₃)₄ (0.29 g) and K₂CO₃ (2.8 g, 0.02 mol) in toluene (100 ml) and ethanol/water (5 to 10 ml) was stirred and refluxed for a weekend. 5-Bromo-furan-2-carbaldehyde (0.0055 mol) and K₂CO₃ (1.4 g, 0.01 mol) were added. The mixture was stirred and refluxed overnight. The mixture (2.25 g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 100/0 to 99/1; 15-40 mm). The pure fractions were collected and the solvent was evaporated. Yield: 0.135 g of compound 104 (6%).

Example B3

The preparation of compound 4




- A mixture of intermediate 15 (see Table 1) (prepared according to A4.c) (0.0005 mol) and NaCN (0.0011 mol) in DMF (5 ml) was stirred at 80°C overnight, poured out into H₂O and extracted with ethyl acetate. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue (0.15 g) was purified by column chromatography over kromasil (eluent: CH₂Cl₂/CH₃OH 99/1; 10 μm). The pure fractions were collected and the solvent was evaporated. The residue (0.024 g) was purified by column chromatography over hypersil (eluent: acetonitrile/H₂O 52/48; 8 μm). The pure fractions were collected and the solvent was evaporated. Yield: 0.02 g of compound 4 (10%).

-70-


Example B4

a) The preparation of compound 5



A mixture of
 and thiomorpholine (0.5 g) was stirred at 120°C for 48 hours, taken up in CH₂Cl₂ and
 the solvent was evaporated. The residue (0.44 g) was purified by column
 5 chromatography over kromasyl (eluent: CH₂Cl₂/CH₃OH 99/1; 10 μm). The pure
 fractions were collected and the solvent was evaporated. Yield: 0.06 g (20%). This
 fraction was crystallized from diethyl ether/2-propanone. The precipitate was filtered
 off and dried. Yield: 0.035 g of compound 5.


b) The preparation of compound 6



A mixture of intermediate 15 (see Table 1) (prepared according to A4.c) (0.000137
 10 mol), *N,N,N'*-trimethyl-1,2-ethanediamine (2 equiv, 0.000275 mol) and K₂CO₃
 (2 equiv, 0.000275 mol) in CH₃CN (q.s.) was stirred at 80 °C for 12 hours. H₂O was
 added. The mixture was extracted with CH₂Cl₂. The extract's solvent was evaporated.
 The residue was purified by chromatography. The product fractions were collected and
 the solvent was evaporated. Yield: 0.006 g of compound 6 (10.16%).


-71-

c) The preparation of compound 7



A mixture of intermediate 15 (see Table 1) (prepared according to A4.c) (0.0005 mol) in 3-hydroxy-propanenitrile (2 ml) was stirred overnight, poured out into H₂O and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 99/1/0.1; 15-40 μm). Two fractions (F1, F2) were collected and the solvent was evaporated. Yield: 0.034 g F1 and 0.514 g F2. F2 was washed with HCl 3N and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue was crystallized from DIPE. The precipitate was filtered off and dried. Yield: 0.039 g of compound 7 (18%)

d) The preparation of compound 105




A mixture of intermediate 50 (prepared according to A4c) (0.001 mol), KCN (0.0011 mol) and KI (0.00005 mol) in EtOH (15 ml) was stirred and refluxed for 4 hours. The solvent was evaporated till dryness. The residue was taken up in CH₂Cl₂/H₂O. The mixture was extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue (0.31 g) was purified by column chromatography over kromasil (eluent: cyclohexane/EtOAc 70/30; 10 μm). Three fractions were collected and the solvent was evaporated. Yield: 0.044 g of fraction 1, 0.11 g of fraction 2 and 0.055 g of fraction 3. Fraction 3 was crystallized from DIPE. The precipitate was filtered off and dried. Yield: 0.046 g of compound 105 (12%) (mp. 140°C).

Example B5

-72-


a) The preparation of compound 8



A mixture of intermediate 9 (0.0001 mol) and hydroxylamine (0.0002 mol) in EtOH (7 ml) was stirred at room temperature for 3 hours, poured out into K₂CO₃ 10% and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue (0.1 g) was crystallized from DIPE/CH₃CN.

5 The precipitate was filtered off and dried. Yield: 0.026 g of compound 8.

b) The preparation of compound 9




A mixture of intermediate 9 (0.0002 mol) and O-methylhydroxylamine (0.0003 mol) in EtOH (10 ml) was stirred at room temperature overnight, poured out into H₂O and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue (0.13 g) was purified by column

10 chromatography over kromasyl (eluent: cyclohexane/iPrOH/NH₄OH; 5 μm). The pure fractions were collected and the solvent was evaporated. The residue (0.06 g) was crystallized from DIPE. The precipitate was filtered off and dried. Yield: 0.036 g of compound 9 (34%).

Example B6

a) The preparation of compound 1 and 10



Compound 1=(E); compound 10=(Z)


15 A mixture of (cyanomethyl)triphenylphosphonium chloride (0.0022 mol) and potassium tert.-butoxide (0.0022 mol) in THF (7 ml) was stirred at 5°C for 30 minutes under N₂ flow, then stirred at 5°C for 30 minutes. A mixture of intermediate 13 (0.0015 mol) in THF (7 ml) was added. The mixture was stirred for 8 hours in darkness, poured out into H₂O and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄),

20 filtered and the solvent was evaporated. The residue (1.4 g) was purified by column chromatography over silica gel (eluent: toluene/iPrOH/NH₄OH 96/4/0.1; 15-40 μm). Two fractions (F1, F2) were collected and the solvent was evaporated. Yield: 0.165 g of F1 (E/Z=32/68) (30%) and 0.225 g of F2 (E/Z=90/10) (41%). F2 was crystallized from

-73-


CH₃CN/diethyl ether. Yield: 0.036 g of compound 1 (7%). F1 was purified by column chromatography over kromasyl (eluent: toluene/iPrOH 98/2; 5 μ m). The pure fractions were collected and the solvent was evaporated. Yield: 0.029 g of compound 10 (5%).

b) The preparation of compound 11 (Z) and compound 103 (E)




Potassium tert-butoxide (0.0196 mol) was added portionwise at 5°C to a mixture of (1-cyanoethyl)-phosphonic acid diethyl ester (0.0196 mol) in THF (25 ml) under N₂ flow. The mixture was stirred at 5°C for 30 minutes, then at room temperature for 30 minutes. A solution of intermediate 13 (0.0130 mol) in THF (25 ml) was added. The mixture was stirred at room temperature overnight, poured out into H₂O and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue (5.8 g) was purified by column chromatography over silica gel (eluent: toluene/iPrOH/NH₄OH 92/8/0.5; 15-40 μ m). Four fractions (F1, F2, F3, F4) were collected and the solvent was evaporated. Yield: 0.21 g of F1 (mixture Z/E=90/10), 0.836 g of F2 (mixture Z/E=57/43), 0.9 g of F3 and 0.87 g of F4. F3 was crystallized from DIPE/iPrOH to give 0.7 g of compound 11 (14%). F4 was crystallized from DIPE/ iPrOH to give 0.67 g of compound 103 (13%).

c) The preparation of compound 12 and 13



compound 12 = (E)
compound 13 = (Z)

Potassium tert.-butoxide (0.0008 mol) was added portionwise at 5°C to a mixture of (cyanomethyl)phosphonic acid diethyl ester (0.0005 mol) in THF (20 ml) under N₂ flow. The mixture was stirred at room temperature for 30 minutes. A solution of




(prepared according to A3.d-1) (0.0005 mol) in THF (4 ml) was added dropwise. The mixture was stirred at room temperature for 4 hours,


-74-

- poured out into H₂O and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. Yield: 0.3 g. This fraction was purified by column chromatography over kromasil (eluent: CH₂Cl₂/CH₃OH 99/1; 5 μ m). The pure fractions were collected and the solvent was evaporated. Yield: 0.21 g. This
- 5 fraction was purified by column chromatography over kromasil (eluent: cyclohexane/ethyl acetate 50/50; 10 μ m). Two fractions (F1, F2) were collected and the solvent was evaporated. Yield: 0.04 g of F1 and 0.047 g F2. F1 was dried at 70°C for 2 hours. Yield: 0.038 g of compound 13 (18%). F2 was dried at 70°C for 2 hours. Yield: 0.041 g of compound 12 (20%).

d) The preparation of compound 14




10. Potassium tert.-butoxide (0.0013 mol) was added at 5°C to a mixture of (cyanomethyl)phosphonic acid diethyl ester (0.0013 mol) in THF (10 ml) under N₂ flow. The mixture was stirred at 5°C for 30 minutes. A mixture of



- (10 ml) was added. The mixture was stirred at room temperature for 4 hours, poured out
- 15 into H₂O and extracted with ethyl acetate. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue (0.17 g) was purified by column chromatography over kromasil (eluent: CH₂Cl₂ 100 to CH₂Cl₂/CH₃OH 99/1; 5 μ m). Two fractions (F1, F2) were collected and the solvent was evaporated. Yield: 0.054 g F1 and 0.05 g F2. F1 was crystallized from DIPE/CH₃CN. The precipitate was
- 20 filtered off and dried. Yield: 0.046 g of compound 14 (12%).


-75-

e) The preparation of compound 15



4-Fluorobenzeneacetonitrile (1.2 equiv, 0.000175 ml) was added to a mixture of intermediate 13 (0.000146 mol) in CH₃OH (1 ml). NaOCH₃/CH₃OH (1.2 equiv, 0.000175 mol) was added at room temperature. The mixture was stirred at 60 °C for 2 hours, then poured out into ice-water and extracted with CH₂Cl₂. The solvent was evaporated. The residue was purified by chromatography. The product fractions were collected and the solvent was evaporated. Yield: 0.009 g of compound 15 (13.42%).

f) The preparation of compound 106




A mixture of intermediate 13 (prepared according to A5.a) (0.0005 mol) and piperidine (0.0005 mol) in ethanol (5 ml) was stirred at room temperature for 30 minutes. 4,4-dimethyl-3-oxo-pentanenitrile (0.0011 mol) was added. The mixture was stirred at room temperature overnight, poured out into H₂O and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue (0.3 g) was purified by column chromatography over kromasil (eluent: CH₂Cl₂/CH₃OH 99/1; 10 μm). The pure fractions were collected and the solvent was evaporated. The residue (0.2 g) was crystallized from DIPE. The precipitate was filtered off and dried. Yield: 0.141 g of compound 106 (54%) (mp. 193°C).

-76-

Example B7


The preparation of compound 16




A mixture of intermediate 14 (0.00005 mol) and carbonothioic dichloride (0.001 mol) in dioxane (10 ml) was stirred at room temperature. H₂O was added. The mixture was extracted with CH₂Cl₂. This fraction was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 90/10/0.1; 15-40 μm). The pure fractions were collected and the solvent was evaporated. Yield: 0.027 g of compound 16 (95.6%).

Example B8

The preparation of compound 17



The mixture of NaOCH₃ (0.001 mol) and 2-(dimethylamino)-*N*-hydroxyethanimidamide (0.001 mol) in EtOH (10 ml) was stirred at room temperature for 30



minutes.


(prepared according to A3.d-1) (0.0005 mol) was added.

The mixture was stirred and refluxed overnight. H₂O was added. The mixture was extracted with CH₂Cl₂. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 95/5/0.1; 15-40 μm). The pure fractions were collected and the solvent was evaporated. Yield: 0.07 g of compound 17 (31%).

-77-

Example B9


The preparation of compound 18



- nBuLi (0.0038 mol) was added dropwise at -70°C to a mixture of $i\text{Pr}_2\text{NH}$ (0.0038 mol) in THF (5 ml) under N_2 flow. The mixture was brought to -20°C , stirred for 30 minutes and cooled again to -70°C . A solution of CH_3CN (0.0038 mol) in THF (6 ml) was
- 5 added dropwise. The mixture was brought to -20°C , stirred for 1 hour, cooled again to -70°C . A mixture of intermediate 13 (0.0009 mol) in THF (1 ml) was added. The mixture was stirred for 2 hours, poured out on ice at -30°C and extracted with ethyl acetate. The organic layer was separated, dried (MgSO_4), filtered, and the solvent was evaporated. The residue (0.433 g) was purified by column chromatography over silica
- 10 gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 98/2; 35-70 μm). Two fractions were collected and the solvent was evaporated. Yield: 0.056 g F1 and 0.23 g F2 (78%). F1 was crystallized from DIPE/ CH_3CN . The precipitate was filtered off and dried. Yield: 0.036 g of compound 18.

Example B9A

a) The preparation of compound 107




- 15 nBuLi[1.6] (0.0026 mol) was added dropwise at -70°C to a mixture of intermediate 13 (prepared according to A5.a) (0.0008 mol) in THF (10 ml) under N_2 flow. The mixture was stirred at -70°C for 30 minutes. A solution of (chloromethyl)triphenylphosphonium chloride (0.0026 mol) in THF (5 ml) was added dropwise. The mixture was stirred at room temperature overnight, poured out into H_2O and extracted with EtOAc. The
- 20 organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The residue (0.7 g) was purified by column chromatography over kromasil (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 99/1; 10 μm). The pure fractions were collected and the solvent was evaporated. The residue (0.155 g) was purified by column chromatography over C18

-78-


(eluent: CH₃CN/NH₄Ac 0.5% 60/40). The pure fractions were collected and the solvent was evaporated. The residue (0.051 g) was crystallized from DIPE. The precipitate was filtered off and dried. Yield: 0.029 g of compound 107 (9%). (mp. 250°C)

b) The preparation of compound 108 and 109



(Z)

compound 108




(E)

compound 109

nBuLi[1.6] (0.00261 mol) was added dropwise at -70°C to a mixture of
 5 (chloromethyl)triphenylphosphonium chloride (0.00261 mol) in THF (10 ml) under N₂ flow. The mixture was stirred for 30 minutes. A solution of intermediate 31 (prepared according to A4.a) (0.00087 mol) in THF (5 ml) was added dropwise. The mixture was stirred at room temperature overnight, then poured out into H₂O and extracted with EtOAc. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was
 10 evaporated. The residue (1.1 g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 98/2/0.1; 15-40 μm). The pure fractions were collected and the solvent was evaporated. The residue (0.3 g) was purified by column chromatography over hypersil C18 (eluent: CH₃OH/NH₄Ac 0.5% 70/30). Two fractions (F1, F2) were collected and the solvent was evaporated. Yield: 0.097 g F1 and 0.085 g
 15 F2. F1 was crystallized from DIPE. The precipitate was filtered off and dried. Yield: 0.045 g of compound 108 (14%) (mp. 165°C). F2 was crystallized from DIPE. The precipitate was filtered off and dried. Yield: 0.049 g of compound 109 (15%) (mp. 200°C).


c) The preparation of compound 110



(E)

nBuLi[1.6] (1.1 ml, 0.0017 mol) was added dropwise at -70°C to a mixture of 1,1,1,3,3,3-hexamethyldisilazane (HN(TMS)₂) (0.0017 mol) in THF (6 ml). The mixture was stirred at -70°C for 30 minutes. Cyanofluoromethyl (0.0017 mol) was added. The mixture was stirred for 30 minutes. Phosphorochloridic acid diethyl ester (0.0017 mol) was added. The mixture was stirred at -70°C for 15 minutes. nBuLi[1.6] (1.1 ml, 0.0017 mol) was added dropwise. The mixture was stirred for 30 minutes. A solution of intermediate 31 (prepared according to A4.a) (0.0008 mol) in THF (4 ml) was added. The mixture was stirred at room temperature overnight, poured out into H₂O and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue (0.5 g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/EtOAc 95/5; 15-40µm). Four fractions (F1, F2, F3, F4) were collected and the solvent was evaporated. Yield: 0.026 g of compound 110 (8%) (mp. 254°C).


d) The preparation of compound 111



A solution of (CuCl)₂ (0.00015 mol) in NH₃ aqueous (500µl) was added to a mixture of intermediate 21 (prepared according to A5.b) (0.0014 mol) in DMSO (1 ml). A solution of CBr₄ (0.0044 mol) in DMSO (1.5 ml) was added at 0°C. The mixture was stirred at room temperature overnight, poured out on ice and filtered. The organic layer was washed with CH₂Cl₂, dried (MgSO₄), filtered and the solvent was evaporated. The residue (2.73 g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 100/0 to 99/1; 15-40µm). Two fractions were collected and the solvent was evaporated. Yield: 0.007 g of fraction 1 and 0.11 g of fraction 2. Fraction 2 was crystallized from DIPE. The precipitate was filtered off and dried. Yield: 0.075 g of compound 111 (mp. 223°C).


Example B9B

a) The preparation of compound 112



A mixture of intermediate 23 (0.0005 mol), 1-hydroxybenzotriazole (0.0007 mol) and EDCI (0.0007 mol) in CH_2Cl_2 (10 ml) and THF (2 ml) was stirred. A solution of $\text{NH}(\text{CH}_3)_2 \cdot \text{HCl}$ (0.0006 mol) and Et_3N (0.0005 mol) was added. The mixture was stirred at room temperature for 12 hours. H_2O was added. The mixture was extracted with CH_2Cl_2 . The organic layer was separated, dried (MgSO_4), filtered, and the solvent was evaporated. The residue was purified by column chromatography over kromasil (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 100/0 to 90/10; $5\mu\text{m}$). The pure fractions were collected and the solvent was evaporated. Yield: 0.124 g (58%). This fraction was purified by column chromatography over kromasil (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 99/1; $5\mu\text{m}$). The pure fractions were collected and the solvent was evaporated. Yield: 0.045 g of compound 112 (21%) (mp. $>264^\circ\text{C}$).


b) The preparation of compound 113



A mixture of intermediate 57 (prepared according to A7.b) (0.0002 mol), 1-hydroxybenzotriazole (0.0003 mol) and EDCI (0.0003 mol) in CH_2Cl_2 (10 ml) was stirred. *N*-methyl-1-butanamine [CAS 110-68-9] (0.0002 mol) was added. The mixture was stirred at room temperature for 12 hours. H_2O was added. The mixture was extracted with CH_2Cl_2 . The organic layer was separated, dried (MgSO_4), filtered, and the solvent was evaporated. Yield: 0.149 g. This fraction was purified by column


chromatography over kromasil (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 100/0 to 90/10; $5\mu\text{m}$). The pure fractions were collected and the solvent was evaporated. Yield: 0.065 g. This fraction was taken up in DIPE. The precipitate was filtered off and dried. Yield: 0.035 g of compound 113 (30%) (mp. 212°C).

c) The preparation of compound 114




- 5 A mixture of intermediate 23 (prepared according A7.a) (0.0005 mol),
1-hydroxybenzotriazole (0.0007 mol) and EDCI (0.0007 mol) in CH_2Cl_2 (10 ml) and
THF (2 ml) was stirred. 3-(methylamino)propanenitrile (0.0006 mol) was added. The
mixture was stirred at room temperature for 12 hours. H_2O was added. The mixture
was extracted with CH_2Cl_2 . The organic layer was separated, dried (MgSO_4), filtered,
10 and the solvent was evaporated. The residue was purified by column chromatography
over kromasil (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 100/0 to 90/10; $5\mu\text{m}$). The pure fractions were
collected and the solvent was evaporated. Yield: 0.068 g. This fraction was crystallized
from DIPE. The precipitate was filtered off and dried. Yield: 0.032 g of compound 114
(14%) (mp. 168°C).

d) The preparation of compound 115




-82-



A mixture of (0.000195 mol) and methylamine (2 equiv, 0.000390 mol) in THF (5 ml) and Et_3N (0.054 ml) was stirred at room temperature. EDCI (2 equiv, 0.000390 mol) and 1-hydroxy-benzotriazole (2 equiv, 0.000390 mol) were added. The reaction mixture was stirred at room temperature for 12 hours and taken up into H_2O . The organic layer was separated, dried, filtered and the solvent evaporated. The product was isolated and purified by column chromatography. Yield: 0.026 g of compound 115 (17.92%).

Example B9C


The preparation of compound 116



A mixture of intermediate 13 (prepared according to A5.a) (0.000291 mol) and isonicotinic acid hydrazide (2.5 equiv., 0.000728 mol) in ethanol (1 ml) and CH_2Cl_2 (2 ml) was stirred and refluxed for 12 hours. The solvent was evaporated till dryness. The residue was purified by chromatography. Yield: 0.033 g of compound 116 (24.50%).


Example B9D

a) The preparation of compound 117



Sodium cyanoborohydride (0.0024 mol) was added at room temperature to a solution of intermediate 26 (prepared according to A9) (0.0008 mol) in formaldehyde (0.5 ml) and CH_3CN (20 ml) under N_2 flow. Acetic acid (0.5 ml) was added. The mixture was stirred at room temperature for 2 hours, poured out into $\text{H}_2\text{O}/\text{K}_2\text{CO}_3$ 10% and extracted with CH_2Cl_2 . The organic layer was separated, dried (MgSO_4), filtered, and the solvent was evaporated. The residue (0.3 g) was purified by column chromatography over hypersol (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 97/3; $5\mu\text{m}$). The pure fractions were collected and the solvent was evaporated. Yield: 0.08 g (28%). This fraction was crystallized from 2-propanone/diethyl ether. The precipitate was filtered off and dried. Yield: 0.012 g of compound 117 (5%) (mp. 132°C).


b) The preparation of compound 118




A mixture of (prepared according to A9) (0.0015 mol) and tetrahydro-2,5-dimethoxyfuran (0.0077 mol) in acetic acid (10 ml) was stirred and refluxed for 1 hour, then poured out into ice water and K_2CO_3 and extracted with CH_2Cl_2 . The organic layer was separated, dried (MgSO_4), filtered, and the solvent was evaporated. The residue (1 g) was purified by column chromatography over silica gel (eluent: cyclohexane/EtOAc 95/5; $15\text{-}40\mu\text{m}$). The pure fractions were collected and the solvent was evaporated. Yield: 0.23 g. This fraction was crystallized from DIPE/diethyl ether. The precipitate was filtered off and dried. Yield: 0.075 g. This fraction was crystallized again from DIPE/diethyl ether. The precipitate was filtered off and dried. Yield: 0.027 g of compound 118 (5%).

Example B9E

a) The preparation of compound 119




Tributylphosphine (0.0015 mol) was added to a mixture of but-2-enedinitrile (0.0015 mol) in THF (8 ml). The mixture was stirred and refluxed for 2 hours.



- 5 The mixture was stirred and refluxed overnight. H₂O was added. The mixture was extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue (0.618 g) was purified by column chromatography over kromasil (eluent: CH₂Cl₂ 100; 10 □m). Two fractions were collected and the solvent was evaporated. Yield : 0.03 g of compound 119 (13%).

b) The preparation of compound 120




- 10 Intermediate 13 (prepared according to A5.a) (0.002 mol) was added to a mixture of propanedinitrile (0.004 mol) and piperidine (0.004 mol) in ethanol (10 ml). The mixture was stirred at room temperature for 5 minutes. The solvent was evaporated. The residue was taken up in CH₂Cl₂ and purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 98/2; 15-40 μm). The pure fractions were collected and the solvent was
- 15 evaporated. Yield: 0.6 g of compound 120.

-85-

Example B9F


The preparation of compound 122



nBuLi [1.6 M] (0.0016 mol) was added dropwise at -78°C to a mixture of intermediate 27 (prepared according to A10) (0.0004 mol) in THF (10 ml) under N_2 flow. The mixture was stirred at -78°C for 1 hour, then brought to room temperature, stirred for 30 minutes and cooled to -78°C . A solution of 2-pyridinecarboxaldehyde (0.0004 mol) in THF (10 ml) was added. The mixture was stirred at room temperature for 2 hours, poured out on ice and extracted with EtOAc. The organic layer was separated, dried (MgSO_4), filtered, and the solvent was evaporated. The residue (0.32 g) was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 98/2/0.1; 10 μm). Two fractions were collected and the solvent was evaporated. Yield: 0.021 g of compound 122 (10.4%) (mp. 120°C).

Example B10

The preparation of compound 20




NaBH_4 (0.0015 mol) was added portionwise at 5°C to a mixture of compound 19 (see table 3) (prepared according to B1) (0.0014 mol) in CH_3OH (15 ml) under N_2 flow. The mixture was stirred at 5°C for 1 hour, poured out into H_2O and extracted with CH_2Cl_2 . The organic layer was separated, dried (MgSO_4), filtered, and the solvent was evaporated. The residue (0.15 g) was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 99/1; 10 μm). The pure fractions were collected and the solvent was evaporated. The residue (0.068 g, 12%) was crystallized from DIPE. The precipitate was filtered off and dried. Yield: 0.032 g of compound 20.

-86-

Example B11


The preparation of compound 21



A mixture of compound 2 (see table 3) (0.0002 mol), 3-thienylboronic acid (0.0005 mol), Pd(PPh₃)₄ (0.00002 mol) and Na₂CO₃ (0.0007 mol) in DME (3 ml) was stirred and refluxed in a sealed tube for 3 hours. H₂O was added. The mixture was extracted with ethyl acetate. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 98/2; 15-40 μm). The pure fractions were collected and the solvent was evaporated. Yield: 0.04 g of compound 21 (40%).

Example B12


The preparation of compound 23



A mixture of compound 22 (see table 3) (prepared according to B4.a) (0.0002 mol) and Raney Nickel (0.1 g) in CH₃OH (10 ml) was stirred at room temperature for 15 minutes under a 2 bar pressure of H₂, then filtered over celite. Celite was washed with CH₃OH. The filtrate was evaporated. Yield: 0.48 g. This fraction was purified by column chromatography over kromasyl (eluent: CH₂Cl₂/CH₃OH 99/1; 15-40 μm). Two fractions (F1, F2) were collected and the solvent was evaporated. Yield: 0.13 g F1 and 0.13 g F2. F2 was crystallized from diethyl ether. The precipitate was filtered off and dried. Yield: 0.09 g of compound 23 (20%).

Example B13

The preparation of compound 24




A mixture of compound 1 (0.0004 mol) and Pd/C (0.07 g) in CH₃OH (10 ml) was hydrogenated at room temperature for 5 hours under a 3 bar pressure of H₂, then filtered over celite, washed with CH₂Cl₂ and the solvent was evaporated till dryness. The

residue was crystallized from DIPE. The precipitate was filtered off and dried. The residue (0.7 g) was purified by column chromatography over kromasyl (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 100/0 to 99/1; $5\mu\text{m}$). The pure fractions were collected and the solvent was evaporated. The residue (0.06 g) was crystallized from DIPE. The precipitate was filtered off and dried. Yield: 0.04 g of compound 24 (27%).

Example B14


The preparation of compound 26



NaH 60% (0.0004 mol) was added at room temperature to a mixture of compound 25 (see Table 4) (prepared according to B6.c) (0.0004 mol) in THF (30 ml). The mixture was stirred at room temperature for 1 hour. A solution of ICH_3 (0.0004 mol) in THF (30 ml) was added. The mixture was stirred at 60°C for 2 hours, then cooled, poured out into H_2O and extracted with CH_2Cl_2 . The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The residue (0.12 g) was purified by column chromatography over kromasil (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 99/1; $10\mu\text{m}$). The pure fractions were collected and the solvent was evaporated. Yield: 0.049 g of compound 26 (32%).

Example B15

a) The preparation of compound 123




Jones's reagent (0.0056 mol) was added at 5°C to a mixture of compound 18 (prepared according to B9) (0.0029 mol) in 2-propanone (20 ml) under N_2 flow. The mixture was stirred at 5°C for 2 hours, then poured out into H_2O , basified with NaHCO_3 and extracted with CH_2Cl_2 . The organic layer was separated, dried (MgSO_4), filtered, and the solvent was evaporated. The residue (1.5 g) was purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 98/2/0.1; 15-40 μm).

-88-

Two fractions (F1, F2) were collected and the solvent was evaporated. Yield: 0.122 g F1 (11%) and 0.19 g F2 (17%). F2 was crystallized from DIPE. The precipitate was filtered off and dried. Yield: 0.034 g of compound 123 (mp. 150°C).


b) The preparation of compound 124



A mixture of compound 123 (0.0005 mol) in POCl_3 (1.5 ml) was stirred at 80°C for 24 hours, poured out into ice and K_2CO_3 10% and extracted with $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$. The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The residue (0.14 g) was purified by column chromatography over kromasil (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 99/1; 10 μm). The pure fractions were collected and the solvent was evaporated. Yield: 0.026 g of compound 124.


10 Example B16

a) The preparation of compound 125



NaOH 5N (2 ml) was added dropwise at 50°C to a mixture of compound 104 (see Table 3) (prepared according to B2.c) (0.0003 mol) and NH_2OH , HCl (0.0004 mol) in ethanol (10 ml). The mixture was stirred at 50°C for 2 hours. Two-third of the mixture was evaporated. The mixture was poured out into H_2O and extracted with CH_2Cl_2 . The organic layer was washed with K_2CO_3 10%, dried (MgSO_4), filtered, and the solvent was evaporated. Yield: 0.21 g of compound 125.


b) The preparation of compound 126



1,1'-carbonyldiimidazole (0.0012 mol) was added to a mixture of compound 125 (0.0003 mol) in THF (20 ml). The mixture was stirred and refluxed overnight, poured out into H₂O and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue (0.17 g) was purified by column chromatography over kromasil (eluent: CH₂Cl₂/CH₃OH 98/2; 10 μm). Two fractions were collected and the solvent was evaporated. Yield: 0.035 g of fraction 1 and 0.05 g of fraction 2. Both fractions were mixed and crystallized from diethyl ether. The precipitate was filtered off and dried. Yield: 0.05 g of compound 126 (38%) (mp. >260°C).

10 Example B17

Preparation of compound 253



a) 2.53 ml of acetonitrile, 0.056 g (0.253 mmol) of Pd(OAc)₂ and 0.154 g (0.506 mmol) of tris(2-methylphenyl)phosphine were brought in a 100 ml flask under nitrogen and the mixture was stirred for 10 minutes. To the mixture was added 1 g (2.53 mmol) of intermediate 58, 0.51 ml (3.8 mmol) of *N,N*-diethylethanamine and 0.36 g (5.06 mmol) of acrylamide. The mixture was heated at reflux (80°C) for 5 days yielding 28 % of compound 253.


b) In a 100ml flask under N₂ were introduced 0,8g (4,33mmol; 1 eq.) of intermediate 3a (E), 1g (4,33 mmol; 1 eq.) of intermediate 5 and 16ml of 2-propanol. To this mixture 0,72ml of HCl 6N in 2-propanol were added. The mixture was stirred under refluxed for 72 hours and then cooled yielding the hydrochloric acid salt of compound 253, i.e. compound 254.

Compound 254 can be converted into the free base according to art-known methodologies (see also Example B1A).
















Compound 253 can be converted into compound 1 according to the method described above in Example A1c)y).

The following Tables 3, 4 and 5 list compounds of formula (I) as prepared according to one of the above examples (Ex. No.).















Table 3




















Comp No.	Ex. No.	R ³	R ⁴	Physical data mp.°C / (MH+)*
2	B2a	2-benzofuranyl	H	mp. > 240
21	B11	3-thienyl	H	mp. 220
3	B2b	2-furanyl	H	mp. 228
28	B2a	2-thienyl	H	mp. 235
29	B2a	phenyl	H	mp. 230
1	B1/B6a	-CH=CH-CN	H	mp. 245, (E)
30	B2a	2,4-dichlorophenyl	H	(460)
31	B2a	2-benzo[b]thienyl	H	(448)
32	B2a	1-naphthalenyl	H	(442)
33	B2a	3-chlorophenyl	H	(426)
34	B2a	3-acetylphenyl	H	(434)
35	B2a	3-methylphenyl	H	(406)
36	B2a	2-naphthalenyl	H	(442)
37	B2a	4-chlorophenyl	H	(426)
38	B2a	4-methoxyphenyl	H	(422)
39	B2a	4-methylthiophenyl	H	(438)





Comp No.	Ex. No.	R ³	R ⁴	Physical data mp. °C / (MH+)*
40	B2a		H	
19	B1		H	mp. 220
8	B5a	-C(=N-OH)-CH(CH ₃) ₂	H	mp. 156
20	B10		H	mp. 205
27	B1		H	mp. 193
41	B10		H	mp. 200
42	B5a		H	mp. 155
43	B4b		H	mp. 110
44	B5b		H	mp. 110
45	B5a	-C(=N-OH)-CH ₃	H	mp. 135
9	B5b	-C(=N-O-CH ₃)-CH(CH ₃) ₂	H	mp. 185
46	B5b		H	mp. 164
47	B4b	-CH ₂ -N(CH ₂ -CH ₃) ₂	H	mp. 150
48	B4b		H	mp. 85
15	B6e		H	(461)
49	B6e		H	(449)
50	B6e		H	(487)
51	B6e		H	(493)
52	B6e		H	(473)











Comp No.	Ex. No.	R ³	R ⁴	Physical data mp.°C / (MH ⁺)*
53	B6e		H	(443)
54	B6e		H	(446)
55	B6e		H	(449)
56	B6e		H	(521)
57	B6e		H	(457)
6	B4b	$-\text{CH}_2-\text{N}(\text{CH}_3)-\text{CH}_2-\text{CH}_2-\text{N}(\text{CH}_3)_2$	H	(430)
58	B4b		H	(506)
59	B4b		H	(428)
60	B4b		H	(532)
61	B4b		H	(504)
62	B4b		H	(503)
63	B4b		H	(472)
64	B4b		H	(491)
65	B4b	$-\text{CH}_2-\text{N}(\text{CH}_3)-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_3$	H	(415)
66	B4b		H	(442)
67	B4b		H	(410)
68	B4b	$-\text{CH}_2-\text{N}(\text{CH}_3)-\text{CH}_2-\text{CH}_2-\text{CH}_3$	H	(401)
69	B4b		H	(399)
70	B4b		H	(396)
71	B4b	$-\text{CH}_2-\text{N}(\text{CH}_2-\text{CH}_2-\text{O}-\text{CH}_3)_2$	H	(461)

Comp No.	Ex. No.	R ³	R ⁴	Physical data mp.°C / (MH+)*
72	B4b		H	(485)
73	B4b		H	(456)
74	B4b		H	(492)
75	B4b	-CH ₂ -N(CH ₃)-CH ₂ -CH ₂ -CN	H	(412)
76	B4b		H	(443)
77	B4b		H	(397)
78	B4b		H	(417)
79	B4b		H	(464)
80	B4b	-CH ₂ -NH-CH ₂ -CH ₂ -N(CH ₂ -CH ₃) ₂	H	mp, 105
81	B1		H	mp. 240
82	B10		H	mp. 170
24	B13	-CH ₂ -CH ₂ -CN	H	mp. 208
83	B8		H	mp.>250°C
14	B6d		H	mp.158
84	B6c	-C(CH ₃)=CH-CN	H	mp.224°C (E)
18	B9	-CH(OH)-CH ₂ -CN	H	mp.252°C
85	B4b		H	(474)
86	B4b		H	(473)
87	B4b		H	(426)

Comp No.	Ex. No.	R ³	R ⁴	Physical data mp. °C / (MH ⁺)*
88	B4b		H	(424)
89	B4b		H	(446)
90	B4b		H	(397)
91	B4b		H	(438)
92	B4b		H	(438)
93	B4b		H	(410)
94	B4b		H	(410)
95	B4b		H	(478)
96	B4b		H	(473)
103	B6b	-CH=C(CH ₃)-CN	H	mp. 201°C (E)
11	B6b	-CH=C(CH ₃)-CN	H	mp. 246°C (Z)
10	B6a	-CH=CH-CN	H	mp. 258°C (Z)
4	B3	-CH ₂ -CN	H	
17	B8		H	mp. 110°C
97	B8		H	mp. 240°C
16	B7		H	mp. >250°C
7	B4c	-CH ₂ -O-CH ₂ -CH ₂ -CN	H	mp >260
5	B4a	4-thiomorpholinyl	-NO ₂	mp. 268
98	B4a	4-morpholinyl	-NO ₂	mp. 210
22	B4a	1-piperidinyl	-NO ₂	mp. 252
23	B12	1-piperidinyl	-NH ₂	mp. 262


Comp No.	Ex. No.	R ³	R ⁴	Physical data mp. °C / (MH ⁺)*
12	B6c	H	-C(CH ₃)=CH-CN	(E) (381)
13	B6c	H	-C(CH ₃)=CH-CN	(Z) (381)
127	B1	-N(CH ₃) ₂	H	mp. 228°C
123	B15a	-C(=O)-CH ₂ -CN	H	mp. 150°C
116	B9C		H	(463)
128	B9C		H	(480)
129	B9C		H	(452)
130	B9C	-CH=N-NH-C(=O)-CH ₃	H	(400)
131	B9C	-CH=N-NH-C(=O)-CH ₂ -CN	H	(425)
132	B9C		H	(468)
115	B9Bd	-C(=O)-NH-CH ₃	H	(373)
134	B9Bd	-C(=O)-N(CH ₃) ₂	H	(387)
135	B9Bd	-C(=O)-N(CH ₃)-CH ₂ -CH ₃	H	(401)
136	B9Bd	-C(=O)-N(CH ₂ -CH ₃) ₂	H	(415)
137	B9Bd	-C(=O)-NH-CH ₂ -CH ₃	H	(387)
138	B9Bd	-C(=O)-NH-CH ₂ -CN	H	(398)
139	B9Bd	-C(=O)-N(CH ₃)-CH ₂ -CN	H	(412)
140	B9Bd	-C(=O)-NH-CH ₂ -C≡CH	H	(397)
141	B9Bd	-C(=O)-NH-CH ₂ -CH=CH ₂	H	(399)
142	B9Bd	-C(=O)-NH-CH(CH ₃) ₂	H	(401)
143	B1	-N[CH ₂ -CH(CH ₃) ₂] ₂	H	mp. 238°C
144	B13	-CH ₂ -CH(CN) ₂	H	mp. 160°C
106	B6f	-CH=C(CN)-C(=O)-C(CH ₃) ₃	H	(E), mp. 193°C
145	B9F		H	(E), mp. 229°C

Comp No.	Ex. No.	R ³	R ⁴	Physical data mp.°C / (MH+)*
146	B9F		H	(Z), mp. 258°C
147	B9Ea	-CH=C(CN)-CH ₂ -CN	H	(Z/E=88/12) (406)
148	B6c	-C(CH ₂ -CH ₃)=CH-CN	H	(E), mp. 173°C
149	B6c	-C(CH(CH ₃) ₂)=CH-CN	H	(E), mp. 132°C
150	B6c	-C(CH(CH ₃) ₂)=CH-CN	H	(Z), mp. 132°C
151	B6b	-CH=C(CH ₃)-CN	H	(Z), mp. 246°C
152	B6b	-CH=C(CH ₃)-CN	H	(E), mp. 201°C
153	B13	-CH ₂ -CH(CH ₃)-CN	H	mp. 187°C
124	B15b	-C(Cl)=CH-CN	H	
154	B9Ba	-CH=CH-C(=O)-N(CH ₃)-CH ₂ -CN	H	(E)
112	B9Ba	-CH=CH-C(=O)-N(CH ₃) ₂	H	(E), mp.>264°C
155	B9Bc		H	(E), mp. 156°C
156	B9Bc		H	(E), mp. 168°C
157	B9Bc		H	(E), mp.>265°C
158	B9Bc	-CH=CH-C(=O)-N(CH ₃)-CH ₂ -CH ₃	H	(E), mp.>260°C
114	B9Bc	-CH=CH-C(=O)-N(CH ₃)-(CH ₂) ₂ -CN	H	(E), mp. 168°C
159	B9Bc	-CH=CH-C(=O)-N(CH ₂ -CH ₃) ₂	H	(E), mp. 249°C
160	B6b	-C(CH ₃)=C(CH ₃)-CN	H	(E)









Comp No.	Ex. No.	R ³	R ⁴	Physical data mp. °C / (MH ⁺)*
107	B9Aa	-CH=CH-Cl	H	(Z), mp. 250°C
161	B9Aa	-CH=CH-Br	H	(Z), mp. 248°C
111	B9Ad	-CH=C(Br) ₂	H	mp. 223°C
122	B9F		H	(E), mp. 120°C
162	B9F		H	(E), mp. >260°C
163	B9F		H	mp. 128°C
164	B9FF		H	mp. 104°C
125	B16a		H	
104	B2c		H	
165	B9F		H	mp. 112°C
166	B9F		H	mp. 194°C
167	B9F		H	mp. 191°C
126	B16b		H	mp. >260°C
168	B4c	-CH ₂ -O-CH ₂ -CH ₃	H	mp. 201°C
117	B9Da	H	-N(CH ₃) ₂	mp. 132°C
120	B9Eb	-CH=C(CN) ₂	H	
253	B17a/b	-CH=CH-C(=O)NH ₂	H	(E)
254	B17b	-CH=CH-C(=O)NH ₂	H	(E) HCl







* (MH⁺) defines the mass of the protonated compound; it was determined with a MicroMass spectrometer equipped with an electrospray probe with a quadrupolar analyser.

Table 4:




Comp No.	Ex. No.	R ³	R ¹	Physical data mp. °C / (MH ⁺)*
25	B6c	-CH=CH-CN	H	mp. 256°C
99	B3	-CH ₂ -CN	H	mp. 184°C
100	B4b	-CH ₂ -N(CH ₂ -CH ₃) ₂	H	mp. 172 °C
102	B13	-CH ₂ -CH ₂ -CN	H	mp. 224°C
101	B4b	-CH ₂ -N(CH ₃)-CH ₂ -CH ₂ -CN	H	mp. 196°C
26	B14	-CH=CH-CN	CH ₃	mp. 195°C
169	B9Bd	-C(=O)-N(CH ₂ -CH ₃) ₂	H	mp. 172°C
170	B4b	-CH ₂ -N(CH ₃)-CH ₂ -CN	H	
171	B4b		H	(398)
172	B2a		H	mp. 158°C
173	B4b	-CH ₂ -N(CH ₃)-CH ₂ -CH ₂ -N(CH ₃) ₂	H	mp. 196°C
174	B4b	-CH ₂ -N(CH ₃)-CH=N-CN	H	mp. 254°C
175	B14	2-furanyl	CH ₃	mp. 178°C
118	B9Db		H	164°C
176	B14		CH ₃	mp. 188°C
177	B9Aa	-CH=CH-Br	H	(Z), mp. 169°C
110	B9Ac	-CH=C(F)-CN	H	(E), mp. 254°C
178	B6b	-CH=C(CH ₃)-CN	H	(Z)
179	B6b	-CH=C(CH ₃)-CN	H	(E)
180	B9Bb		H	(E)
181	B9Bc	-CH=CH-C(=O)-NH-cyclopropyl	H	(E) (426)
182	B9Bc	-CH=CH-C(=O)-NH-CH ₂ -CH ₂ -N(CH ₃) ₂	H	(E) (427)
183	B9Bc	-CH=CH-C(=O)-NH-CH ₂ -CH ₂ -CH ₂ -O-CH ₃	H	(E)(458)

Comp No.	Ex. No.	R ³	R ¹	Physical data mp. °C / (MH ⁺)*
184	B9Bc	-CH=CH-C(=O)-NH-CH ₂ -CH(CH ₃) ₂	H	(E)(442)
185	B9Bc	-CH=CH-C(=O)-NH-CH ₂ -CH ₂ -CN	H	(E)439)
186	B9Bc		H	(E)(468)
187	B9Bc	-CH=CH-C(=O)-NH-CH ₂ -CH ₂ -CH ₂ -N(CH ₃) ₂	H	(E)(471)
188	B9Bc	-CH=CH-C(=O)-NH-(CH ₂) ₃ -O-CH ₂ -CH ₃	H	(E)(472)
189	B9Bc	-CH=CH-C(=O)-NH-CH ₂ -CH ₃	H	(E)(414)
190	B9Bc	-CH=CH-C(=O)-NH-CH ₂ -CH ₂ -O-CH ₃	H	(E)(444)
191	B9Bc	-CH=CH-C(=O)-NH-CH(CH ₃) ₂	H	(E)(428)
192	B4b		H	(E)(491)
193	B4b		H	(E)(444)
194	B4b	-CH=CH-CH ₂ -N(CH ₃)-CH ₂ -CH ₂ -CN	H	(E)(439)
195			H	(E)(483)
196	B4b	-CH=CH-CH ₂ -N(CH ₂ -CH ₂ -O-CH ₃) ₂	H	(E)(488)
197	B4b		H	(E)(476)
198	B4b	-CH=CH-CH ₂ -N(CH ₃)-CH ₂ -CH ₂ -CH ₃	H	(E)(428)
199	B4b	-CH=CH-CH ₂ -N(CH ₃)-CH ₂ -CH ₂ -N(CH ₂ -CH ₃) ₂	H	(E)(485)
200	B4b	-CH=CH-CH ₂ -N(CH ₂ -CH ₃)-CH ₃	H	(E)(414)
201	B4b	-CH=CH-CH ₂ -N(CH ₂ -CH ₂ -CH ₃) ₂	H	(E)(456)
202	B4b	-CH=CH-CH ₂ -N(CH ₃)-CH ₂ -CH ₂ -CH ₂ -CH ₃	H	(E)(442)
203	B4b		H	(E)(438)
204	B4b		H	(E)(442)
205	B4b		H	(E)(455)
206	B4b	-CH=CH-CH ₂ -N(benzyl)-CH ₂ -CH ₂ -N(CH ₃) ₂	H	(E)(533)
207	B4b	-CH=CH-CH ₂ -N(CH ₃) ₂	H	(E)(457)
208	B4b	-CH=CH-CH ₂ -N(isopropyl) ₂	H	(E)(456)

Comp No.	Ex. No.	R ³	R ¹	Physical data mp. °C / (MH ⁺)*
121	B9Bb	-CH=CH-C(=O)-NH ₂	H	(E)
209	B9Bb		H	(E), mp. 116°C
210	B9Bb		H	(E), mp. 254°C
211	B9Bb	-CH=CH-C(=O)-N(CH ₃)-CH ₂ -CH ₂ -OH	H	(E), mp. 222°C
212	B9Ba	-CH=CH-C(=O)-N(CH ₃)-CH ₂ -CN	H	(E), mp. 198°C
213	B6c	-C(CH ₃)=CH-CN	H	(E)
214	B9Bc	-CH=CH-C(=O)-N(CH ₃)-CH ₂ -CH ₂ -CN	H	(E), mp. 204°C
215	B9Bc	-CH=CH-C(=O)-N(CH ₃)-CH ₂ -CH ₃	H	(E), mp. 211°C
216	B9Bc		H	(E), mp. 246°C
217	B9Bc	-CH=CH-C(=O)-N(CH ₂ -CH ₃) ₂	H	(E), mp. 226°C
218	B9Bc		H	(E), mp. 196°C
219	B9Ba	-CH=CH-C(=O)-N(CH ₃) ₂	H	(E), mp. 225°C
220	B9E	-CH=C(CN)-CH ₂ -CN	H	(Z), mp. 195°C
109	B9Ab	-CH=CH-Cl	H	(E), mp. 200°C
108	B9Ab	-CH=CH-Cl	H	(Z), mp. 165°C
221	B9Ba	-CH=CH-C(=O)-NH-CH ₃	H	(E), mp. 260°C
222	B9Bb	-CH=CH-C(=O)-N(CH ₂ -CH ₂ -O-CH ₃) ₂	H	(E), mp. 158°C
223	B9Bb		H	(E), mp. 208°C
224	B9Bb		H	(E), mp. 208°C
113	B9Bb	-CH=CH-C(=O)-N(CH ₃)-CH ₂ -CH ₂ -CH ₂ -CH ₃	H	(E), mp. 212°C
225	B4b	-CH ₂ -N(CH ₂ -CH ₂ -CN) ₂	H	mp. 154°C
226	B2a	2-furanyl	H	mp. 162°C

* (MH⁺) defines the mass of the protonated compound; it was determined with a MicroMass spectrometer equipped with an electrospray probe with a quadrupolar analyser.

Table 5:



Com p No.	Ex. No.	R ³	R ^{4a}	R ^{4b}	X ¹	Physical data mp. °C
227	B13	-CH ₂ -CH ₂ -CN	CH ₃	H	-NH	mp. 186°C
228	B4b	-CH ₂ -N(CH ₃)-CH ₂ -CN	CH ₃	H	-NH	mp. 138°C
229	B6b	-CH=C(CH ₃)-CN	CH ₃	H	-NH	mp. 190°C
230	B6c	-CH=CH-CN	CH ₃	H	-O-	(E), mp. 254°C
231	B6b	-CH=C(CH ₃)-CN	CH ₃	H	-O-	mp. 150°C
232	B6c	-C(CH ₃)=CH-CN	CH ₃	H	-O-	(E), mp. 234°C
105	B4d	-CH ₂ -O-CH ₂ -CH ₃	CH ₃	H	-O-	mp. 140°C
233	B6b	-CH=C(CH ₃)-CN	CH ₃	Cl	-NH	mp. 214°C
234	B13	-CH ₂ -CH ₂ -CN	CH ₃	H	-O-	mp. 199°C
235	B13	-CH(CH ₃)-CH ₂ -CN	CH ₃	H	-O-	mp. 195°C
236	B13	-CH ₂ -CH(CH ₃)-CN	CH ₃	H	-O-	mp. 161°C
237	B6c	-CH=CH-CN	CH ₃	H	-NH	(E), mp. >264°C
238	B3	-CH ₂ -CN	CH ₃	Cl	-NH	mp. 184°C
239	B6c	-CH=CH-CN	CH ₃	2-furanyl	-NH	(E) mp. 175°C
119	B9E	-CH=C(CN)-CH ₂ -CN	CH ₃	2-furanyl	-NH	
240	B9F		CH ₃	Cl	-NH	mp. 248°C Z/E=50/50
241	B4b	-CH ₂ -N(CH ₃)-CH ₂ -CH ₂ -CN	CH ₃	Br	-NH	mp. 148°C
242	B1	-CH=CH-CN	H	isopropyl	-NH	(E) 30%-(Z) 70%
243	B4b	-CH ₂ -N(CH ₃)-CH ₂ -CH ₂ -CN	CH ₃	Cl	-NH	mp. 85°C
244	B6c	-CH=CH-CN	H	Br	-NH	(E), mp. 270°C
245	B6c	-CH=CH-CN	H	-OCH ₃	-NH	(E), mp. 258°C
246	B6b	-C(CH ₃)=C(CH ₃)-CN	CH ₃	H	-O-	(E), mp. 214°C
247	B6b	-CH=C(CH ₃)-CN	CH ₃	Br	-NH	mp. 212°C
248	B6c	-CH=CH-CN	CH ₃	Br	-NH	(E), mp. 250°C
249	B6b	-CH=C(CH ₃)-CN	H	-OCH ₃	-NH	mp. 166°C

Comp No.	Ex. No.	R ³	R ^{4a}	R ^{4b}	X ¹	Physical data mp. °C
250	B6b	-CH=C(CH ₃)-CN	H	Br	-NH	mp. 186°C
251	B13	-CH ₂ -CH ₂ -CN	H	-OCH ₃	-NH	mp. 228°C
252	B4c	-CH ₂ -O-CH ₂ -CH ₂ -CN	H	Cl	-NH	mp. 168°C
133	B6c	-CH=CH-CN	CH ₃	Cl	-NH	(E), mp, 258°C

C. Pharmacological example

The pharmacological activity of the present compounds was examined using the following test.

- 5 A rapid, sensitive and automated assay procedure was used for the *in vitro* evaluation of anti-HIV agents: An HIV-1 transformed T4-cell line, MT-4, which was previously shown (Koyanagi et al., *Int. J. Cancer*, **36**, 445-451, 1985) to be highly susceptible to and permissive for HIV infection, served as the target cell line. Inhibition of the HIV-induced cytopathic effect was used as the end point. The viability of both HIV- and
- 10 mock-infected cells was assessed spectrophotometrically via the *in situ* reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). The 50% cytotoxic concentration (CC₅₀ in M) was defined as the concentration of compound that reduced the absorbance of the mock-infected control sample by 50%. The percent protection achieved by the compound in HIV-infected cells was calculated by the
- 15 following formula :

$$\frac{(\text{OD}_T)_{\text{HIV}} - (\text{OD}_C)_{\text{HIV}}}{(\text{OD}_C)_{\text{MOCK}} - (\text{OD}_C)_{\text{HIV}}} \quad \text{expressed in \%},$$

- whereby (OD_T)_{HIV} is the optical density measured with a given concentration of the test compound in HIV-infected cells; (OD_C)_{HIV} is the optical density measured for the control untreated HIV-infected cells; (OD_C)_{MOCK} is the optical density measured for
- 20 the control untreated mock-infected cells; all optical density values were determined at 540 nm. The dose achieving 50% protection according to the above formula was defined as the 50% inhibitory concentration (IC₅₀ in M). The ratio of CC₅₀ to IC₅₀ was defined as the selectivity index (SI).

- 25 Table 6 lists the pIC₅₀ (-logIC₅₀), pCC₅₀ (-logCC₅₀) and pSI (pCC₅₀-pIC₅₀) values for the compounds of formula (I). For example, a compound with a IC₅₀ value of 10⁻⁹M, i.e. pIC₅₀=9, and a CC₅₀ value of 10⁻⁵ M, i.e. pCC₅₀= 5 , has a SI of 10⁻⁵ M/10⁻⁹M = 10.000, i.e. a pSI of 5-9 = -4.

Table 6

Co. No.	pIC ₅₀ (M)	pCC ₅₀ (M)	pSI
21	8.4	4.9	-3.5
3	8.4	5.5	-2.9
1	9.4	5.0	-4.4
34	8.0	4.8	-3.2
19	8.4	4.8	-3.6
45	8.7	5.0	-3.8
49	8.0	4.8	-3.2
70	8.1	4.8	-3.3
75	9.0	5.0	-4.0
78	8.4	4.9	-3.5
79	8.0	5.3	-2.7
84	9.0	4.5	-4.5
18	8.8	4.9	-4.0
25	9	4	-5
24	9.1	5.7	-3.4
81	9.1	5.6	-3.5
11	9.2	5.7	-3.5
10	9.2	6.3	-2.9
174	8.8	5.3	-3.5
227	9.5	<4.0	<-5.5
144	8.6	6.4	-2.2
229	8.8	<4.0	<-4.8
118	8.4	4.1	<-4.1
177	8.3	<4.0	<-4.3
106	7.7	5.2	-2.5
145	8.7	5.3	-3.4
147	9.4	5.7	-3.7
148	8.8	4.9	-3.9
230	9.2	<4.0	<-5.2
231	9.2	<4.0	<-5.2
232	8.4	<4.0	<-4.4
105	7.2	<4.0	<-3.2

-104-

Co. No.	pIC50 (M)	pCC50 (M)	pSI
110	8.6	4.3	-4.3
233	9.3	5.7	-3.6
234	8.7	<4.0	<-4.7
235	9.3	<4.0	<-5.3
236	8.8	<4.0	<-4.8
149	9.1	5.3	-3.8
150	8.8	4.8	-4.0
237	8.9	<4.0	<-4.9
151	9.1	5.5	-3.6
152	9.1	4.8	-4.3
178	8.8	5.7	-3.1
179	8.9	<4.0	<-4.9
153	9.2	6.3	-2.9
124	8.5	4.7	-3.8
238	9.5	5.6	-3.9
112	9.1	4.9	-4.2
244	9.2	4	-5.2
209	8.6	4.9	-3.7
210	8.3	4.8	-3.5
155	8.8	6.3	-2.5
156	7.7	5.1	-2.6
158	8	5.5	-2.5
212	9.1	5	-4.1
114	8.6	5.1	-3.5
213	9	4.8	-4.2
214	8.6	5.1	-3.5
215	9.1	5.5	-3.6
216	8.2	5	-3.6
219	9.1	5	-4.1
245	8.8	4	-4.8
146	8.4	5.4	-3
247	9.2	6.2	-3
248	9.3	5.7	-3.5
249	8.5	4	-4.5

-105-

Co. No.	pIC ₅₀ (M)	pCC ₅₀ (M)	pSI
42	9	6.3	-2.7
251	8.9	5	-3.9
133	9.2	4	-5.2
9	8.8	4.8	-4
239	8.9	5	-3.9
241	9.4	5.3	-4.1
126	8.4	4.9	-3.5

The compositions of the present invention may further comprise an organic polymer.

5 The supersaturated solution of the drug compound created by the components of the composition upon exposure to water as indicated above, may be stabilized by the viscosity enhancing effects of an organic polymer. The presence of the organic polymer will hinder precipitation of the drug compound as the microenvironment becomes more dilute as more water enters.

10 The organic polymer used in the compositions of the invention may be any of the physiologically tolerable water soluble synthetic, semi-synthetic or non-synthetic organic polymers.

15 Thus for example the polymer may be a natural polymer such as a polysaccharide or polypeptide or a derivative thereof, or a synthetic polymer such as a polyalkylene oxide (e.g. PEG), polyacrylate, polyvinylpyrrolidone, etc. Mixed polymers, e.g. block copolymers and glycopeptides may of course be used.

20 Since it is believed that the effect of the organic polymer arises from an enhancement in viscosity which serves to stabilize supersaturated solutions of the drug compound on dissolution of the composition of the invention, the polymer conveniently has a molecular weight in the range 500D to 2 MD, and conveniently has an apparent viscosity of 1 to 100 mPa.s when in a 2% aqueous solution at 20°C. For example, the water-soluble polymer can be selected from the group comprising

- 25
- alkylcelluloses such as methylcellulose,
 - hydroxyalkylcelluloses such as hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and hydroxybutylcellulose,
 - hydroxyalkyl alkylcelluloses such as hydroxyethyl methylcellulose and hydroxypropyl methylcellulose,

- carboxyalkylcelluloses such as carboxymethylcellulose,
- alkali metal salts of carboxyalkylcelluloses such as sodium carboxymethylcellulose,
- carboxyalkylalkylcelluloses such as carboxymethylethylcellulose,
- carboxyalkylcellulose esters,
- 5 - starches,
- pectins such as sodium carboxymethylamylopectin,
- chitin derivates such as chitosan,
- heparin and heparinoids,
- polysaccharides such as alginic acid, alkali metal and ammonium salts thereof,
- 10 carrageenans, galactomannans, tragacanth, agar-agar, gum arabic, guar gum and xanthan gum,
- polyacrylic acids and the salts thereof,
- polymethacrylic acids and the salts thereof, methacrylate copolymers,
- polyvinylalcohol,
- 15 - polyvinylpyrrolidone, copolymers of polyvinylpyrrolidone with vinyl acetate,
- polyalkylene oxides such as polyethylene oxide and polypropylene oxide and copolymers of ethylene oxide and propylene oxide, e.g. poloxamers and poloxamines.
- 20 Non-enumerated polymers which are pharmaceutically acceptable and have appropriate physico-chemical properties as defined hereinbefore are equally suited for preparing compositions according to the present invention.

Preferably the organic polymer is a cellulose ether, e.g. methyl cellulose, hydroxyethylmethylcellulose, or hydroxypropylmethylcellulose (HPMC), for example a Methocel® (available from Colorcon, England) such as Methocel A, Methocel E, Methocel F, Methocel K, Methocel J or Methocel HB or a Metolose® such as Metolose SM, Metolose SH or Metolose SE. Especially preferably the organic polymer is a hydroxypropylmethylcellulose, e.g. from 5 cps Methocel E to 15000 cps Methocel K15M.

Even very small quantities of the organic polymer serve to achieve a beneficial effect in the compositions of the invention. Thus in the compositions of the invention the organic polymer may conveniently be present at 0.05 to 35% by weight, preferably 0.1 to 20%, more preferably 0.5 to 15%, and most preferably 2 to 11% by weight (relative to the total weight of drug compound, acid or base, surfactant and organic polymer). The content and viscosity grade of the organic polymer both affect the dissolution

profile for the drug compound in the compositions of the invention, with increased organic polymer content and/or increased viscosity grade (e.g. 15000 mPa.s in place of 5 mPa.s (mPa.s values being at 2% aqueous solution at 20°)) both tending to decelerate drug compound dissolution). Accordingly the selection of the identity and quantity of the organic polymer will generally depend upon the dissolution profile that is desired. For example, a composition that provides sustained release of the drug, will comprise a water soluble polymer having an apparent viscosity of more than 1,000 mPa.s when dissolved in a 2% aqueous solution at 20°C.

Thus, the compositions according to the invention can be designed in such a way as to provide a particular favourable drug dissolution profile. For instance, dissolution may be sufficiently rapid to ensure substantially complete availability of the drug compound for biological uptake (e.g. from the mouth, nose, stomach or vagina) yet sufficiently slow to provide a more prolonged plasma uptake profile e.g. by avoidance of drug reprecipitation before the composition reaches the stomach.

As a preferred embodiment, the invention provides a pharmaceutical composition comprising a basic drug compound, a surfactant, a physiologically tolerable acid and optionally an organic polymer, characterised in that at 5, 15 and 45 minutes after addition of a quantity of said composition containing 100 mg of said drug compound to 600 mL of 0.1N hydrochloric acid at 37°C, from 7 to 25 (preferably 10 to 20, especially 12 to 18) %, 45 to 70 (preferably 50 to 65, especially 54 to 63) % and at least 96 (preferably at least 97, especially at least 98) % respectively of said drug compound is in solution in said hydrochloric acid. These figures relate to *in vitro* dissolution studies conducted in accordance with the monograph USP 23, <711> Dissolution, pp. 1791-1793.

For example, in determining the dissolution profiles set out above, the composition is placed without a coating or with a rapidly soluble coating (e.g. a gelatin capsule shell) in 0.1 N HCl (or an other appropriate medium) and the mixture is stirred using the USP-method with a paddle, apparatus 2, at a speed of 50 or 100 rpm.

The compositions of the invention may if desired be aqueous, but in general will preferably be substantially water-free, e.g. containing up to 3% by weight, preferably less than 1% by weight water, and most preferably less than 0.5% water, but may be mixed with water immediately before administration or may be coated and dispersed in an aqueous medium whereby the coating is only broken down after administration. Such aqueous compositions are deemed to fall within the scope of the invention.

-108-

Depending on the selection of components, the compositions of the invention may be liquid, solid or semi-solid - e.g. gel-like. Preferably the compositions are non-freeflowing at ambient temperature (e.g. 21°C), other than as free flowing particulates. Thus the compositions at ambient temperature are preferably solids or semi-solids or, less preferably, highly viscous fluids.

In the compositions of the invention the drug compound, surfactant, acid respectively base and optionally the organic polymer are intimately admixed.

Thus where the composition is particulate, the acid (base), drug compound, surfactant and optionally the organic polymer are mixed together within the particles (e.g. at the molecular level; this may be achieved by solvent removal from a solution of these components resulting in the formation of a solid or semi-solid dispersion). Granulate mixtures where individual particles do not contain all three or optionally four components, or have cores of one or more components coated with other components are not preferred. This intimate admixture is important since the effects of the components are complimentary at the microscopic level during dissolution of the compositions of the invention as explained hereinabove.

Preferably, all components are dispersed so as to form a system that is chemically and physically uniform or homogenous throughout, or consists of one phase as defined in thermodynamics ; such a dispersion will be called a thermoplastic phase or system hereinafter. The components of the thermoplastic system are readily bioavailable to the organisms to which they are administered. This advantage can probably be explained by the ease with which said thermoplastic system can form liquid solutions when contacted with a body liquid such as gastric juice. The ease of dissolution may be attributed at least in part to the fact that the energy required for dissolution of the components from a thermoplastic system is less than that required for the dissolution of components from a crystalline or microcrystalline solid phase.

The term "a solid dispersion" used hereinbefore or hereinafter defines a system in a solid state (as opposed to a liquid or gaseous state) comprising the components of the present compositions, wherein one component is dispersed more or less evenly throughout the other components (the components may include additional pharmaceutically acceptable formulating agents, generally known in the art, such as plasticizers, preservatives and the like). When said dispersion of the components is such that the system is chemically and physically uniform or homogenous throughout or consists of one phase as defined in thermo-dynamics, such a solid dispersion will be

called "a solid solution". Solid solutions are preferred physical systems because the components therein are usually readily bioavailable to the organisms to which they are administered. This advantage can probably be explained by the ease with which said solid solutions can form liquid solutions when contacted with a liquid medium such as the gastro-intestinal juices. The ease of dissolution may be attributed at least in part to the fact that the energy required for dissolution of the components from a solid solution is less than that required for the dissolution of components from a crystalline or microcrystalline solid phase.

The term "a solid dispersion" also comprises dispersions which are less homogenous throughout than solid solutions. Such dispersions are not chemically and physically uniform throughout or comprise more than one phase. For example, the term "a solid dispersion" also relates to a system having domains or small regions wherein amorphous, microcrystalline or crystalline drug compound, and/or amorphous, microcrystalline or crystalline surfactant, and/or amorphous, microcrystalline or crystalline acid or optionally amorphous, microcrystalline or crystalline polymer, are dispersed more or less evenly in another phase comprising a solid solution comprising a drug compound, a surfactant, an acid (base) and optionally a polymer. Said domains are regions within the solid dispersion distinctively marked by some physical feature, small in size, and evenly and randomly distributed throughout the solid dispersion.

The compositions of the invention may be prepared by making an intimate admixture of the drug compound, surfactant, acid (base) and optionally the organic polymer. This may be effected most straightforwardly by dissolving these components in a liquid solvent therefor and subsequently removing the solvent. Thus viewed from a further aspect the invention provides a process for the preparation of a pharmaceutical composition, said process comprising: dissolving a drug compound, a surfactant, a physiologically tolerable water-soluble acid (base) and optionally a physiologically tolerable water-soluble organic polymer in a solvent; removing solvent from the resultant solution; optionally forming the resultant product into desired shapes; and optionally coating the resulting product with a physiologically tolerable coating material.

Alternatively, when the components of the composition are thermostable, then the intimate admixture of said components can also be prepared by co-melting them. Therefore, the present invention also provides for a process for preparing the present pharmaceutical composition, said process comprising co-melting a drug compound, a

surfactant, a physiologically tolerable water-soluble acid (base) and optionally a physiologically tolerable water-soluble organic polymer; and optionally forming the resultant product into desired shapes; and optionally coating the resulting product with a physiologically tolerable coating material.

5

In particular, the above described processes can be performed by using one of the following technologies :

a) spray-drying :

10

The components of the present compositions can be dissolved in a suitable solvent and the thus obtained solution can be spray-dried to obtain a powder. The powder can further be processed in for instance tablets or filled into capsules.

b) Freeze-drying :

15

The components of the present compositions can be dissolved in a suitable solvent and the thus obtained solution can then be freeze-dried in order to obtain a powder which can further be processed in for instance tablets or filled into capsules. Alternatively, the solution can also be freeze dried directly into a suitable mold, said suitable mold comprising the final blister pack.

c) Super critical fluid (SCF) technology:

20

The components of the present compositions may be dissolved in a compressible fluid, in particular a supercritical fluid (i.e. any substance above its critical temperature and critical pressure, said supercritical fluid possessing both gas- and liquid-like properties) (in this case the SCF is considered as a solvent; reference therefore is made to RESS (Rapid Expansion of Supercritical Solutions) or PGSS (particles from Gas Saturated Solutions)) followed by removing the SCF (e.g. by decompression) and thus obtaining a powder which can further be processed in for instance tablets or filled into capsules. The super critical fluid technology can also be applied when the SCF is considered as an anti-solvent (reference therefore is made to GAS (Gas Anti Solvent), SEDS (Solution Enhanced Dispersion by Supercritical fluids), ASES (Aerosol Solvent Extraction System), SAS (Supercritical Anti Solvent) or PCA (Precipitation with Compressed Antisolvent). In this case, the components of the composition are dissolved in an appropriate solvent and the SCF is used to enhance solvent evaporation thus obtaining a powder, which can further be processed as described above.

35

d) Carrier coating:

The components of the present compositions can be dissolved in a suitable

solvent and the resulting solution can be coated, sprayed, granulated onto a suitable carrier followed by evaporating the solvent. Appropriate carriers that can be used depend on the technology used, for instance microcrystalline cellulose can be used when pelletization is envisaged and then the appropriate equipment is for instance a fluid bed equipment, or fumed SiO₂ can be used for the formation of granulates and this can be achieved in for instance a high shear granulator or the carrier can be an inert core, e.g. a sugar bead, on which the solution of the components of the present composition can be sprayed. Evaporation of the solvent can be achieved by for instance drying at elevated temperatures and/or under vacuum or by applying microwaves.

e) Co-melting :

When the components of the composition are thermostable, they can be physically mixed, melted and mixed again. The melted mix can then directly be shaped into desired shapes (calendarizing; injection molding) e.g. the melt can be directly filled or injected in the final blister pack or can be filled or injected in desired molds or can be directly filled or injected into a capsule, followed by cooling. The melted mix can also first be allowed to cool and then further processed, e.g. by milling to powder and compressing into tablets or filling into capsules. The co-melting of the components of the present composition may be performed by simply heating the physical mixture or by meltextrusion. In the latter case, the components are physically mixed and fed into a hot stage extruder in which the mix is heated, melted and compounded followed by shaping the resulting meltextrudate as described above, e.g. by injection molding or the meltextrudate can be cooled followed by milling into a powder which can further be processed into a tablet or which can be filled into a capsule.

Alternatively, the melt can also be granulated (melt granulation; high shear granulator), sprayed or coated onto a suitable carrier (reference therefore is made to item d)). In the case of melt granulation, the melting can be performed in a melt-extruder where the carrier is added during the extrusion process and the resulting extrudate can be shaped as described above. In case the carrier is a suitable excipient which allows spheronization, the obtained extrudate can be spheronized, for instance by using a marumizer.

f) Extrusion

The components of the composition can be mixed and fed into an extruder, for instance via the dry powder feeder, and the solvent optionally containing the surfactant can be added to the extruder, for instance via an inlet port. The

-112-

solvent is evaporated while the mixture is still in the extruder. After extrusion, the extrudate is shaped (calendaring).

Alternatively, a solution containing the components of the invention can be fed into the extruder, the solvent is evaporated while the product is still in the extruder and finally the extrudate is shaped.

Alternatively, a solution of the components of the composition can be granulated onto a suitable carrier, e.g. microcrystalline cellulose, and the wetted powder is extruded. The resulting extrudate is then spheronized for instance by using a marumarizer after which the resulting pellets are dried to remove the solvent. The pellets can be filled directly into capsules or they can further be processed into tablets.

Preferably, the present compositions are prepared by extrusion as described under point f) above. A skilled man is able to recognize the appropriate steps and process parameters to perform extrusion of a composition comprising a solvent, wherein the solvent is evaporated in the extruder. Reference therefore is made to e.g. WO98/10752.

The solvent used in the processes described above is preferably a physiologically tolerable material, suitably an organic solvent such as a C₁₋₆ alkanol (e.g. ethanol), acetone, *N,N*-dimethylformamide, a linear or cyclic ether (e.g. diethyl ether, dimethyl ether, or tetrahydrofuran), cyclohexane, dimethylsulfoxide, etc. or a solvent mixture that also may comprise water. For an acid with a high melting point, solvents or solvent mixtures which have high boiling points may conveniently be used; generally however the boiling point of the solvent or solvent system will be no more than about 100°C. Such solvents may be used efficiently in the production of the compositions of the invention and the level of residual solvent will be minimal. The solvent may conveniently be removed by evaporation, e.g. under reduced pressure, and as this may leave some solvent residue (e.g. up to 3% by weight) it is particularly desirable to use a solvent such as ethanol (or an ethanol-water mixture) which is a permitted pharmaceutical excipient.

As described above, super critical fluids can also be used. Suitable SCF are for instance CO₂, N₂O, N₂, short chain alkanes, such as for instance methane, ethane and the like.

If the drug compound is insoluble or poorly soluble in the solvent of choice, the process of the invention may involve dispersion of microparticles (e.g. nanoparticles having a particle size of 1 to 100 nm) of the drug compound in the solvent rather than full

-113-

dissolution of the drug compound. If this is done, it is desirable that the drug compound particles be as small as possible. Nanoparticles of insoluble compounds may be prepared for example by various precipitation techniques or by milling with physiologically tolerable inorganic beads, e.g. of zirconia (EP-0,499,299).

5

The solvent removal may be essentially complete or it may be incomplete, in the former case to produce a solid or a gel-like solid or semi-solid, and in the latter case to produce a viscous fluid which can for example be filled into capsules.

- 10 In general, essentially complete solvent removal will be preferred as the resultant product can then readily be shaped. As already indicated above, shaping may be effected by spray-drying the solution (to provide the product in particulate form), by evaporation of solvent from solution disposed in molds, by molding (e.g. injection molding), by extrusion and the like. As already indicated, the product can be formed
- 15 when hot and allowed to solidify on cooling. The shaped product may likewise be produced in film or sheet form by evaporation or by pouring a heated mass onto a plate and evaporating off the solvent.

- In one preferred embodiment the product is shaped by filling into (e.g. by pouring or by
- 20 extrusion or by injecting) capsule shells, e.g. of gelatin.

An alternative process to prepare the compositions of the invention is to prepare the dispersion of the drug compound, surfactant and acid (base) as described above and to mix the thus obtained product physically with the organic polymer.

25

Yet a further alternative process to prepare the present compositions is to prepare a dispersion of the drug compound, the acid (base) and optionally the organic polymer by dissolving them in a solvent followed by removing the solvent, and subsequently mixing the thus obtained product with the surfactant optionally at elevated temperature.

30

- It will be recognized that for the above described processes a skilled person is able to recognize the most favourable parameters and the most appropriate equipment. It is also well-known to the skilled person that particle size, particle size distribution, crystallinity and morphology of the obtained powders according to the processes
- 35 described above can be adapted to specific requirements by appropriately adjusting process parameters, such as for instance the temperature, nozzle size and shape, gas addition in case of spray processes.

The compositions of the present invention may be formulated into a suitable dosage form.

Thus the present invention also provides pharmaceutical dosage forms comprising a therapeutically effective amount of a composition as described hereinbefore.

For example if the drug is to be delivered in a standard capsule (e.g. with a 900 mg capacity for a glass thermoplastic system as described in the present invention, and the desired drug dose is 100 mg/capsule) then the quantities and natures of the other composition components may be selected to give the desired drug dissolution profile - in general only a small quantity of organic polymer, e.g. 20 to 50 mg, may be necessary, and the balance may be made up from acid (base) and surfactant with the ratio of acid to surfactant being set according to the required dissolution profile, e.g. with 200 to 400 mg surfactant and 450 to 650 mg acid (base).

Besides the drug compound, the organic polymer, the acid (base) and the surfactant, the compositions of the invention may contain other conventional pharmaceutical excipients, e.g. flavours, colouring agents, antioxidants, bulking agents, glidants, lubricants, fats, waxes, coating agents, dispersants, suspension fluids (e.g. where the composition coated with a gastric juice resistant coating and dispersed as particles in a suspension fluid such as water or a syrup), etc. Preferably such components when in intimate admixture with the drug compound will make up only a minor proportion of the composition, e.g. 0.01 to 10% by weight (relative to the total weight of acid (base), surfactant, drug compound and optionally the organic polymer). However where the composition of the invention is encapsulated or disposed in a carrier (e.g. a fluid or a solid or semi-solid matrix), the further components not in intimate admixture with the drug compound (e.g. coating or encapsulating materials, dispersion media, etc.) may of course make up a minor or major proportion, e.g. 5 to 95% by weight, of the overall composition.

The product may be hygroscopic, and thus may be "tacky" if touched by hand due to its absorption of moisture from the skin. Accordingly it is particularly preferred for the product to be provided with a protective coating to prevent moisture uptake during handling. Such coatings may for example take the form of capsule casings (as described above), tablet coatings, protective film or web coatings, and moisture-proof removable wrappings. Tablet coatings may be applied in conventional manner and may be such as to dissolve in the mouth or stomach (e.g. sugar or sugar/beeswax coatings),

or alternatively may be gastric juice resistant polymers (such as the gastric juice resistant Eudragit® coatings produced by Röhm GmbH) where it is desired that drug uptake should occur in the intestines. Protective films or webs may for example be used where the product is to be applied topically, e.g. for uptake across the skin or a toe
5 or finger nail. In this event a pad of the composition will generally be disposed between an adhesive upper protective layer and a lower removable layer. An example of a topical application form for application on nails and adjoining tissue, e.g. for the treatment of fungal infection, is shown in US-A-5181914.

The present compositions may also comprise suitable lubricants such as for example
10 sodium stearyl fumarate, to avoid sticking.

Where the product is produced in particulate form, e.g. by spray-drying, the particles can be loaded into water-tight administration devices (e.g. spray devices or powder dosing devices such as inhalers) for oral, nasal or topical administration of the
15 particulate. Alternatively particulates may be loaded into capsules or mixed with bulking agents such as lactose, starch, microcrystalline cellulose and mixtures thereof, and compressed to form tablets. In any event, the particles may additionally be provided with one or more coatings, e.g. to provide a delayed or prolonged release administration forms.

20 Generally however it will be preferred to shape the product into individual doses and to provide these with a protective coat, e.g. to produce a capsule, coated tablet or film covered pad single dosage unit.

25 The compositions according to the invention may be in any form convenient for topical administration or administration into an externally voiding body cavity (e.g. nose, lungs, mouth, ear, stomach, rectum or vagina). Typical administration forms include patches, tablets, buccal tablets, lozenges, ear-plugs, nose plugs, coated tablets, capsules, suppositories, chewing gum, gels, powders, granules, syrups and dispersions, although
30 patches and powders and more especially capsules and coated tablets are preferred. The drug dosage will depend upon the drug compound as well as on the condition being treated and on the species and size of the subject being treated.

Further, this invention comprises a pharmaceutical composition or a pharmaceutical
35 dosage form as described hereinbefore for use in a method of prophylaxis, therapy or diagnosis of the human or non-human animal body.

-116-

This invention also relates to a pharmaceutical composition for use in the manufacture of a pharmaceutical dosage form for oral administration to a mammal in need of treatment, characterized in that said dosage form can be administered at any time of the day independently of the food taken in by said mammal.

5 Or, in other words, the present invention also concerns the use of a pharmaceutical composition as described hereinbefore for the manufacture of a pharmaceutical dosage form for oral administration to a mammal in need of treatment, characterized in that said dosage form can be administered at any time of the day independently of the food
10 taken in by said mammal.

This invention also relates to a method of prophylaxis, therapy or diagnosis of the human or non-human animal body which comprises administering to said body a therapeutically or diagnostically effective dose of a pharmaceutical composition
15 according to the present invention.

This invention also relates to a pharmaceutical package suitable for commercial sale comprising a container, an oral dosage form as claimed in any one of claims 16 to 18, and associated with said package written matter non-limited as to whether the dosage
20 form can be administered with or without food.

The invention will now be described further with reference to the following non-limiting Examples.

25 Example 1

The following compositions according to the present invention were prepared :

Composition 1

	Cisapride	114 mg
30	Tartaric acid	35.6 mg
	Lutrol F68	457 mg

Composition 2

	Cisapride	114 mg
35	Tartaric acid	10 g
	Lutrol F68	457 mg

-117-

Preparation of composition 1

114 mg of cisapride and 457 Lutrol F68 were dissolved in 1,14 g of acetone. Tartaric acid 35.6 mg was dissolved in 1.90 ml of EtOH and this solution was added to the acetone solution. The resulting mixture was evaporated under vacuum (rotavapor) at a temperature of 85°C. The residue was grounded and further dried under vacuum at 80°C, followed by grounding.

Preparation of composition 2

Composition 2 was prepared analogously to composition 1 except that the 10 g of tartaric acid were dissolved in 53.3 ml of EtOH.

The in vitro dissolution profiles of compositions 1 and 2 were determined by placing that amount of composition 1 or 2 containing 5.7 mg of cisapride in 10 ml of USP buffer pH 6.8 (USP buffer pH 6.8 was prepared by bringing 6.805 g of KH_2PO_4 , 109.5 ml of a 0.2 N NaOH solution and 700 ml of distilled water in a 1 liter beaker. After complete dissolution while stirring, the resulting mixture was brought to a volume of 1 liter with distilled water in an appropriate recipient) at 37°C and by measuring the percentage of dissolved cisapride as a function of time (stirring was effected by a magnetic stirrer and the concentration of dissolved cisapride was measured by UV absorption).

The results are set out in Table 7.

Table 7

<u>Percentage of cisapride in solution</u>			
Time	Composition 1	Composition 2	
0	0	0	
5	1.68	98.15	
30	1.51	98.33	
60	1.47	98.15	
120	1.45	98.24	

Composition 2 clearly shows a much faster in vitro dissolution compared to composition 1. Thus, incorporating a significant amount of acid in the composition results in an enhanced solubility and hence the drug compound is made much more readily bioavailable.

-118-

Example 2

Gelatine capsules were prepared containing the following composition :

Composition 3

	R103757*	100 mg
5	Citric acid monohydrate	500 mg
	Cremophor RH 40	250 mg
	Methocel E 5	50 mg

* R103757 corresponds to (-)-[2S-[2 α ,4 α (S*)]]-4-[4-[4-[4-[[2-(4-chlorophenyl)-2-[[4-methyl-4H-1,2,4-triazol-3-yl]thio]methyl]-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one

The above composition was prepared by dissolving 500 mg of R103757, 2.5 g of citric acid monohydrate, 250 mg of methocel E5 and 1,250 mg of Cremophor RH 40 in 2.5 ml of EtOH. After complete dissolution, the solution was poured onto a teflon plate which was then placed in a drying oven for 2 hours at 80°C under vacuum. The resulting residue was scrapped off and the amount corresponding to 100 mg of R103757 was filled into gelatin capsules (size No 0).

The in vitro dissolution profile of composition 3 was determined by placing one capsule containing composition 3 in 600 mL of stirred 0.1 N HCl at 37°C and observing (UV absorption) the percentage of dissolved drug compound at times 0, 5, 15, 30, 45 and 60 minutes (stirring was effected using the USP-method with paddle, apparatus 2, 100 rpm).

The results are set out in Table 8.

Table 8

<u>Composition 3</u>			
<u>Percentage of R103757 in solution</u>			
	Time	Sample 1	Sample 2
	0	0	0
	5	14.94	14.34
	15	62.70	59.10
35	30	94.32	93.12
	45	101.64	102.06

-119-

60 102.84 103.14

Example 3

Gelatine capsules were prepared containing the following composition :

5

Composition 4

	R112625*	100 mg
	Citric acid monohydrate	325 mg
	Laureth 23	325 mg
10	Methocel E 5	25 mg

* R112625 corresponds to (+)-(trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-piperazine acetamide

- 15 The above composition was prepared by dissolving 1 g of R112625, 3.25 g of citric acid monohydrate and 250 mg of methocel E5 in 6 ml of EtOH at 70°C. Adding 3.25 g of Laureth 23 to said solution while further stirring. After complete dissolution, the solution was poured onto a teflon plate which was then placed in a drying oven for 2 hours at 80°C under vacuum. The resulting residue was scrapped off and the amount
- 20 corresponding to 100 mg of R112625 was filled into gelatin capsules (size No 0).

The in vitro dissolution profile of composition 4 was determined according to the procedure described for composition 3.

- 25 The results are set out in Table 9.

Table 9

Composition 4
Percentage of R112625 in solution

30	Time	Sample 1
	0	0
	5	10.98
	15	51.87
	30	80.82
35	45	97.08
	60	101.91

-120-

Example 4Stability testing

Gelatine capsules were prepared containing the following composition :

5

Composition 5

R112625	100 mg
Citric acid monohydrate	325 mg
Cremophor RH40	325 mg
10 Methocel E 5	25 mg

The composition was prepared analogously according to the procedure described in Example 3.

Capsules containing composition 5 were stored for 1 month at room temperature.

15 Dissolution measurements were made according to the method described above for composition 3.

The results are set out in Table 10.

20 **Table 10**Composition 5Percentage of R112625 in solution

	Time	Testing at time 0	Testing after 1 month at room temperature
	0	0	0
25	5	9.26	9.75
	15	43.74	44.16
	30	78.13	80.22
	45	92.64	99.09
	60	101.64	102.39

30

The above results support the stability of the compositions of the invention.

Example 5Immediate release-Extended release formulations

35 The following compositions according to the present invention were prepared :

-121-

Composition 6

R165335*	50 mg
Citric acid monohydrate	500 mg
Cremophor RH 40	250 mg

5

Composition 7

R165335*	50 mg
Citric acid monohydrate	500 mg
Cremophor RH 40	250 mg

10	Polyox WSR 303	30 mg
----	----------------	-------

Composition 8

R165335*	50 mg
Citric acid monohydrate	500 mg
Cremophor RH 40	250 mg

Polyox WSR 303	50 mg
----------------	-------

*R165335 corresponds to 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethylbenzonitrile.

20

Composition 6 was prepared by dissolving 5000 mg of R165335 in 150 ml of acetone at 60°C followed by adding 50 g of citric acid monohydrate while stirring until complete dissolution. Consequently 25 g of Cremophor RH 40 was added to the solution. After complete dissolution, the solution was poured onto teflon plates which were then placed in a drying oven for 2 hours at 80°C under vacuum. The resulting residue was scrapped off. Compositions 7 and 8 were prepared starting from composition 6 by mixing the appropriate amount of Polyox WSR 303 with the corresponding amount of composition 6.

25

30 The in vitro dissolution profile of compositions 6, 7 and 8 were determined by placing that amount of compositions 6, 7 or 8 that contains 50 mg of R165335 in a basket in 900 mL of stirred 0.01 N HCl containing 2.5 % of sodium lauryl sulfate at 37°C and observing (UV absorption) the percentage of dissolved drug compound at times 0, 5, 15, 30, 45, 60 up to 360 minutes (stirring was effected using the USP-method with basket, apparatus 1, 100 rpm).

35

-122-

The results are set out in Table 11.

Table 11

<u>Composition 5</u>				
<u>Percentage of R165335 in solution</u>				
	Time	Composition 6	Composition 7	Composition 8
	0	0	0	0
	5	22.86	8.42	4.12
	15	65.88	20.03	7.45
5	30	95.82	35.96	12.17
	45	100.18	47.89	16.67
	60	100.70	58.24	24.07
	75		69.65	29.52
	90		78.24	35.25
10	105		84.73	40.61
	120		90.35	47.00
	150		101.01	56.28
	180		101.90	65.30
	240			79.29
15	300			93.45
	360			100.70

From the results gathered in Table 11 it can be concluded that the dissolution rate of the compositions of the invention can be extended by adding an organic polymer to the compositions.

Composition 6 was also subjected to a stability test. The composition was stored for 8 months at room temperature and then the percentage of R165335 in the composition was determined by High Performance Liquid Chromatography. After the 8 months storage period, the composition still contained 98.5% of R165335, supporting the stability of the drug compound in the composition.

Example 6

In vivo study

The following compositions were prepared

-123-

Composition 9

	R165335	125 mg
	Citric acid monohydrate	492 mg
	Cremophor RH 40	242 mg
5	Methocel E5	42 mg

Composition 10

	R278474*	50 mg
	Citric acid monohydrate	500 mg
10	VitE TPGS	250 mg
	Methocel E5	25 mg

R278474* corresponds to 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile.

15

Composition 9 was prepared by dissolving 500 mg of R165335 in 5 ml of tetrahydrofuran at boiling temperature (solution A). 1966.6 mg of citric acid monohydrate, 966 mg of Cremophor RH 40 and 166.66 mg of Methocel E5 were dissolved in 4 ml of EtOH at 80°C (solution B). Solution A was added to solution B while stirring. The thus obtained solution was poured onto a teflon plate which was then placed in a drying oven for 2 hours at 80°C under vacuum. The resulting residue was scrapped off and filled into gelatine capsules (sizeNr 0) for use in the in vivo study.

Composition 10 was prepared by dissolving 300 mg of R278474, 3 g of citric acid monohydrate and 150 mg of methocel E5 in 5 ml of EtOH at 70°C. The solution was evaporated at 85°C under vacuum for 1 hour. 3 g of the thus obtained residue was mixed with 1.304 g of VitE TPGS at 80°C.

R165335 was orally administered to male beagle dogs as a capsule containing composition 9 and as a PEG-400 solution (10 mg of R165335/ml PEG 400) at a dose of 10 mg/kg. Each formulation was tested in 2 dogs. Plasma levels of R165335 were measured (HPLC) for 32 hours after oral administration. The results are set out in Table 12.

R278474 was orally administered to male beagle dogs as a capsule containing composition 10 and as a PEG-400 solution (40 mg of R278474/ml PEG 400) at a dose of 5 mg/kg. Each formulation was tested in 2 dogs. Plasma levels of R278474 were

measured (LC-MS) for 72 hours after oral administration. The results are set out in Table 13. Table 14 reports the mean values for C_{max} , T_{max} and AUC_{0-72h} for the PEG-400 solution study and the composition 10 study.

5

Table 12

Formulation	Day	Time	Plasma levels (ng/ml) of R165335	
			Dog 1	Dog 2
PEG-400 solution	0	0 h	NQ	NQ
		0.5 h	160	93.9
		1 h	251	183
		2 h	420	301
		4 h	498	351
		8 h	283	384
	1	24 h	105	167
		32 h	92.2	120
Capsule with composition 9	0	0 h	NQ	NQ
		0.5 h	53.3	NQ
		1 h	898	97.2
		2 h	2930	1011
		4 h	1868	548
		8 h	873	243
	1	24 h	301	113
		32 h	227	82.5

NQ = Not quantifiable

-125-

Table 13

Formulation	Day	Time	Plasma levels (ng/ml) of R278474	
			Dog 1	Dog 2
PEG-400 solution	0	0 h	0	0
		0.5 h	1.8	203
		1 h	8.4	404
		2 h	35.8	520
		4 h	115	460
		6 h	162	367
		8 h	148	365
	1	24 h	74.0	187
		32 h	38.4	147
	2	48 h	31.9	94.6
	3	72 h	19.3	70.1
Capsule with composition 10	0	0 h	0	0
		0.5 h	NQ	80.2
		1 h	13	694
		2 h	260	1178
		4 h	899	1040
		6 h	1056	1052
		8 h	1111	850
	1	24 h	427	497
		32 h	316	490
	2	48 h	236	232
	3	72 h	181	226

NQ = Not quantifiable

Table 14

Mean values	PEG-400 solution	Composition 10
C _{max} (ng/ml)	341	1144.50
T _{max} (h)	4	5
AUC _{0-72 h} (ng.h/ml)	8359	31008

5

The above results clearly demonstrate the outstanding performance of composition 10 compared to PEG 400 solution. Composition 10 clearly has an improved

pharmacokinetic profile compared to the PEG 400 solution.

Example 7

- 5 Effect of surfactant on solubility and on stability of the supersaturated condition.

Aqueous solutions of 2.5 % (w/v) of hydroxypropyl- β -cyclodextrin (HP β CD) [1], 2.5 % (w/v) of Vit E TPGS [2], 2.5 % (w/v) Cremophor RH 40 [3], 2.5 % (w/v) of sodium lauryl sulfate [4] or 2.5 % (w/v) of PEG 4000 [5] in 0.01 N HCl at 37°C were prepared.

10

To 10 ml of these solutions, with stirring, a concentrated solution of R278474 or R165335 in *N,N*-dimethylformamide (100 mg/ml) was added dropwise until precipitation of the drug compound was observed. After 5, 30, 60 and 120 minutes, the concentration of dissolved R278474 or R165335 expressed in mg% (i.e. the number of

15 mg dissolved in 100 ml) was determined. The results are set out in Table 15.

Table 15

	Time (minutes)	0.01 N HCl	[1]	[2]	[3]	[4]	[5]
concentration		mg%	mg%	mg%	mg%	mg%	mg%
R278474	5	18.02	27.68	91.75			23.60
	30	16.30	24.80	83.50			21.60
	60	15.90	24.40	76.25			20.60
	120	15.95	24.10	75.25			20.10
R165335	5	NM*	0.04		54.20	35.09	0.02
	30	NM	0.12		24.88	37.85	0.04
	60	NM	0.17		20.06	38.80	0.07
	120	NM	0.07		18.44	38.35	0.04

* NM stands for not measurable

The results set out in Table 15 clearly demonstrate the higher solubilizing effect (creating a supersaturation condition) of the surfactant compared to that of a cyclodextrin, such as HP β CD, or a cosolvent, such as PEG 4000. The results also indicate that the surfactants are able to maintain the supersaturated condition for some time.

20

Claims

1. A pharmaceutical composition comprising a basic drug compound, a surfactant and a physiologically tolerable water-soluble acid characterized in that the acid:drug
5 compound ratio is at least 1:1 by weight;
or
comprising an acidic drug compound, a surfactant and a physiologically tolerable water-soluble base characterized in that the base:drug compound ratio is at least 1:1 by weight.
- 10 2. A composition according to claim 1 comprising a basic drug compound, a surfactant and a physiologically tolerable water-soluble acid characterized in that the acid:drug compound ratio is at least 1:1 by weight.
- 15 3. A composition according to claim 1 or 2 characterized in that the physical state of said composition is a solid dispersion.
4. A composition according to any one of claims 1 to 3 wherein the acid is selected from the group comprising citric, fumaric, tartaric, maleic, malic, succinic, oxalic,
20 malonic, benzoic, mandelic and ascorbic acid.
5. A composition according to any one of claim 4 wherein the acid is citric acid.
6. A composition according to any one of claims 1 to 5 further comprising an organic
25 polymer.
7. A composition according to 6 wherein the polymer is selected from the group comprising
- alkylcelluloses such as methylcellulose,
 - 30 - hydroxyalkylcelluloses such as hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and hydroxybutylcellulose,
 - hydroxyalkyl alkylcelluloses such as hydroxyethyl methylcellulose and hydroxypropyl methylcellulose,
 - carboxyalkylcelluloses such as carboxymethylcellulose,
 - 35 - alkali metal salts of carboxyalkylcelluloses such as sodium carboxymethylcellulose,
 - carboxyalkylalkylcelluloses such as carboxymethylethylcellulose,

-128-

- carboxyalkylcellulose esters,
 - starches,
 - pectins such as sodium carboxymethylamylopectin,
 - chitin derivates such as chitosan,
 - 5 - heparin and heparinoids,
 - polysaccharides such as alginic acid, alkali metal and ammonium salts thereof, carrageenans, galactomannans, tragacanth, agar-agar, gum arabic, guar gum and xanthan gum,
 - polyacrylic acids and the salts thereof,
 - 10 - polymethacrylic acids and the salts thereof, methacrylate copolymers,
 - polyvinylalcohol,
 - polyvinylpyrrolidone, copolymers of polyvinylpyrrolidone with vinyl acetate,
 - polyalkylene oxides such as polyethylene oxide and polypropylene oxide and copolymers of ethylene oxide and propylene oxide, e.g. poloxamers and
 - 15 poloxamines.
8. A composition according to claim 6 or 7 wherein the polymer has an apparent viscosity of 1 - 100 mPa.s when dissolved in a 2% aqueous solution at 20°C.
- 20 9. A composition according to any one of claims 6 to 8 wherein the polymer is hydroxypropylmethylcellulose.
10. A composition according to claim 6 or 7 that provides sustained release of the drug, characterized in that it comprises a water soluble polymer having an apparent
- 25 viscosity of more than 1,000 mPa.s when dissolved in a 2% aqueous solution at 20°C.
12. A composition according to any one of the preceding claims wherein the surfactant is an alcohol-oil transesterification product.
- 30 13. A composition according to claim 12 wherein the surfactant is cremophor RH 40 or Vitamin E TPGS.
14. A composition according to any one of the preceding claims wherein the drug compound is no more than sparingly soluble in water.
- 35 15. A composition according to any one of the preceding claims wherein the drug compound is selected from

-129-

- 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile;
4-[[2-[(cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylbenzonitrile;
4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
5 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]-benzonitrile;
a *N*-oxide, an addition salt, a quaternary amine and a stereochemically isomeric form thereof.
- 10 16. A pharmaceutical dosage form comprising a therapeutically effective amount of a pharmaceutical composition as defined in any one of the preceding claims.
17. The dosage form of claim 16 adapted for topical administration or administration into an externally voiding body cavity such as the nose, lungs, mouth, ear, stomach,
15 rectum and vagina.
18. The dosage form of claim 16 wherein said composition is filled into a standard capsule, or alternatively is mixed with bulking agents and compressed into tablets.
- 20 19. A pharmaceutical composition according to any one of claims 1 to 15 for use in the manufacture of a pharmaceutical dosage form for oral administration to a mammal in need of treatment, characterized in that said dosage form can be administered at any time of the day independently of the food taken in by said mammal.
- 25 20. Use of a pharmaceutical composition according to any one of claims 1 to 15 for the manufacture of a pharmaceutical dosage form for oral administration to a mammal in need of treatment, characterized in that said dosage form can be administered at any time of the day independently of the food taken in by said mammal.
- 30 21. A pharmaceutical package suitable for commercial sale comprising a container, an oral dosage form as claimed in any one of claims 16 to 18, and associated with said package written matter non-limited as to whether the dosage form can be administered with or without food.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/13558

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/48 A61K47/12 A61K47/38 A61K47/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 596 705 A (SCHEPKY GOTTFRIED ET AL) 24 June 1986 (1986-06-24) examples 14,17,18	1-14, 16-21
X	WO 95 20384 A (ABBOTT LAB) 3 August 1995 (1995-08-03) examples 10,11,14	1-14, 16-21
X	WO 95 07696 A (ABBOTT LAB) 23 March 1995 (1995-03-23) examples 20,29	1-14, 16-21
X	US 2001/049366 A1 (SINGH ONKAR N ET AL) 6 December 2001 (2001-12-06) claims 1-12; tables 1-3	1-14, 16-21
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

3 June 2003

Date of mailing of the international search report

16/06/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Blott, C

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 02/13558

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 23594 A (GERGELY GERHARD ;GERGELY IRMGARD (AT); GERGELY STEFAN (AT); GERGEL) 8 September 1995 (1995-09-08) claim 12; examples 5,10,11 ---	1-14, 16-21
A	WO 01 23362 A (BREITENBACH JOERG ;HANTKE THOMAS (DE); KNOLL AG (DE); REHBOCK BETT) 5 April 2001 (2001-04-05) claims 6,13; table 1 ---	1-21
A	WO 97 02017 A (ELAN CORP PLC ;CLANCY MAURICE JOSEPH ANTHONY (IE); CUMMING KENNETH) 23 January 1997 (1997-01-23) cited in the application claims 1-21; examples 1-13 ---	1-21
A	WO 01 30319 A (GORE ASHOK Y ;JOSHI RAJASHREE (US); SUPERGEN INC (US); RUBINFELD J) 3 May 2001 (2001-05-03) examples 1-3 ---	1-21
A	PEETERS, J. ET AL: "Development of an extended release oral dosage form using experimental design" PROCEEDINGS - 28TH INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE OF BIOACTIVE MATERIALS AND 4TH CONSUMER & DIVERSIFIED PRODUCTS CONFERENCE, SAN DIEGO, CA, UNITED STATES, JUNE 23-27, 2001 (2001), VOLUME 1, 704-705 PUBLISHER: CONTROLLED RELEASE SOCIETY, XP001152635 the whole document ---	1-21
A	WO 01 22938 A (VERRECK GEERT ;BAERT LIEVEN (BE); JANSSEN PHARMACEUTICA NV (BE)) 5 April 2001 (2001-04-05) the whole document -----	1-21

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/EP 02/13558

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-21
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-21

Present claims 1-15 relate to an extremely large number of possible compositions. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compositions claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to

- a) the compositions prepared in the examples and
- b) compositions comprising a drug compound as defined in claim 15, a surfactant as defined in claim 13 and an acid as defined in claim 4, in a weight ratio as defined in claim 1.

The same remarks apply mutatis mutandis to claims 16-21.

A preliminary search on the general concepts of claim 1 (basic drug compound, surfactant, acid...) lead to the identification of the cited documents, although certainly more could be cited.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/13558

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4596705	A	24-06-1986	DE 3237575 A1	12-04-1984
			AT 21481 T	15-09-1986
			AU 560251 B2	02-04-1987
			AU 1998583 A	12-04-1984
			CA 1228546 A1	27-10-1987
			DE 3365465 D1	25-09-1986
			DK 460683 A ,B,	10-04-1984
			EP 0108898 A1	23-05-1984
			ES 8500743 A1	01-02-1985
			FI 833605 A ,B,	10-04-1984
			GB 2128088 A ,B	26-04-1984
			GR 79015 A1	02-10-1984
			IE 56058 B1	10-04-1991
			IL 69930 A	31-08-1986
			JP 1987827 C	08-11-1995
			JP 7000558 B	11-01-1995
			JP 59089615 A	23-05-1984
			NO 833638 A	10-04-1984
			NZ 205894 A	08-08-1986
			PT 77467 A ,B	01-11-1983
			US 4650664 A	17-03-1987
			ZA 8307499 A	26-06-1985
WO 9520384	A	03-08-1995	AT 210441 T	15-12-2001
			AU 700942 B2	14-01-1999
			AU 1524895 A	15-08-1995
			CA 2178632 A1	03-08-1995
			DE 69524567 D1	24-01-2002
			DE 69524567 T2	05-09-2002
			DK 732923 T3	08-04-2002
			EP 0732923 A1	25-09-1996
			ES 2169121 T3	01-07-2002
			IL 111991 A	26-07-2000
			JP 9508383 T	26-08-1997
			PT 732923 T	31-05-2002
			WO 9520384 A1	03-08-1995
			US 5484801 A	16-01-1996
WO 9507696	A	23-03-1995	AU 695516 B2	13-08-1998
			AU 7717694 A	03-04-1995
			CA 2167412 A1	23-03-1995
			EP 0719142 A1	03-07-1996
			IL 110752 A	26-07-2000
			JP 9502715 T	18-03-1997
			WO 9507696 A1	23-03-1995
			US 5948436 A	07-09-1999
			US 5725878 A	10-03-1998
			US 5876749 A	02-03-1999
US 2001049366	A1	06-12-2001	NONE	
WO 9523594	A	08-09-1995	US 5792473 A	11-08-1998
			AT 182073 T	15-07-1999
			AU 681256 B2	21-08-1997
			AU 1811495 A	18-09-1995
			BR 9506964 A	09-09-1997
			CA 2183952 A1	08-09-1995
			CN 1142182 A	05-02-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/EP 02/13558

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9523594 A		CZ 9602519 A3	15-01-1997
		DE 69419492 D1	19-08-1999
		DE 69419492 T2	03-02-2000
		DE 670160 T1	14-03-1996
		DK 670160 T3	14-02-2000
		WO 9523594 A1	08-09-1995
		EP 0670160 A1	06-09-1995
		ES 2136157 T3	16-11-1999
		FI 963385 A	30-10-1996
		HU 75677 A2	28-05-1997
		IL 112779 A	30-11-1999
		JP 9509669 T	30-09-1997
		NO 963588 A	31-10-1996
		NZ 281228 A	24-06-1997
		PL 316113 A1	23-12-1996
		RU 2153331 C2	27-07-2000
		TW 403658 B	01-09-2000
		ZA 9501652 A	28-08-1996
WO 0123362 A	05-04-2001	DE 19945982 A1	29-03-2001
		AU 7520700 A	30-04-2001
		CA 2387536 A1	05-04-2001
		CN 1376148 T	23-10-2002
		WO 0123362 A2	05-04-2001
		EP 1214300 A2	19-06-2002
		NO 20021409 A	21-03-2002
WO 9702017 A	23-01-1997	IE 80467 B1	29-07-1998
		AT 208192 T	15-11-2001
		AU 700654 B2	14-01-1999
		AU 6239496 A	05-02-1997
		BG 102228 A	30-10-1998
		BR 9609663 A	18-05-1999
		CA 2226008 A1	23-01-1997
		CZ 9704134 A3	15-04-1998
		DE 69616795 D1	13-12-2001
		DE 69616795 T2	08-08-2002
		EP 0836475 A1	22-04-1998
		HU 9900231 A2	28-06-1999
		WO 9702017 A1	23-01-1997
		JP 11508587 T	27-07-1999
		NO 975872 A	03-03-1998
		NZ 311145 A	29-06-1999
		SK 175997 A3	03-06-1998
		TW 426528 B	21-03-2001
		ZA 9605609 A	27-01-1997
WO 0130319 A	03-05-2001	US 6136846 A	24-10-2000
		AU 7490200 A	08-05-2001
		CA 2388613 A1	03-05-2001
		CN 1382038 T	27-11-2002
		EP 1225872 A1	31-07-2002
		JP 2003512416 T	02-04-2003
		WO 0130319 A1	03-05-2001
		US 6509370 B1	21-01-2003
		US 6319943 B1	20-11-2001
		US 2002103254 A1	01-08-2002

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/13558

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0122938	A	05-04-2001	AU 1046200 A	29-05-2000
			AU 7512700 A	30-04-2001
			BG 105419 A	30-11-2001
			BG 106521 A	29-12-2002
			BR 0014271 A	21-05-2002
			BR 9915176 A	14-08-2001
			CA 2351203 A1	18-05-2000
			CA 2384188 A1	05-04-2001
			CN 1376057 T	23-10-2002
			CN 1325387 T	05-12-2001
			CZ 20011532 A3	17-10-2001
			CZ 20020907 A3	15-05-2002
			EE 200100253 A	16-12-2002
			EE 200200151 A	15-04-2003
			WO 0122938 A1	05-04-2001
			WO 0027828 A2	18-05-2000
			EP 1225874 A1	31-07-2002
			EP 1129079 A2	05-09-2001
			HR 20010310 A1	30-06-2002
			HU 0104395 A2	29-04-2002
			HU 0203568 A2	28-02-2003
			JP 2002529457 T	10-09-2002
			JP 2003510264 T	18-03-2003
			NO 20011934 A	19-04-2001
			NO 20021443 A	22-03-2002
			PL 348145 A1	06-05-2002
			SK 3762002 A3	10-09-2002
			SK 6022001 A3	07-01-2002
			TR 200101319 T2	22-10-2001